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Chapter 1
Introduction
1.1 Types of dementia and their diagnosis
Dementia is defined as a loss of memory and other cognitive functions relevant to daily life which
persists for more than six months. The cause of the disease is the destruction or death of brain
cells. In order for dementia to be diagnosed, at least two of the following four cognitive functions
should be impaired:
"(1) memory; (2) ability to speak or understand language; (3) capacity to plan,
make sound judgments, and carry out complex tasks; and (4) ability to process and
interpret visual information"
[70]. Clinically dementia can be classified into different categories shown in Figure 1.1.
 
 
 
 
 
 
 
 
 
Parkinson, 
Frontotemporal dementia, 
HIV encephalopathy 
Vascular dementia 
MIXED dementia 
Alzheimer disease 
Dementia with 
Lewy bodies 
Figure 1.1: Forms of dementia; after Bosser, 1992 (modified) [17]
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Table 1.1: Risk factors for dementia
category of dementia factor reference
cognitive decline sex [1]
cognitive decline age [1]
cognitive decline education [1]
dementia income [1]
PD3 no cigarette smoking [97]
neuronal damage no consumption of nicotine and caffeine [97]
cognitive decline chronic health conditions [1]
cognitive decline inflammatory markers (CRP2, cytokines) [1]
AD, PD3 no nonsteroidal anti-inflammatory drugs [97]
AD, PD3 infections (influenza? Borelia? others?) [97]
cognitive decline1 serum antibodies to CMV, HSV-1, HSV-2 [146]
cognitive decline maybe high anti-CMV IgG antibody levels [1]
cognitive decline HSV-1 + positive for ApoE-E4 allele [1]
AD ApoE-E4 gene mutation / ApoE status [70]
AD PS1 / PS2 gene mutation [58]
AD family history of AD [70]
AD Down Syndrome [70]
PD3 excess weight / bmi4in midlife [97]
AD obesity [70]
PD3 high caloric intake [97]
AD hypercholesterolemia [70]
AD high homocysteine [70]
AD hypertension [70]
AD type 2 diabetes [70]
AD metabolic syndrome [70]
AD heart disease [70]
AD cerebrovascular disease [70]
AD folate or other B-vitamin deficiencies [70]
1 in elderly Finish with vascular disease
2 C-reactive protein
3 Parkinson’s disease
4 body mass index
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1.1.1 Mild cognitive impairment (MCI) and the difficulties of its diagnosis
Mild cognitive impairment (MCI) is a brain disorder associated with a decline in cognitive func-
tion that does not interfere with daily life [90]. It is considered a transitional state that in many
cases leads to dementia [9]. There are many subtypes of MCI with amnestic MCI (aMCI) be-
ing the most prominent. aMCI is diagnosed when cognitive decline is accompanied by memory
impairment [112]. Both types can, but must not necessarily, progress to the different types of
dementia, including Alzheimer’s Disease (AD) [53, 174, 43]. Dubois et al. studied a cohort
of people with amnestic mild cognitive impairment. Of those which - according to the criteria
of that time - were clinically identified to have progressed to dementia only 70% met the neu-
ropathological criteria for AD. Therefore a question is posed as to when MCI can be considered
to have progressed to AD and where to draw the defining line in what appears to be a continuous
process [32]. In order to identify predictive markers for this progression, Tabert and colleagues
analysed 148 patients and 63 age-matched controls in a follow-up study. The main conclusion
was that "deficits in verbal memory and psychomotor speed/executive function abilities strongly
predicted conversion to AD" [148]. Other risk factors for dementia are listed in Table 1.1. For
diagnostic visualisation of the conversion from MCI to AD, MRI (Magnetic Resonance Imaging)
patterns of hippocampus atrophy were proposed [165] or in a more recent study a "Short-form
Everyday Technology Use Questionnaire" that can be used as a screening tool for evaluating
the use of everyday technology (e.g. using a telephone or household equipment, managing fi-
nances and transportation) [72]. Using MRI it is possible to analyse loss of grey matter, while
questionnaires can assess memory function, but neither technique is able to explain the origin
of disease. Another idea discussed in this context is the use of biological markers, such as spe-
cific immune signatures which may contribute to understanding the disease process itself. In this
context, the present work was performed with the hypothesis that Cytomegalovirus (CMV) and
dementia (primarily AD) influence the immune system. CMV infection has been implicated as a
potential risk factor for AD (Table 1.1). It has a major impact on immune signatures which may
be relevant to MCI and in determining which patients with MCI may progress to AD. Earlier,
more accurate diagnoses would allow earlier therapeutic intervention which might increase the
cognitively healthy time period of affected individuals.
1.1.2 Alzheimer’s Disease (AD)
First reports on AD
Alzheimer’s Disease is the most common form of dementia, it occurs predominately in elderly
people above 65 years of age. According to the 2007 Facts and Figures report of the Alzheimer’s
Association of the United States, 96% of all AD patients are over 65 years of age. The worldwide
prevalence of AD was estimated to be 18 million in 2008 [70], with a predicted increasing preva-
lence due to rising life expectancies and a reduction in deaths from infectious diseases associated
with advances in modern medicine. Because of this, the study of dementia is becoming more rel-
evant to societal health and the burden of disease. AD was first described by Aloysius Alzheimer
in the beginning of the 20th century. Alzheimer observed memory decline, disorientation and
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confusion in a 51 year-old patient in 1901 [70]. After autopsy in 1906, Alzheimer described
the main characteristics of AD: an atrophied brain, dead and dying brain cells, plaques consist-
ing of amyloid beta and neurofibrillary tangles (NFT) [5]. This led eventually to the "amyloid
hypothesis".
Amyloid beta and tau
Despite controversial issues surrounding the cause and classification of AD, formation of amyloid
plaques remains the main diagnostic and causative factor. It has been suggested by the group of
La Ferla that amyloid beta (Aβ) may change from being a beneficial molecule with antimicrobial
activity that is involved in protection against oxidative stress, cholesterol transport and is im-
plicated in certain signalling pathways, to one of the major candidate molecules suggested to
contribute to AD pathology (Fig. 1.2). The amyloid precursor protein (APP) is processed in
cholesterol rich membrane regions, so-called lipid rafts. Secretases cleave APP into proteins be-
tween 36 and 43 amino acids long. The most important forms for AD pathology are suggested
to be Aβ-40 and Aβ-42. Aβ can accumulate and aggregate, which according to the amyloid
hypothesis initiates the onset of AD [117]. It is believed that Aβ exerts negative (for exam-
ple neurotoxic) effects and has an immunomodulatory role. Synaptic dysfunctions within the
brain and a systemic inflammation are some of the consequences of Aβ accumulation. With mi-
croscopy studies the La Ferla group showed co-localisation of ubiquitin and Aβ, implying that
proteasomal functions are involved in the role that Aβ may play in AD pathology. One target for
proteasomal degradation is phosphorylated tau, which can accumulate and form neurofibrillary
tangles, as observed by Alzheimer within the brain of one of his patients. Tau is a microtubule-
binding protein, which is involved in axonal transport, also of APP, and can so influence Aβ
distribution and/or production. Another hypothesis is that Aβ activates tau kinases which lead to
hyperphosphorylation of tau. The consequence is dissociation from microtubuli which then de-
polymerise, which results in axonal transport deficits and accumulation of hyperphosphorylated
tau in AD patients. Additionally, consistent with a state of systemic inflammation, microglia and
astrocytes are activated and are located near Aβ plaques, - as for example shown by La Ferla.
These cells possess phagocytic activity and degrade Aβ plaques. In addition they produce high
levels of pro-inflammatory cytokines, which can activate certain kinases, leading to tau hyper-
phosphorylation [13].
Amyloid beta as the cause of AD - a controversial hypothesis
Among several theories suggested to explain the cause of AD, the amyloid beta hypothesis is
the most prominent. In 1991 Hardy and Allsop proposed a sequence of events characteristic
of AD. Due to an imbalance between production and clearance of Aβ, the primary component
of the plaques seen by Alzheimer, there is an accumulation of Aβ. This leads to formation of
neurofibrillary tangles and subsequent to neuronal death [57]. This hypothesis is supported by
the fact that the gene for the Aβ precursor protein (APP) is located on chromosome 21 and that
individuals suffering from Down Syndrome that possess an extra copy of chromosome 21 fre-
quently develop AD [89]. In addition, mutations in the APP gene could cause Aβ accumulation
4
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Figure 1.2: Suggested pathophysiological effects of amyloid beta
Contributions of Aβ to systemic inflammation and AD pathology. According to the amyloid hypothesis
Aβ causes tau hyperphosphorylation and the formation of characteristic neurofibrillary tangles. Through
inhibition of its own proteasomal degradation Aβ enhances this effect. In addition some studies showed
Aβ stimulation of immune cells. They can secrete chemokines and cytokines and recruit peripheral cells
which can enter the brain via a blood-brain barrier which is compromised, e.g. by Aβ. These peripheral
cells can secrete cytokines and so contribute to the inflammatory milieu in AD.
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outside the brain parenchyma and promote Aβ self-aggregation into fibrils [58]. In the limited
number of cases of hereditary AD, mutations in the presenilin genes were detected. Presenilins
are a family of transmembrane proteins that are found in the complex which processes APP to
Aβ. Mutations in the PS1 and PS2 genes, which code for presenilins, were observed to result in
enhanced Aβ production. Apolipoproteins play an important role in Aβ catabolism. The ApoE
protein promotes proteolytic Aβ degradation. The gene for the E4 isoform ApoE-E4, with inef-
ficient catabolic function, facilitates Aβ accumulation, and is a prominent genetic risk factor for
AD. APP transgenic mice accumulate Aβ and show AD pathology. When these were crossed
with ApoE-deficient mice, the offspring showed less Aβ accumulation in the brain [58].
It is also possible that mutations in the tau gene could be responsible for AD. As reviewed by
Hardy & Selkoe, mutations in this gene cause frontotemporal dementia with parkinsonism in-
cluding severe neurodegeneration. In contrast to AD, in this neurodegenerative disorder whereas
aggregation of tau in neurofibrillary tangles in the brain occurs, no Aβ accumulation is present.
The amyloid cascade model is not applicable in these cases. Therefore the authors concluded
that tau aggregation in AD follows alterations in Aβ metabolism. In another study (by Braak and
Braak) human brains were analysed postmortem. In younger people without amyloid plaques,
age-dependent damage to neurofibrills and cells was already present [58]. Hardy & Selkoe pos-
tulate that it is not possible to predict whether the neurofibrillary alterations seen in nondemented
elderly of this study would have resulted in AD. Rather they attribute these lesions to a "process
separate from AD" pathology. To strengthen their hypothesis they cite studies performed with
Down Syndrome patients at different ages which show amyloid plaques prior to the formation of
neurofibrillary tangles and AD onset. In contrast, mice with mutations in the APP gene showed
Aβ accumulation without neuronal loss. This could be explained - according to Hardy & Selkoe
- by the absence of human tau and / or cytokines. It appears as though interplay of both tau and
Aβ is essential for AD development, as studies using primary mouse cell cultures showed Aβ
toxicity to be tau dependent. Additionally, mutations in the APP gene resulted in more rapid
production of neurofibrillary tangles in APP/tau double transgenic mice [58].
There are other observations which are difficult to explain with the amyloid hypothesis. Given
the hypothetical central role of Aβ, it would be expected that a correlation between cognitive de-
cline and amyloid plaque formation would exist, but this has not been confirmed. Some healthy
individuals show plaque formation, but no associated neuronal damage [97]. On the other hand,
the amount of soluble Aβ does correlate with disease severity [58].
An overview of different hypotheses and the role of suggested key players is presented in Figure
1.3. This suggests that not all factors act independently, but instead within a complex network
in which they may influence each other. An explanation of Aβ accumulation is genetic variabil-
ity, while another hypothesis proposes that infections, especially with herpesviruses like HSV-1
(Herpes simplex virus 1) play a role [171]. HSV primarily infects infants, but the virus is latent
in the peripheral nervous system for life. In some cases HSV can result in herpes simplex en-
cephalitis - a severe brain disorder. In this disorder the same brain regions are affected as in AD
[172]. However, among different viruses studied, HSV-1 was not found to be a risk factor for AD
[60] - but in combination with the possession the ApoE-E4 allele it was shown to be a risk factor
[64]. One hypothesis is that carriers of this allele degrade Aβ less efficiently, so that much more
Aβ is able to accumulate. It has therefore been suggested that HSV-1 inhibits degradation of Aβ
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as well as tau [63]. Another herpesvirus, Cytomegalovirus (CMV), can be present in the brain of
healthy elderly and AD patients [83]. In longitudinal studies, higher anti-CMV antibody levels
were reported to correlate with more rapid cognitive decline, although the cause remains unclear
[1, 146]. Further issues regarding the contribution of CMV to AD are discussed in Section 1.3.
Yet another AD risk factor is oxidative stress, which has been observed to be elevated from early
AD onwards. Serum oxidative load is higher and antioxidant capacity lower in AD patients
compared to controls [70]. Brain lesions due to reactive oxygen species and reactive nitrogen
species have been observed in AD patients [116]. In response to oxidative stress, heat shock
proteins (HSPs) are over-expressed. For example, HSP70 was identified as a protective factor
against intracellular Aβ accumulation. Its over-expression was shown to rescue neurons from
Aβ-mediated toxicity [35, 91]. Therefore, it has been proposed that HSP70 acts to attenuate the
cytotoxicity of Aβ by binding amyloidogenic peptides and restoring the balance between aggre-
gation, folding and degradation [35]. Although the oxidative stress hypothesis is based on several
findings in AD patients, including the observation that dietary intake of antioxidants reduces the
risk of AD, clinical trials using antioxidant supplementation have shown only a marginal positive
effect or no benefit at all [116]. This indicates that none of these hypotheses is by itself capable
of explaining AD cause and pathology.
Diagnosis of AD
Given the above, it is not surprising that the diagnosis of AD cannot be made on the basis of a
single test, but several measures are compiled into an overall picture. Some of these are mea-
sured with the use of questionnaires, such as the Folstein test (see Section 1.1.5), others with
MRI images (as discussed for MCI above), positron emission tomography (PET) scans which
show brain metabolism and Aβ deposition, analysis of blood or CSF (cerebrospinal fluid). To
diagnose AD, other diseases with similar symptoms, such as delirium, HIV-infection, encephali-
tis and other forms of dementia must be excluded. Non-specific early AD symptoms are memory
loss and language alterations, but an unequivocal diagnosis of pathological hallmarks, such as
amyloid plaques and neurofibrillary tangles are often still only detectable at autopsy. At the cel-
lular level, reduced numbers of nerve cells, dendrite branches and synaptic densities within the
brain are characteristic of AD. According to Kidd, pathological deterioration is detectable years
prior to diagnosis [70]. Therefore it is essential to find biomarkers that detect AD in early stages.
Robust biomarkers would allow earlier therapeutic intervention. Of the possible biomarkers,
those detectable in the peripheral blood would be most convenient for diagnosis. These may
include plasma levels of tau and Aβ and the presence of specific immune signatures [42, 110].
As discussed in a following section, cells from the periphery may enter the brain of AD patients
(Section 1.4). There they could contribute to Aβ phagocytosis and cytokine secretion by immune
cells, which are also altered in AD patients [39], and potentiate disease.
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Figure 1.3: Proposed mechanisms of pathophysiology in AD
Diagram displaying how the alternate AD hypothesis interact
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Rapidly progressive AD (rpAD)
According to Goldberg, disease duration of slowly progressing AD is around 93 months, ∼24
months from the onset of clinical symptoms until definitive diagnosis, then∼25 months until ad-
mission to a care facility, such as a nursing home, and a further∼44 months patient survival time)
[50]. When the disease is rapidly progressive, it is referred to as "rpAD". The term "rapidly" is
defined as a decline of the MMSE value (value defining the rate of cognitive decline, see Section
1.1.5) of five points per year or by a survival time <4 years compared to up to ten years for "usual"
AD patients. This type of rapid progression is not limited to AD, but can also be observed in
other dementia. The symptoms of rpAD can mimic those of other neurological diseases, such as
Creutzfeldt-Jakob disease [136], making diagnosis even more problematic.
1.1.3 Vascular dementia (VaD)
In Western countries vascular dementia (VaD) ranks as the second most common type of demen-
tia after AD, while in Asia it may actually be the most prevalent form [11]. The incidence of
VaD increases significantly above age 65. The NINDS-AIREN (National Institute of Neurologi-
cal Disorders and Stroke and Association Internationale pour la Recherche et l’Enseignement en
Neurosciences) gives the criteria for VaD as mentioned by Black [11]: "a) cognitive decline in
memory and two other domains sufficient to impair functional abilities (attributable to cognitive
decline, not just physical disabilities); and b) evidence for CVD (cerebrovascular disease), indi-
cated by focal (i.e. sensory-motor) signs and relevant imaging evidence of stroke." Once these
criteria are confirmed, time of onset determines whether diagnosis of VaD is probable, possible
or definite [11]. For a definite diagnosis to be made, other brain diseases need to be excluded,
especially other forms of dementia. One way to achieve this is through the use of neuroimag-
ing techniques to study the structure, biochemistry, metabolic state and functional capacity of
the brain. Tartaglia et al. postulate that "All of the major neurodegenerative disorders have re-
latively specific imaging findings that can be identified." and which support a diagnosis [150].
A three year follow-up study with 193 patients reviewed by Pantoni and Gorelick provides an
example of the information that imaging can contribute to a diagnosis. In approximately 80 %
of the cases, MRI combined with single photon emission CT provided useful information for
diagnosis. Another study with 588 patients suggested that AD could be diagnosed by patients
having solely medial temporal atrophy, whereas vascular dementia was diagnosed along with
other information, such as patient history of stroke, white matter changes in addition to medial
temporal atrophy [108]. A summary of methods to discriminate between these two forms of
dementia is provided in the following section.
1.1.4 Differential diagnosis
Discrimination between different forms of dementia is a major challenge. Multiple criteria
to achieve effective discrimination have been developed and evaluated in different schemes.
NINCDS-ADRDA (National Institute of Neurological and Communicative Diseases and Stroke
- Alzheimer’s Disease and Related Disorders Association) and DSM (Diagnostic and Statistical
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Manual of Mental Disorders) propose two sets of features for AD which achieve approximately
90% sensitivity of diagnosis. In the past, AD diagnosis largely relied on the exclusion of other
diseases with similar symptoms. The major reason that accounted for these difficulties in ef-
fective diagnosis was insufficient knowledge of the disease, as the authors of the first NINCDS-
ADRDA publication stress [95]. Currently, there is more emphasis placed on discovering new
and utilising existing biomarkers. Changes in brain structure, for example volumetric loss of the
hippocampus, and tau distribution are detected using MRI and metabolic differences are visua-
lised by PET scans. In addition, CSF biomarkers, such as presence of Aβ and tau, are potential
candidate biomarkers. These advances may help to reduce the incidence of incorrect diagnosis.
Therefore, Dubois et al. published revised NINCDS-ADRDA criteria for research, used for the
patients studied in one series of studies presented in this thesis. The authors state that "a more
refined definition of AD is still needed to reliably identify the disease at its earliest stages". In
addition, incorrect patient diagnosis led to unsuccessful (and expensive) trials with novel the-
rapeutics with hundreds of participants. The basis for diagnosis is the progressive reduction in
memory function, along with impaired recall and recognition. These symptoms should be ac-
companied by other factors, such as: 1. Volume loss of certain brain regions, as detected by
MRI; 2. Altered concentrations of CSF markers (low levels of Aβ and high levels of tau and as
the authors state "other well validated markers to be discovered in the future"); 3. A particular
pattern of functional neuroimaging measured with PET; 4. Specific genetic influences. Next,
the authors list several exclusion criteria, for example the presence of other non-AD dementias.
Nonetheless, these symptoms collectively can only lead to a diagnosis of probable AD. For a con-
firmed diagnosis, only post-mortem examination is sufficient. Another important consideration
is that lumbar puncture to obtain CSF is not routinely performed in clinical patient assessment
but only in certain cases. This reinforces the need for novel biomarkers [32].
In addition to these diagnostic criteria, others are included for VaD diagnosis. One of these is the
Ischemic Scale - first introduced by Hachinski and subsequently modified by Rosen. Therein,
several clinical symptoms are considered, such as nocturnal confusion, depression, evidence of
atherosclerosis and history or presence of hypertension or strokes. Each of these features is as-
signed one or two points which are then tallied to give the ischemic score. These values are used
to discriminate between AD, multi-infarct dementia (a kind of VaD) and a mixed form of both
(mixed dementia) as summarized in Table 1.2. However, this scale has disadvantages. It does
not consider the locations of the vascular lesions nor the type of cognitive syndrome. Therefore,
the following alternative list of criteria was developed [167]:
• The DSM (Diagnostic and Statistical Manual of Mental Disorders) criteria (DSM-III,
DSM-III-R, and DSM-IV)
• ICD-10 (International Statistical Classification of Diseases) criteria with six subtypes of
VaD
• ADDTC (The State of California Alzheimer’s Disease Diagnostic and Treatment Centers)
criteria
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• NINDS-AIREN (National Institute of Neurological Disorders and Stroke - Association
Internationale pour la Recherche et l’Enseignement en Neurosciences) criteria
These classification strategies differ in several aspects and are variably strict. For example, the
number of exclusion criteria differs, some diagnostic criteria exclude vascular brain lesions that,
although typical for VaD, are still controversial. Each list also provides a different assessment of
subtypes, in some sets of criteria mixed dementia is clearly defined, but in others it is not [167]. In
another review, Wiederkehr et al. conclude from the results of clinical studies that there is a large
degree of variability regarding sensitivities and specificities, incidence, and prevalence rates and
a lack of discrimination between VaD and mixed dementia. They suggest several improvements,
such as the use of the ADDTC criteria for clinical settings, while reserving the NINDS-AIREN
criteria for research only [166]. Pohjasvaara et al. studied 107 patients comparing the different
sets of criteria. The conclusion of this study was that comparability of the features is difficult.
The authors suggested that new criteria should be tested in longitudinal studies [113]. Hence,
there is need for improved methods of diagnosis.
Table 1.2: Dementia classification according to Ischemic Scales [167]
category of dementia Hachinski Ischemic score Ischemic score of Rosen
Alzheimer’s Disease ≤4 ≤2
mixed dementia 5-6 3
multi-infarct dementia ≥7 4-10
Some criteria applied for VaD are summated in the Ischemic Scale, which was first
introduced by Hachinski and then modified by Rosen. Therein, several clinical symptoms
are considered, e.g. nocturnal confusion, depression, evidence of atherosclerosis and his-
tory or presence of hypertension or strokes, etc. Each of these features is given one or two
points which are then tailled as the ischemic score. These values are used to discriminate
between AD, multi-infarct dementia (a kind of VaD) and a mixed form of both.
1.1.5 The Folstein Test and the MMSE value
In 1975, Folstein et al. introduced the mini-mental state examination (MMSE) consisting of
a 30-point questionnaire designed to screen for dementia as well as to estimate the severity of
cognitive impairment. In the span of approximately five to ten minutes, the MMSE tests various
mental functions including arithmetic, memory and orientation. One advantage of this test is
that it is quick to administer, which is important given that elderly people, particularly those
suffering from a condition, cooperate well only for a short period of time [45]. The maximum
score is 30 and the lower the value, the unhealthier a participant is. A method for estimating the
rate of progression in AD was proposed by Doody et al. in 2001, after studying AD patients in
a longitudinal study. A decrease of five points in the MMSE per year was considered as rapidly
progressing AD. These patients developed clinically-detected symptoms significantly earlier than
patients that had an initial score that was lower or equal, but decreased by two or fewer points
per year. These patients were labelled as slow progressors, while average progressors showed a
loss between two and 4.9 points per year [31].
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1.1.6 Treatments for AD
Currently, there is no cure for AD. Existing therapies are only able to extend functioning by six
to 18 months, if at all [70]. As of 2008, five drugs with approval from the U.S. Food and Drug
Administration were available. Tacrine (brand name Cognex R©), donepezil (Aricept R©), galan-
tamine (Razadyne R©) and rivastigmine (Exelon R©) are cholinesterase inhibitors. They are now
rarely prescribed as they have shown minimal efficacy in improving cognitive function, while in
the case of tacrine adverse side effects, such as liver toxicity, have been reported. These drugs
are designed to prevent a decrease in the acetylcholine neurotransmitter at synaptic junctions.
This decrease has been observed in the brains of AD patients [70]. Memantine (Namenda R©)
is an n-methyl-d-aspartate-receptor antagonist. When glutamate, another brain neurotransmit-
ter, binds to this receptor calcium entry and nerve cell stimulation occurs - this is required for
learning and the formation of memory. High levels of calcium due to overstimulation can lead
to functional disruption and cell death. Pharmacological blocking of the n-methyl-d-aspartate
receptors can reduce these negative effects. Memantin has been shown to result in improved
cognitive functioning, behaviour and the performance of daily living activities in patients with
moderate to severe AD [70]. As these drugs are only able to slow disease progression, if they
even do that, other strategies such as Aβ-targeted immunotherapy have been considered. Wis-
niewiski and Konietzko describe six possible mechanisms of Aβ-directed immunomodulation.
These approaches are not mutually exclusive and their effectiveness might differ depending on
the stage of disease [170]. The six are as follows:
• Direct disassembly of plaques can be achieved by conformation-selective antibodies.
• Antibodies capable of activating microglial cells so that they dissolve plaques by Fc medi-
ated phagocytosis.
• Microglia can also be activated via Fc-independent pathways, as suggested by experiments
with mice and passive immunisation.
• Creation of a peripheral amyloid sink with the clearance of circulating amyloid may reduce
amyloid burden in the brain.
• A humoral response resulting in IgM-mediated plaque-hydrolysis may be created with
amyloid beta peptides as adjuvants.
• Antibodies may be capable of neutralising oligomer toxicity.
After promising studies in mice, a trial of the AN1792 vaccine was initiated. This vaccine con-
sisted of preaggregated Aβ-42 in an adjuvant. In the phase I trial, 53% of the treated patients
developed a humoral response against amyloid beta. The phase II trial was terminated when 5%
of the patients showed signs of menigoencephalitis. Postmortem autopsies of selected patients
revealed effective amyloid beta clearance after treatment with the vaccine, but this was not as-
sociated with a significant improvement in cognitive function or prolonged survival. Because
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tau pathology remained in these patients, Wisniewski and Konietzko suggest that active vaccina-
tion needs to begin earlier - before AD-related pathology with neurofibrillary tangels develops
[170, 154]. One possible explanation for the observed toxicity in the phase II trial is a strong Th1
response, which led to increased inflammation followed by amyloid beta-induced apoptosis of
Th1 cells. This was modelled with the in vitro stimulation of PBMCs from the trial participants
in which production of IL-2 and interferon gamma was observed. In order to prevent the induc-
tion of a Th1 response, it has been suggested that IgM be applied, which, due to its relatively
large size compared to other immunoglobulins, may be less likely to enter the brain, where it can
activate T-cells. This strategy relies on the creation of a peripheral Aβ sink and is T-cell inde-
pendent. Studies using passive immunisation of monoclonal amyloid beta antibodies were tested
in clinical trials, but were not continued, because no clinical benefit was observed. Yet another
approach sought to exploit the innate immune system by CpG oligodeoxynucleotides adminis-
tration. CpG binds and activates Toll-like receptors on microglia via T- and B-cell independent
pathways [170].
Considering the results of all trials performed to date, it must be concluded that none has resulted
in a therapy able to cure AD. Instead, disease progression could at best be delayed only by several
months [70]. The mechanism for this beneficial, if marginal effect has been suggested to be via
a reduction of inflammation. Reale et al. demonstrated that treatment with acetylcholinesterase
inhibitors was followed by reduced expression of pro-inflammatory cytokines such as TNFα,
IL-1β and IL-6 by peripheral blood cells of AD patients. These cytokines play a role in amyloid
beta metabolism as they increase APP levels. One proposed role of acetylcholine is that of an im-
munomodulator which facilitates a Th2 response [120]. Other studies demonstrated that IL-4 can
activate microglia and block the increase of pro-inflammatory cytokines and toxic nitric oxide
in vitro [120]. Suggestions for future treatments include modulation of immune cell migration
in order to reduce their brain entry. This process contributes to inflammation and supports the
trafficking of cells with Aβ phagocytic ability (Fig. 4.1).
1.2 Immune signatures of healthy individuals and AD patients
1.2.1 T-cell heterogeneity
T-cell differentiation following antigen exposure
Pathogens which enter the body encounter antigen presenting cells (APCs), such as dendritic
cells (DCs), macrophages or B-cells. Receptors, for example toll-like receptors (TLRs) located
on the surface of APCs, recognise foreign structures such as lipopolysaccharide on bacterial cell
walls, or nucleic acids. They may also bind and present self components, such as Aβ under
certain conditions. This recognition leads to the migration of APCs to the lymph nodes. After
development in the thymus, T-cells circulate between the bloodstream and peripheral lymphoid
organs as naïve T-cells. Cell adhesion molecules mediate the initial interaction between APCs
and naïve T-cells in the lymph nodes. The T-cells then may become activated by interaction with
antigen and cell surface and soluble mediators from the APC, and then migrate into infected
tissues. Foreign antigens are presented by APCs on major histocompatibility complexes (MHCs).
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The MHC molecules on APCs bind to the T-cell receptor and a co-receptor (either CD4 or CD8).
This interaction initiates a signalling cascade which leads to T-cell activation. For this, additional
interactions are necessary, involving the binding of co-receptors to their ligands on APCs (e.g.
CD28 on T-cells to B7, CD27 to CD70 or CD40L to CD40). One function of these co-receptors
is the maintenance of T-cell survival by inhibiting apoptosis pathways and stimulating secretion
of the IL-2 growth factor. Once T-cells differentiate into effector cells, co-stimulation is not
longer required. CD8+ T-cells can differentiate into cytotoxic lymphocytes with the ability to kill
infected target cells. In contrast, CD4+ T-cells can develop different effector functions. CD4+
T-cells control infected macrophages, stimulate neutrophils to act against extracellular bacteria
and fungi, promote eosinophil and mast cell responses towards parasitic infections and stimulate
B-cells to produce antibodies. In addition, CD4+ T-cell subsets referred to as regulatory T-cells
(Treg) can suppress T-cell responses (Section 1.2.3) thereby limiting autoimmune responses.
T-cell phenotype models
After activation, T-cells differentiate into memory and effector cells. These are characterised
by the presence of several marker proteins including CD27 and CD28. Sallusto et al. pro-
posed a T-cell phenotype model based on the chemokine receptor CCR7 or alternatively the
homing receptor CD62L, together with the phosphatase CD45RA. In this model T-cells are di-
vided into naïve cells (CCR7+CD45RA+), central memory (CM) (CCR7+CD45RA-), effector
memory (EM) (CCR7-CD45RA-) and effector memory cells re-expressing CD45RA (TEMRA),
which represent the more antigen experienced cells (CCR7-CD45RA+) (Fig. 1.4) [130]. Fol-
lowing priming by antigen, CCR7+ memory cells migrate into secondary lymphoid organs and
stimulate other immune cells, such as B-cells and DCs. In contrast, CCR7- T-cells predominately
mediate inflammation or defend against invasive pathogens in peripheral tissues, for example via
the production of cytokines such as IL-4, IL-5 or IFNγ or by the release of perforin. In co-culture
experiments CCR7+ memory T-cells were more potent activators of DCs than CCR7+ naïve T-
cells, which stimulated them less effectively in terms of IL-12 production [130]. One explanation
suggested by Romero et al. for this apparent division of labour is the different lifetimes of these
cell types. CM and a subset of EM T-cells expressed high levels of CD127, a molecule necessary
for the survival of memory T-cells. This is the likely reason why CM cells are more effective
against systemic infections [126]. Furthermore, Romero et al. presented an expanded model
suggesting that the progression of differentiation is naïve > CM > EM > TEMRA, with several
stages further discriminated by their CD27 and CD28 expression. This sequence correlated with
progressively reduced telomere lengths and higher granzyme B and perforin expression at each
CD8+ T-cell differentiation stage.
Additional T-cell characterisation markers
Additional markers of T-cell phenotypes have been reviewed many times, e.g. by Appay et al.
[6]. These authors defined naïve T-cells as CD45RA+CCR7+ CD27+CD28+ and suggested dif-
ferent T-cell differentiation phases following antigen contact where these markers are different
to those proposed in other models. The authors describe the expression of several other mar-
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Naïve 
- Mostly CD27+ and CD28+ 
apoptosis protection 
- Longer telomeres 
- Mainly CD95- 
- CD45RO- 
- CD62L+ 
- CXCR4high CXCR1- 
TEMRA 
T-effector re- 
expressing CD45RA 
- ↑ KLRG-1 and ↑ CD57 (markers 
of replicative senescence) 
- Have shorter telomeres 
- Mostly CD27-CD28- 
- Contain anti-CMV specific cells 
- After stimulation: low IFNγ
and low IL-2 production 
- CD11b+ CXCR1high
EM 
Effector memory 
- Increased granzyme A+B 
and perforin expression 
- High expression of PD-1 
- CCR5+ CCR6+ 
- After stimulation: TNF 
and high IFNγ production 
CM 
Central memory 
- Express high levels of 
CD127 for survival 
- After stimulation: high 
IL-2 production 
promotion of clonal 
expansion 
CD45RA
CCR7
Figure 1.4: T-cell differentiation model
T-cells classified according to Sallusto et al. including naïve, central memory, effector memory and
effector memory re-expressing CD45RA cells [130]. Characteristics such as surface marker expression,
cytokine and chemokine receptor profile and telomere length of each phenotype are listed.
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kers at each stage. While losing CD45RA expression, expression of the CD45RO isoform is
increased. Another marker which is absent in naïve cells but increases during differentiation
is CD57. This protein is considered by some to be a marker for replicative senescence and
immune deficiency. CD4+ CD45RO+CD57+ cells possess a tendency for increased apoptosis
while CD4+CD57+ cells do not support immunoglobulin production by B-cells [44]. For CD8+
T-cells, other markers such as the coinhibitory receptor KLRG1 (Killer cell lectin-like receptor
subfamily G member 1) have been utilised. The expression of this protein increases in memory
T-cells. Another marker used to define T-cell subsets is the Fas receptor CD95 (APO1/FASR),
enhanced expression of which might be indicative of apoptosis. CD95 is expressed on memory
cells and its expression, either alone or together with CD45RO, can be considered a sign for
late-stage differentiation or immunosenescence [114]. Some marker proteins, such as the T-cell
regulator PD-1, are absent in naïve cells, but are expressed during differentiation, and are down-
regulated again in late-stage cells [6].
1.2.2 T-cell phenotypes in healthy elderly and AD patients
Age-related accumulation of late-differentiated T-cells
Ageing is associated with changes in the immune system, for example greater susceptibility to
infectious diseases with increasing age. Due to age-related thymic involution, generation of
naïve T-cells is decreased in the elderly. A more detailed description using the model previously
described indicates a shift from naïve to late-differentiated TEMRA cells within the CD8+ T-cell
subset, with less pronounced changes in CD4+ T-cells, where percentages of central memory,
but not TEMRA cells are higher in the elderly. CD4+ T-cell differentiation with increasing age
was not associated with shifts in naïve, CM, EM and TEMRA stages, but are more apparent
when describing these phenotypes using additional markers such as CD27, CD28, CD57 and
KLRG1 [71]. Although frequencies of the CD4+ T-cell sub-populations are changed with age,
functionality in terms of proliferation and cytokine production assays have been reported not to
differ [74]. An age-related decrease in naïve CD8+ T-cells and an increase in effector memory
T-cells were also observed by Yan et al., who also investigated the influence of gender. This
commonly observed age-related increase in the frequency of CD3+CD45RA-CCR7- effector
memory cells in peripheral blood leukocytes of healthy individuals occurred earlier in men than
in women [175].) It has been suggested that although these observations are associated with age,
they may be in fact be caused by chronic antigenic stress associated with viral infection [109].
Antigen-experienced T-cells accumulate more in AD-patients than in healthy elderly
Amyloid beta may be able to act as an immune stimulus in AD, as Monsonego and colleagues
demonstrated. There may be an increased T-cell reactivity to Aβ-42 in the elderly and AD
patients [103]. Tan et al. proposed that T-cell differentiation, as indicated by a switch from
CD45RA to CD45RO expression, may be a marker for AD [149]. Togo et al. demonstrated
that memory cells were present in the brains of AD patients. In their study, they also assessed
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the expression of CD45 isoforms, and reported that CD45RA+ cells were rarely found in the
brains of AD patients, whereas CD45RO, a marker for memory T-cells, was highly expressed on
brain T-cells. In the hippocampus, the authors could detect a greater frequency of CD3+CD27-
than CD3+CD27+ T-cells [151]. Further signs of T-cell differentiation in AD were reported by
Pellicanó et al. who showed that stimulation of PBMCs from AD patients with Aβ-42 lead to an
increased production of, amongst other cytokines, IFN-γ, but not IL-2 [110]. It has been reported
that IL-2 expression by naïve cells is decreased as they differentiate [106]. Other studies report
that "shorter telomeres may indicate dementia status in older individuals with Down syndrome"
[67] and that "telomere shortening in T cells correlates with Alzheimer’s disease status" [107].
Even if a longitudinal study was able to demonstrate that "telomere length is not predictive of
dementia or MCI conversion in the oldest old" [177], the majority of published literature sug-
gests that shorter telomere length is indicative of antigen experienced T-cells in AD patients, as
telomere length is negatively correlated with T-cell differentiation [6]. A discrimination between
AD-associated and CMV-associated effects on the immune system was not present in these pub-
lications. For this reason, some of the work described in this thesis aimed at discriminating
between CMV+ and CMV- AD patients and healthy elderly.
1.2.3 Treg phenotypes and their association with ageing and dementia
Regulatory T-cells (Tregs) are important for immune tolerance. They control the immune system
by suppressing activation, proliferation and effector functions of several immune cell types. Ac-
cordingly, they could be beneficial by reducing strong inflammatory responses in diseases such as
AD. A hallmark of Tregs is their expression of the transcription factor forkhead box P3 (Foxp3)
and high levels of the IL-2 receptor α-chain (CD25). Increased expression of these surface
proteins is associated with greater suppressive function of Tregs and their reduced proliferative
capacity. Slightly different from other T-cells, this shift from a resting to an activated effector
state is accompanied by a loss of the naïve phenotype (CD45RA+) and elevated expression of
CD28, CD95 and CD45RO [128]. A list of additional Treg surface marker proteins and their
association with differentiation states are provided in Table 1.3. Tregs are typically produced in
the thymus, but they can also derive from naïve CD4+ T-cells following stimulation of the TCR
(T-cell receptor) in the presence of TGFβ, as in vitro experiments have demonstrated, although
it has not yet been confirmed if these cells occur in vivo [128]. As with other T-cells, Treg phe-
notype changes are associated with age. Despite the presence of activated Tregs in fetal tissues,
in cord blood, predominately naïve CD45RA+Foxp3low Tregs are found, while in adults and the
elderly a greater frequency of effector Tregs is observed. Age associated thymic involution leads
to lower production, but not a total absence of T-cells, including Tregs [128]. Naïve and differ-
entiated Tregs are distributed differently in different tissues. The former express CXCR4 and
are found mainly in the bone marrow, while CD45RO+ Tregs express skin homing chemokine
receptors as CCR4. That the proportion of Tregs in the skin is increased with age might help to
account for the reduced immune responses observed in the elderly [16].
In diseases such as AD, several factors may influence T-cell function and differentiation.
Tregs can suppress other T-cells, but not necessarily completely. When T-cells are strongly ac-
17
tivated, they become resistant to Treg suppression [128]. Higher levels of T-cell activation and
later differentiation phenotypes are found in CD4+ T-cells in AD patients [111]. During in-
flammation, Tregs secrete the pro-inflammatory cytokine IL-17. The suppressive capacity of
IL-17+Foxp3+ Tregs is high when there is low TCR activation, but the greater the TCR signal,
the lower the Treg efficacy [128]. One scenario of strong TCR-activation is an environment con-
sisting of high levels of pro-inflammatory cytokines, such as in AD. Regarding the frequencies of
Tregs and CD25+ activated T-cells, disparate observations have been reported. In a pilot study,
CD25 expression was reported to be downregulated in T-cells of Canadian patients with mild
AD [77]. In contrast, an opposite relationship was found in a Sicilian cohort of AD patients.
In order to characterise CD4+ Tregs in more detail, Foxp3 and CD127 were included as Treg
markers in the latter study. No differences between AD patients and controls were found with
respect to CD25+CD127lowFoxp3+ CD4+ T-cells [111]. In order to assess functionality, Sare-
sella et al. measured the intracellular and cell surface expression of programmed death receptor 1
(PD-1). CD4+CD25highFoxp3+ cells, especially those also PD-1-positive, were found in higher
percentages in patients with MCI or severe AD, compared to healthy controls. On the other
hand, PD-1-negative Tregs - those Tregs with the strongest suppressive capacity - were only in-
creased in MCI patients. When T-cells were stimulated with Aβ in MCI patients, proliferation
was reduced and Treg-mediated suppression was more efficient in comparison with AD patients
and healthy controls. These investigators place their findings in the context of the systemic in-
flammation present in AD and suggest "a possible beneficial role of these cells in MCI that is
lost in patients with fullblown AD" [132]. In another study, the same investigators demonstrated
an impairment of the PD-L1/PD1 pathway in AD and MCI, which in turn influenced cytokine
production and apoptosis of immune cells [133].
In addition to CD4+ Tregs, CD8+ regulatory T-cells are also present. These cells are characterised
by the tissue specific homing receptor CD103. CD8+ Tregs specifically target activated T-cells
by recognising peptides either presented by the TCR or derived from heat shock proteins. Among
their functions is the ability to induce cell death, secrete immune suppressive cytokines and in-
hibit cell functions via cell-cell contact and signalling pathways [143]. Little is known about
their presence and function in AD.
1.2.4 B-cell phenotypes
As with T-cells, B-cell phenotypes can be categorised according to the expression of certain
surface proteins. One rudimentary model utilises CD27 and Immunoglobulin D (IgD). IgD is ex-
pressed in place of IgM on immature B-cells during development and its expression is associated
with early stages of B-cell activation. One function of IgD is to stimulate basophils and mast
cells in the defence of microbes, resulting in a pro-inflammatory environment [24]. Throughout
differentiation stages the following progression of B cell phenotypes has been suggested: CD27-
IgD+, CD27+IgD+, CD27+IgD- and finally CD27-IgD- may represent the most differentiated
phenotype. B-cell functions are impaired in the elderly. They show a reduced response to novel
antigens, but also have lower levels of memory cells (IgG+IgD-CD27-) which may be exhausted
[21, 20]. A shift from early- to late-differentiated phenotypes is considered to be associated
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Table 1.3: Characteristic markers of Treg differentiation according to Sakaguchi et al. [128]
Marker Naïve Activated Memory Activated converted Naïve Effector Terminal effector
cell T-cell T-cell T-cell Treg-like Treg Treg Treg
Foxp3 - low - + low hi hi
CD45RA + - - - + - -
CD45RO - + + + - + +
CD62L + -
CD95 - + + -
CD127 + -/low + -/+ -/low low -
CD25 - hi + + hi hi hi
HLA-
DR
- + - - +
CD69 +
CTLA4 - + + + - + +
ICOS -/+ -/+ -/+ -/+
Ki67 + +
IL-2 +
IL-10 -/+
IL-17 -/+
All T-cell lineages are produced in the thymus as naïve cells and migrate to the peripheral tissues and organs. After ac-
tivation they differentiate into conventional T-cells and Tregs. In addition naïve T-cells can differentiate into converted
Treg-like cells with similar marker expression as conventional Tregs and possibly further to effector Tregs.
with B-cell senescence, as with T-cells. Another factor to be considered is the total number of
B-cells. In addition to changes in T-cell numbers, CD19+ B-cells have been shown to be di-
minished in AD patients compared to age-matched controls as reviewed by Rezai-Zadeh et al.
[123]. Thus, for these reasons and because disease-driven differences in the frequencies of T-cell
sub-populations can be observed in AD patients, one aim of the work presented in this thesis was
to investigate the influence of AD on B-cells.
1.2.5 Systemic inflammation in AD
As discussed at length above, the major pathological hallmark of AD is Aβ accumulation form-
ing plaques within the brain. Molecules of this type are in principle cleared by the innate immune
system, but studies by Fiala et al. suggest that Aβ phagocytosis by macrophages is deficient in
AD patients. One proposed compensatory mechanism for this loss of function is further activa-
tion of macrophages and microglia and higher levels of pro-inflammatory cytokines. This inflam-
matory state may result in side effects such as tissue damage and neurodegeneration [38]. This
inflammation is not limited to the brain, but occurs systemically, as shown by other investigators
with genomic and proteomic analysis, as reviewed by Pellicanó et al. [110]. In addition to mono-
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cytes and macrophages, other types of immune cells play an important role in AD. Rezai-Zadeh
et al. provide an overview of this emerging field and suggest blood lymphocytes as noninvasive
biomarkers and therapeutic targets [123]. The work presented in this thesis was undertaken to
increase our understanding of the role of peripheral immune cells and its contribution to AD
pathology in more detail by characterising immune cells in AD patients and comparing these to
healthy individuals.
1.2.6 Plasma and serum cytokine levels in the context of inflammation in
AD
Thus in AD an inflammatory state is typically present in the brain. This state may have both
beneficial and detrimental consequences [13]. In the AD-affected brain, increased levels of
several pro-inflammatory cytokines and chemokines (IL-1β, IL-6, TNF, TGF-β and IL-8) have
been reported to occur in proximity damaged regions. One source of inflammation are microglia
which are activated by fibrillar Aβ or by monocyte chemoattractant protein-1 (MCP-1) which is
increased in association with senile plaques. These cytokines can decrease phagocytic activities
of microglia which may be restored by anti-inflammatory drugs. In addition pro-inflammatory
cytokines has been shown to accelerate tau pathology and NFT formation. For example, IL-1 or
IL-6 can enhance kinase activity to hyperphosphorylate tau [13]. AD associated inflammation
is not limited to the brain, but also occurs in the periphery. A number of studies have been per-
formed to measure cytokine and chemokine levels in plasma and serum, several of which have
been proposed as biomarkers for AD. In their critical review Lee et al. outline the hypothesis
that peripheral molecules activate neurons, astrocytes and microglia to secrete pro-inflammatory
cytokines and to enhance APP synthesis. In turn, Aβ can trigger further cytokine production
and induce neurotoxicity. CSF is one source of information regarding inflammation states and
Aβ levels, but given that it is not routinely collected, blood biomarkers are likely be of more of
value. One of the main advantages of blood biomarkers is that blood collection is inexpensive,
quick and minimally invasive. Brain proteins and metabolites that pass through the blood-brain
barrier (BBB) into the plasma become "markedly diluted into a biochemically complex medium"
[78]. Therefore, many molecules are present in concentrations so low that they are below current
methods of detection. One example given in the review by Lee et al. is an IL-1β ELISA with
a detection limit of 10 pg/ml. Many investigators nevertheless publish data using these assays,
producing potentially controversial results. Multiplex systems with higher levels of sensitivity
are becoming more widespread. These have the advantage of measuring several cytokines si-
multaneously. As indicated by Lee et al., information regarding the level of multiple cytokines
measured in a single assay is more likely to be trustworthy [78].
In AD, the levels of certain cytokines, such as IL-12, IL-16 and IL-18, differ according to the
disease stage. Of note is that IL-18 induces Th1 cytokine production and IL-16 is a CD4+ T-cell
growth factor. In patients with mild and moderate AD, elevated plasma levels of these cytokines
have been observed, whereas lower levels were found in patients with severe AD. There are
studies that indicate elevated TNF concentrations in the serum of AD patients. TNF, amongst
others, is produced by activated microglia. Given that the BBB is altered in AD, these cytokines
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might be able to enter the serum. In addition to these alterations, lower serum concentrations of
neuroprotective factors have been observed in AD patients. The concentration of factors such
as insulin-like growth factor is negatively correlated with TNF levels. TNF itself plays a role in
neuroprotection and is implicated in apoptosis. Considering the body of literature, it is not possi-
ble to draw conclusions. The studies investigating other cytokines are also inconclusive. TGF-β
is claimed to stimulate astrocytes to produce Aβ peptides, in addition to inducing Aβ clearance
by microglia. Not only have discrepancies in the blood level of cytokines been reported, but also
of those in the CSF [78].
1.3 CMV, dementia and the immune system
Cytomegalovirus (CMV) is a herpesvirus transmitted via bodily fluids which can remain latent
within the body. The incidence of infection increases with age and varies across countries, but is
strongly related to living standards. CMV acts as a stimulus to immune cells. As discussed above
one possible stimulus causing AD-associated immune alterations is Aβ [110], which shares the
feature of affecting the BBB with CMV - Aβ directly [73] and CMV via induction of T-cell
effectors [155]. Both CMV-seropositive individuals and AD patients typically have higher per-
centages of late-differentiated CD4+ and CD8+ T-cells. To investigate this in more detail, both of
these potential drivers of immunosenescence were analysed in the work presented in this thesis.
In order to discriminate between CMV- and AD-related effects on the immune system, CMV
status in healthy controls and AD patients was assessed. The hypothesis was that CMV and AD
process act in concert to promote disease. Supporting this is the observation that high anti-CMV
IgG titres are considered a risk factor for AD (Table 1.1 above). This is associated with an ex-
hausted immune system which is more susceptible to other diseases. Several comorbidities in the
elderly share inflammation as a feature. Considering inflammation as a driving force for disease
development and progression, patients with pre-existing diseases such as those listed in Table 1.1
may be at risk for developing AD.
1.3.1 Association between CMV infection and T-cell differentiation
CMV represents a chronic stimulus for the immune system. As Pourgheysari et al. demonstrated,
the percentage of CMV-specific CD4+ T-cells increases with age. The authors of this study de-
scribe a T-cell phenotype which they suggest is associated with immunosenescence. The authors
observed higher CD57 expression concomitantly with decreased CD27 and CD28 expression
in CMV+ people who were otherwise considered a healthy elderly cohort. This therefore sug-
gested that CMV is capable of altering immune functions [115]. Further characterisation of these
T-cells showed that in CMV+ subjects the frequencies of late-differentiated CD4+ cells (CD27-
CD45RA- and CD27-CD45RA+) were higher than in CMV-seronegative people, in whom some
investigators fail to find them at all. These CD27-CD45RA+ CD4+ T-cells produce granzyme B
and perforin, two markers of T-cell-mediated cytotoxicity [82]. A correlation between the fre-
quency of CD27-CD45RA+ T-cells and CMV infection status was demonstrated for the CD8+
T-cell subset [75]. Weinberger et al. discriminated between age- and CMV-related differences
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in the immune system analysing T-cell phenotypes in a healthy elderly population. They re-
ported lower frequencies of naïve (CD45RA+CD28+) and memory (CD45RA-CD28+) T-cells,
while higher levels of effector (CD28-) CD4+ and CD8+ T-cells in CMV+ compared to CMV-
elderly individuals were observed. Within the CMV-negative cohort, these authors observed
negative correlations for the CD8+ but not the CD4+ T-cell subset, while correlations within
CMV+ elderly individuals were detected in both CD4+ and CD8 T-cells. From these experi-
ments the authors concluded that "in the elderly different T-cell subsets compete for space within
the CD8+, but not the CD4+ T-cell population" and that differences in CD4+ T-cells in CMV+
elderly are virus induced, as they differed from the age-related alterations observed in the CMV-
cohort [161]. Higher frequencies of late-differentiated CD4+ and CD8+ T-cells were seen in
CMV-seronegative, but not HSV-infected, donors pointing out the special role of CMV [30].
1.3.2 Herpesviruses and AD
Age is the most significant risk factor for AD. The risk of developing AD increases with age,
while CMV seropositivity is also observed to increase with age, but obviously not all CMV+
elderly individuals suffer from AD. In elderly individuals, the majority are CMV-seropositive.
Amyloid plaques and neurofibrillary tangles occur not only in AD patients, but also healthy el-
derly individuals; but hence there still might be some connection. Some authors have postulated
that the neurofibrillary tangles are an ageing marker. These tangles may be influenced by Aβ
which in turns acts to accelerate the ageing process. Is CMV another modulator of ageing and
AD? Are CMV+ individuals more susceptible to AD? Given the fact that CMV affects the im-
mune system, it may contribute to inflammation that is characteristic in AD patients, potentially
increasing the risk of developing AD. Given that CMV specific T-cells are present in CMV-
seropositive individuals, the question is then posed; are there Aβ specific T-cells present in AD
patients as well?
One of the small number of genes that has been associated with AD risk is the ApoE (Apolipopro-
tein E) gene. The ApoE protein plays an important role in lipoprotein catabolism. ApoE pro-
motes Aβ degradation. Within the ApoE isoforms the E4 isoform is less efficient than the E3 and
E2 isoforms and as a consequence is associated with greater Aβ deposition. The E4 allele of the
AopE gene is therefore associated with a higher risk of AD development [68, 42]. This allele of
the ApoE gene correlates with the expression of the apoptosis-related T-cell marker CD95 [87].
Lin et al. have shown that when viewed in combination, the AopE-E4 allele and the presence of
herpes simplex virus 1 in the brain may be a major risk factor for developing AD. Other herpes
viruses are capable of entering the brain and potentially contributing to disease. For example
HSV2 increases the risk of developing a form of AD and HHV6 correlates in a small number
of cases with mental retardation. Whether HHV6 is the cause or the consequence of the disease
has so far not been determined [83]. In AD, the area of the brain that is most compromised by
the disease is the frontotemporal region. This area is also the region that is commonly invaded
by herpesviruses. Also CMV can be present in the brains of healthy and AD-affected elderly
[83]. In another study, Lin et al. indicated that CMV, but not HSV1 or HHV6 is more prevalent
in VaD patients than healthy controls [84]. In longitudinal studies, higher levels of antibodies
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against CMV correlated with more rapid cognitive decline [1, 146]. But in the NONA longitu-
dinal study performed in an elderly Swedish population, CMV seropositivity did not correlate
with cognitive impairment, nor did it correlate with the inflammatory marker IL-6 (detected in
plasma), although both factors separately predicted 2- 4- and 6-year mortality [168, 109].
1.4 Brain infiltration by peripheral immune cells along a che-
mokine gradient in AD
Immune cells must first develop in distinct tissues before they are able to execute their func-
tion. Precursor T-cells are produced in the bone marrow. Following maturation in the thymus
they migrate to the periphery. At sites of development, injury or inflammation small proteins
(8–14 kDa), referred to as chemoattractant cytokines, or chemokines, are secreted. Certain cell
types are attracted to these proteins, and they modulate cell migration along concentration gra-
dients. Chemokines may also play roles in cell activation, proliferation, apoptosis and cytokine
secretion. They interact with G protein-coupled seven-transmembrane domain receptors. Mi-
croglia, astrocytes, PBMCs and monocytes have been reported to show increased production of
chemokines after stimulation with Aβ in vitro [40, 119]. In one study, microglia were obtained
from the brains of AD patients. Aβ levels were observed to be associated with levels of CCL2,
CCL3 and CXCL8 chemokines in vitro. Regarding the role of chemokine receptors in AD, Lee et
al. propose a suppressive role for Aβ by CCR5. These authors showed that mice lacking CCR5
developed Aβ deposits, increased expression of CCR2, more activated astrocytes, higher levels
of β-secretase and impaired memory [78]. Another study demonstrated that Aβ accumulated
earlier in CCR2-deficient AD mice than in control mice. The following mechanism was in-
voked to explain these results; "Ccr2-dependent microglial accumulation plays a protective role
in the early stages of Alzheimer’s disease by promoting Abeta clearance" [34]. The brain of AD
patients is infiltrated by peripheral immune cells through an altered BBB. Several factors such
as Aβ, tau and others affect the permeability of the BBB (see list below). With regard to the sys-
temic inflammation observed in AD, it has been reported that brain cells such as astrocytes and
microglia become activated and secrete cytokines and chemokines. When these cytokines and
chemokines are secreted into the bloodstream they form a gradient which leads to the attraction
of peripheral leukocytes via chemotaxis [40].
Factors which affect the BBB in AD
• The expression of adhesion molecules on endothelial cells was shown to be enhanced in
inflammatory diseases, such as AD. [3, 4, 162]
• The endothelial low-density lipoprotein receptor-related protein 1 (LRP-1) and P-glyco-
protein are responsible for the export of small molecules, whereas Aβ influx transport
occurs via the receptor for advanced glycation end products. The expression of these
markers correlated with age-related accumulation of brain Aβ. [28, 140, 141]
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Figure 1.5: CCR expression on different immune cell subsets
Chemokine receptors expressed on different subsets of leukocytes and endothelial cells as currently
reported [130, 155, 129, 19, 23, 51, 52, 56, 62, 139].
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• Aβ led to higher expression of MIP-1α (macrophage inflammatory protein-1α) on the pe-
ripheral T-cells of AD patients. This induced the expression of CCR5 on brain endothelial
cells. MIP-1α and CCR5 interactions facilitated brain infiltration of T-cells. [81, 93]
• Aβ upregulated CXCR2 expression in rats, which resulted in enhanced T-cell mobility
through the BBB. Inhibition of the CXCR2 ligand IL-8 in human brain microvascular
endothelial cells by an anti-TNF antibody led to reduced T-cell migration. [85]
• Infarctions that are regularly found in the brains of AD patients damage the BBB. They
led to a "complication of hypoxic and ischemic episodes". Additionally, anatomical and
functional alterations of cerebral microvessels and endothelial cells were reported. [40]
• Aβ increased microvascular permeability. [73]
• In rats, basolateral treatment of the BBB with truncated tau led to a very strong polarity-
dependent effect. A significant decrease of transendothelial electrical resistance and in-
crease of endothelial permeability resulted. In addition Kovac et al. reported cytotoxic
effects on astrocyte-microglia. In addition to tau, TNF and the chemokine MCP-1 also
play a role. [73]
• "CMV-induced effector T-cells cause endothelial cell damage." [155]
• "Cytomegalovirus directly enhances MHC class I and intercellular adhesion molecule-
1 (ICAM-1) expression on cultured proximal tubular epithelial cells." ICAM also plays
an essential role in B-cell migration through the BBB. Although not definitively demon-
strated, CMV may affect the BBB. [156, 4]
• Damage to the tight junctions in the BBB has been shown to be caused by proteases and
gelatinases from neutrophils recruited by MMP-3. The activation of MMP-3 is induced by
the production of IL-17 - a cytokine secreted during inflammatory states. [157, 158]
• CSF and plasma levels of the inflammatory mediator soluble CD40L (sCD40L) are el-
evated in cognitively impaired, HIV infected individuals and its receptor, CD40, is ex-
pressed on brain endothelial cells. The HIV transactivator of transcription (Tat) can induce
activation of platelets which secrete sCD40L. CD40-CD40L interactions led to increased
inflammation and production of adhesion molecules in endothelial cells. In addition levels
of reactive oxygen species were enhanced, which promoted chemokine secretion. sCD40L
decreases ATP levels - required for maintenance of tight junction permeability in the BBB.
In mice, Tat has also been shown to be associated with increases in inflammatory monocyte
subsets with adherent potential to BBB cells. These results were supported by migration
experiments using an in vitro BBB model. [27, 118]
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1.5 Rationale of the present study
The brain of AD patients is infiltrated by immune cells [151]. T-cells and other immune cell
types are able to migrate into the brain of AD patients possibly due to alterations in the BBB
associated with AD pathophysiology. Under normal physiological conditions, an intact BBB
regulates the transport of many molecules and cell types present in the blood. In typical inflam-
matory diseases, permeability of the BBB increases and lymphocytes migrate into the CNS and
inflammation-associated molecules reach the periphery. Because not only the brain but also the
periphery is affected in AD, the inflammation is considered to be systemic. Peripheral immune
cells can contribute to brain inflammation, thus changes in the periphery may have a significant
impact on the brain. The root cause of the systemic inflammation observed in AD is not yet fully
understood. Persistent CMV infection has a large impact on the immune system. Therefore this
study separately considered impacts that both CMV and AD may have on the immune system.
It was important to determine if CMV+ individuals are under additional antigenic load and thus
have more stressed immune systems, thereby potentially making them more susceptible to de-
mentia. To investigate this, immune signatures were compared in a cohort of CMV- and CMV+
healthy individuals and additionally CMV- and CMV+ AD patients.
In order to investigate the systemic immunopathology of AD, this study examined several
leukocyte subsets, including T-cell populations, B-cells and monocytes found in PBMCs isolated
from the blood of AD patients and healthy age-matched controls. This study was performed in
three phases. In phase one, the differentiation stages of leukocyte populations were investigated
by analysing the expression of surface marker proteins. For this analysis, the CMV status of
the individual was considered, since it has a significant impact on the immune system. In phase
two, the activation state of the aforementioned leukocyte subsets was examined by measuring
the expression of HLA-DR, CD25, CD69 along with other markers. In phase three, the cytokine
secretion of T cells in response to Aβ and/or PMA-Ionomycin was measured using functional
assays. Not only cytokines but also chemokines play an important role in inflammation and
leukocyte migration. Therefore the expression of several chemokine receptors (CCR2, CCR4,
CCR5 and CCR6) on leukocytes was also studied.
The aim of this study was to identify immune signatures that are characteristic of AD, and
which therefore might qualify as biomarkers or as novel therapeutic targets. It has been specu-
lated that the specific interactions between various immune cells types may be beneficial during
the early stages of AD, but harmful in advanced stages of disease. This idea is supported in
several experimental settings [41, 34, 153, 176]. In addition, CMV infection should be consid-
ered in the context of the immunopathology of AD as it influences brain infiltration of T-cells
[155]. The results of the present study suggest new therapeutic targets. These are based on
biomarkers that are more highly expressed by peripheral blood cells from AD patients than from
controls. Town et al. reviewed the role of T-cells in AD and highlighted the beneficial role that
Th2 T-cells may play in murine AD models. In AD patients, one reason why T-cells fail to ex-
ert similar beneficial effects to limit disease progression may be due to the high NO production
surrounding amyloid plaques, which may result in T-cell apoptosis [154]. Therefore, promoting
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chemotaxis to result in increased brain infiltration by anti-inflammatory peripheral T-cells may
help curb disease progression. On the other hand, decreasing migration of inflammatory T-cells
with antibodies directed against certain chemokines or their receptors such as CCR6 could re-
duce the inflammation present in AD. But before therapeutic advances along these lines can be
made, it is important to first investigate the chemokine receptor expression in AD patients. It
is also of importance to assess the frequencies of leukocyte subsets and differentiation stages in
AD patients compared with healthy controls. For these reasons, this is study aimed to investigate
the immune profiles associated with different disease stages in AD and other forms of dementia.
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Chapter 2
Materials and Methods
2.1 Reagents
2.1.1 Buffers and reagents
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Table 2.1: List of buffers and reagents
abbreviation reagent company catalogue num-
ber
Aβ1-42 [Asp22]-beta-Amyloid (1-42);
E22D beta-Amyloid (1-42)
Mobitec, AnaSpec 65217-05AS
Ampuwa Ampuwa Fresenius Kabi 0571041/00
Compbeads Negative Control
(FBS)
BD 51-90-9001291
Compbeads Anti-Mouse BD 51-90-9001229
Compbeads Anti-Rat BD 51-90-9001189
Compbeads Anti-Rat and Anti-
Hamster
BD 51-90-9000949
cytofix cy-
toperm
Cytofix cytoperm BD 554714
CS&T Cytometer setup & tracking
beads
BD 642412
DMSO Dimethylsulfoxide, research
grade
Serva 20385
EDTA Ethylenediaminetetraacetic acid Serva 11278
EDTA Ethylenediaminetetraacetic acid Sigma E-1644
FBS Fetal bovine Serum Sigma F0804
FicoLite FicoLite-H (human) Linaris GTF1511YK
fix/ perm Foxp3 fix /perm buffer set BioLegend 421403
gamunex Gamunex (human IgG) Talecris
Golgi Plug Golgi Plug (Brefeldin A) BD 555029
HBSS Ca2+Mg2+ free Hank’s BSS PAA H15-009
ionomycin Ionomycin Calcium Salt Calbiochem 407952
mouse
serum
Mouse serum Milipore S25-10ML
PBS Phosphate buffered saline PAA H15-002
PMA Phorbol 12-myristate 13-acetate Sigma P-8139
RPMI RPMI1640 + GlutamaxTM-I +
25 mM HEPES
Gibco (Invitrogen) 72400-054
NaN3 Sodiumazide Sigma S-8032
XVIVO-15 XVIVO-15 BioWhittaker/ Lon-
za/ Cambrex
EO4-418Q
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2.1.2 Antibodies
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Figure 2.1: Antibodies used
Antibody panels employed. For each antibody the conjugated fluorochrome and the company from
which it was purchased is given.
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2.1.3 Kits
anti-CMV IgG kit: Genesis Diagnostics CMVIgG ELISA kit GD84
cytokine kit: BD Cytometric Bead Array (CBA) human Th1/Th2 cytokine kit
2.1.4 Instruments
Plate reader for ELISA measurements: Dynex Technologies MRX Revelation Microplate reader
Flow cytometer: 14 channel three laser BD LSRII (violet, blue and red lasers). The configuration
according to Table 2.1 columns 1 and 2 was used.
Incubator for cells: Hera Cell 150, Heraeus
2.2 Sample collection and processing
PBMCs are typically isolated from fresh blood before undergoing experimental analysis, but
some samples in this study were only available in the form of frozen blood. This therefore
required the development of a protocol to allow for this. The final product of this protocol has
been validated and published in Journal of Immunoassay & Immunochemistry [2]. This method
has several advantages. Blood is more likely to better represent the in vivo conditions compared
to isolated PBMCs. For the laboratory performing the blood collection, no special equipment
is required as in the case for PBMCs that require isolation. While long term storage of isolated
PBMCs is not possible at -80 ◦C, it is possible to obtain viable cells when whole blood is stored
at this temperature, liquid nitrogen storage is not necessary. This is particularly advantageous
in case of field studies. The following section provides an overview of this protocol. Isolated
PBMCs were obtained from one source. These samples were processed following subsequently
described standard protocols.
2.2.1 Collaborators who provided samples
• PBMCs from healthy young and elderly and patients with mild or moderate AD: Prof.
Dr. Calogero Caruso and Dr. Guiseppina Colonna-Romano at the Immunosenescence
Unit, Department of Pathobiology and Medical and Forensic Biotechnologies, University
of Palermo, Corso Tukory 211, 90134, Palermo, Italy
• Frozen whole blood from healthy elderly patients suffering from VaD, AD or mixed de-
mentia: Prof. Dr. Roberto Paganelli, Università degli Studi G. d’Annunzio Chieti e
Pescara, Dipartimento di Medicina e Scienze dell’Invecchiamento, Chieti, Italy
• PBMCs from healthy elderly and AD patients at different stages: Prof. Dr. Tamas Fulop
of the Immunology Program, Geriatric Division, Faculty of Medicine, Research Center on
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Aging, University of Sherbrooke, Sherbrooke, Quebec, Canada
• Frozen whole blood from AD and rpAD patients: Dr. Christian Schmidt and Prof. Dr.
Inga Zerr, Clinical Dementia Center, Dept. of Neurology, University Medical School,
Georg August University Göttingen, Germany
• Fresh whole blood from healthy participants of the Berlin Ageing Study BASE-II: Prof.
Dr. Elisabeth Steinhagen-Thiessen, Charité–Universitätsmedizin Berlin, Germany
• Buffy coats from healthy blood donors: Prof. Dr. Dorothee Wernet, Zentrum für Klinische
Transfusionsmedizin, Tübingen, Germany
2.2.2 PBMC isolation, freezing and storage
According to a standard laboratory protocol, fresh whole blood was diluted 1:2 with HBSS
(phosphate buffer) and carefully layered over Ficoll-Hypaque. After centrifugation for 30 min-
utes (810 g, no brake, room temperature) a gradient containing separated PBMCs was formed.
Mononuclear cells (PBMCs) were removed from the interphase and washed three times with
HBSS, before undergoing centrifugation for ten minutes (300 g, room temperature). After the
third washing step, cell numbers were determined using a Neubauer Chamber and the required
volumes of freezing solutions determined. Centrifuged cells are resuspended carefully in 40%
(v/v) FBS dissolved in RPMI at room temperature. Following this, half the volume of 20% (v/v)
DMSO in RPMI was added and the solution was carefully mixed. After 5 min the remaining
volume of DMSO was added. The samples were then aliquoted in pre-prepared vials at room
temperature. The vials were then immediately stored at -80 ◦C overnight. Vials were trans-
ferred to liquid nitrogen storage the following day as they require temperatures below -80 ◦C for
optimal long term storage. Samples were stored on dry ice during shipping.
2.2.3 Frozen whole blood storage
For the storage of whole blood, ten percent (v/v) DMSO was added before being stored at -80◦C.
In the case of the samples obtained from Dr. Schmidt and Prof. Zerr in Göttingen, samples were
kept at room temperature for 24 h before the addition of DMSO and subsequent storage at -80◦C.
2.2.4 Preparation of samples for flow cytometric analysis
Thawing of frozen blood samples
Frozen whole blood was thawed in a 37 ◦C waterbath until the majority of ice clumps had disap-
peared. The samples were then transferred to a 50 ml centrifuge tube, diluted 1:25 with washing
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buffer (PBS, 2 mM EDTA, 2% (v/v) FBS) in order to reduce the toxic effects of DMSO and
centrifuged for 5 min at 300 g.
Thawing of PBMCs
Vials were taken from liquid nitrogen storage and placed directly into a +37 ◦C waterbath. Vials
were gently shaken until all of the larger ice clumps had disappeared. The samples were then
immediately transferred to a fresh tube with an equal volume of 4 ◦C RPMI. After gently shaking
for 5 min another equal volume of RPMI was added. The tubes were shaken gently before
being centrifuged (5 min, 300 g). The cell pellet was resuspended in medium / buffer and the
number of cells determined with the use of a Neubauer chamber. Cells were divided according
to experimental requirements and centrifuged. Following centrifugation, the supernatant was
discarded and the appropriate volume medium / buffer added. The experiments performed with
the PBMCs from Canada are listed in Table 2.2.
2.2.5 Experimental design
Different experiments were performed for each sample cohort. T-cell phenotypes were analysed
for all sample cohorts, while Treg, leukocyte subsets and functional assays were analysed in se-
lected cohorts. For these experiments, it is important to consider that some samples consisted of
whole frozen blood, while others were separated PBMCs. An overview of the studies performed
can be seen in Table 2.2. The samples obtained from Dr. Schmidt and Prof. Zerr at Göttingen
were taken at 2 time points. These samples were shipped and analysed separately. To ensure
consistency of results, PBMCs from one control donor were stained with the same panel of an-
tibodies for each experiment and compared. Blood samples of healthy elderly individuals from
Berlin were additionally included as controls.
Table 2.2: Overview of the sample cohorts and the analysis performed for each1
panel Chieti Göttingen 12 Göttingen 22 Berlin3 Palermo Canada14 Canada24
T-cells 2 ml 2 ml 2 ml 1 ml PBMC5 PBMC PBMC
Tregs/CCR 2 ml - 1 ml 1 ml PBMC5 - PBMC
Leukocytes 2 ml 2 ml 2 ml 1 ml - - -
Aβ uptake 2 x 2 ml 2 x 2 ml - - - - -
Cytokines - - - - PBMC - PBMC
ml indicates the volume of blood used for each experiment. Depending on availability, separated PBMCs were
used for the samples from Palermo and Canada. Pilot tests indicate that the volume of blood used does not
affect experimental results [2].
1 The details of each panel are listed in Table 2.1.
2 Göttingen 1 includes the first batch of 20 samples, Göttingen 2 the second with 30 samples, including follow-up
samples.
3 The Berlin controls were processed in parallel to Göttingen 2 ones. Out of 20, ten controls per panel were used.
4 From Canada 2 independent cohorts were recruited.
5 T-cell and Treg analysis was performed together with one panel.
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2.2.6 Staining cell surface proteins and intracellular Foxp3 with fluorochrome-
conjugated antibodies for flow cytometric analysis
Cells were first equilibrated in PFEA staining buffer (PBS, 2% (v/v) FBS, 2 mM EDTA and
0.01% (w/v) Na azide). Experiments were performed on ice (PBMCs) or room temperature
(blood). After centrifugation for 5 min at 300 g, the cell pellet was resuspended in 50 µl of
1% Gamunex R© solution (100 µl of 10% Gamunex into 900 µl of PFEA) in order to block Fc
receptors and promiscuously binding proteins. Optionally, 1 µg EMA for the discrimination
between living and dead cells was included. After a 10 min incubation (plus an additional 10
min under light when EMA was used) 1 ml PFEA was added in order to wash the Gamunex
solution from the cells. The following step was optionally used in the case indirect stainings
with non-conjugated antibodies. Cells were stained for 20 min with primary antibody, washed
with 1 ml PFEA, stained for 20 min with secondary antibody and washed again with one ml
PFEA. The final step involved blocking with 50 µl 10% serum derived from the animal that the
primary antibody was raised in (mouse in the case of this study). Cells were washed with 1 ml
PFEA and centrifuged (300 g, 5 min) before the mixture of conjugated antibodies was applied to
the samples. Samples were protected from light once the fluorochrome-labelled antibodies were
applied. The total volume of each antibody incubation solution was adjusted to 50 µl.
Parallel to the above procedure, compensation controls were made for each antibody in order to
to allow the flow cytometer to adjust for spectral overlap of the fluorochromes used in each exper-
iment. For each antibody separately, an equal volume as used in experiments was incubated with
10 µl mouse or rat compensation beads, depending on the animal that the antibodies were raised
in. Each sample also contains unstained beads. When discrimination between living and dead
cells was required (for example with EMA or Vivid staining), no compensation was performed
as only the living cells (Vivid or EMA negative) were gated and used for analysis. Samples and
controls were incubated for 20 min (30 min with gentle agitation for blood samples) in the dark.
During this time the flow cytometer was switched on in order to prewarm the lasers. Following
the incubation, samples were washed with one ml PFEA and centrifuged for 5 min at 300 g.
Cells were resuspended in 100-200 µl (200-300 µl for blood samples) of PFEA and measured
with the flow cytometer.
In the case of analysing Foxp3 expression, it was possible to detect this intracellularly expressed
protein following antibody incubation for cell surface proteins. To achieve this, 0.5 ml 1x Foxp3
Fix/Perm solution was applied to samples, vortexed and incubated for 20 min at room tempera-
ture in the dark. Following washing with 1 ml PFEA cells were centrifuged (300 g, 5 min) and
washed with one ml of 1x Foxp3 Perm buffer for 15 min in the dark. After centrifugation (300
g, 5 min) cells were resuspended in 100 µl of 1x Foxp3 perm buffer along with a Foxp3 anti-
body. Additional antibodies recognising other intracellularly expressed proteins were included
depending on the experiment. The antibodies were incubated for 30 min at room temperature
in the dark. Samples were then washed with 1 ml PFEA, centrifuged (300 g, 5 min), and resus-
pended in 100-200 µl PFEA (200-300 µl for blood samples) before being measured on a flow
cytometer.
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2.2.7 Intracellular cytokine staining
PBMCs were thawed according to the procedure described in Section 2.2.4 and a maximum of
1x106 cells were suspended in X-VIVO-15 cell culture medium. For each experiment, the same
PBMC donor from the local blood bank was used as a control. The PBMC samples from each
donor were divided into three conditions: untreated, PMA (50 ng/ml) and Ionomycin (750 ng/ml)
treated, and amyloid beta (1 µg/ml) treated. For each condition, 1 µl Golgi Plug was included.
After 17 h of incubation (37 ◦C, 5% CO2, 95% humidity) cells were collected by washing the
wells of the culture plates with PFEA. After centrifugation (300 g, 5 min) cells are incubated with
50 µl 1% Gamunex to block non-specific antibody binding sites and with a live-dead discrimi-
nation marker (1 µg EMA under strong light). Following this, cells were washed with PFEA and
fixed with 250 µl BD cytofix/cytoperm for 15 min. After washing with 1 ml perm/wash, cells
were incubated for 15 min with perm/wash. Following this, 50 µl of the antibody mastermix di-
luted in perm/wash was added to the centrifuged pellet and incubated for 30 min. After the final
washing step with PFEA, 100-200 µl of PFEA was added and samples measured with the flow
cytometer. Compensation controls were prepared as described in Section 2.2.6 and measured
before samples were analysed.
2.2.8 Testing PBMC uptake of amyloid beta
Two times 2 ml blood from each donor were thawed and washed as described in Section 2.2.4.
Following, two 1 ml aliquots of the cell samples (suspended in XVIVO-15 medium) were plated
on a 24 well plate. To 1 well 10 µl of 1:10 diluted of fluorochrome-labelled Aβ was added
(0.1 mg + 50 µl buffer -> 10 µl + 190 µl PBS -> 1 µg/10 µl -> 10 µl for 1 ml to achieve
1 µg/ml). In parallel, 1x106 PBMCs (suspended in 1 ml XVIVO-15) from a local blood bank
donor was used as internal control. In addition, 1 sample of cells incubated with Aβ was used for
compensation. Incubation was performed for 16 h (37 ◦C, 5% CO2). Following the incubation
period, cells were harvested by washing the wells thoroughly with PFEA in order to detach
adherent cells, particularly the monocytes. After 10 min of blocking with Gamunex at room
temperature samples were washed with 1 ml PFEA buffer and centrifuged for 5 min at 300 g.
Then cells were stained with fluorochrome-conjugated antibodies for 30 min at RT (or on ice in
case of the blood bank donor). Finally, the cells were washed with 1 ml PFEA and resuspended
in 200-300 µl PFEA before being measured with the flow cytometer.
2.3 Testing CMV serostatus
The CMV serostatus of the donors from Canada was established by collaborators at Sherbrooke
University in Canada. The Chieti and Göttingen rpAD-study plasma samples were analysed
in-house with an anti-IgG-CMV ELISA kit (Genesis Diagnostics CMV IgG ELISA kit GD84),
according to the manufacturer’s instructions. In case of the rpAD study, plasma was obtained by
centrifugation frozen-thawed blood for 10 min at 1000 g. Given that elderly patients commonly
possess high anti-CMV IgG titres, the Chieti samples were prediluted 1:10 in PBS. According
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To the level of anti-CMV IgG titre, samples were categorized in CMV accordingly; < 3 U/ml <
low < 5 U/ml < high.
2.4 Flow cytometry
The analysis of flow cytometry data was performed with either FlowJo version 7.2.5 or FACS-
DIVA 6.1. The FlowJo gating strategy for the analysis of T-cells from the Chieti samples is
shown in Figure 2.3, and an example of the leukocyte analysis from a sample from Göttingen in
Figure 2.2. For each sample the cell numbers were not controlled and therefore the number of
cells recorded by the flow cytometer varied. This was because of the difficulty in determining
cell numbers with microscopy for whole blood samples due to the interference of debris and ery-
throcytes. Gated subsets of cells from donors where the parent population contained less than 50
events were excluded from the analysis. For example, if a donor contained 1,000 CD3+ events,
the frequency of CD4+ and CD8+ cells was examined, but CD4+ subsets were only assessed if
at least 50 CD4+ events were accumulated.
For the assessment of Aβ uptake by leukocytes, the mean fluorescence of HiLyte FluorTM 488
conjugated to Aβ was measured. To calculate the degree of uptake, the fold difference in fluores-
cence was calculated by dividing the mean fluorescence of the Aβ-treated samples by the mean
fluorescence of the untreated samples. The mean fluorescence values were taken from CD45+
leukocytes after gating for leukocyte subsets
2.5 Statistics
All statistical analysis were performed with Graphpad Prism 4.02 (2004) or JMP 8.0 (SAS
Institute, 2008). Non-parametric Mann-Whitney U test was used for the comparison of inde-
pendent groups.
2.6 Samples
Parameters for patients and controls analysed in these studies are summarized in the following
tables. All patients included in this analysis as AD patients required a diagnosis of probable AD
consistent with the DSM-IV as set out by the American Psychiatric Association in 1994. In the
case of the Göttingen patients, the Dubois criteria for research [32] were also considered. For the
Canadian donors the criteria of the National Institute of Neurological and Communicative dis-
orders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA)
were included, while for the Chieti study participants the Hachinski score was used to discrim-
inate between AD, mixed dementia and vascular dementia. A CT or MRI scan was required
to corroborate the AD diagnosis. Major Stroke or massive vascular lesions on imaging were
exclusion criteria. All patients gave their written informed consent. All healthy controls and
AD patients underwent the Folstein Mini-Mental State Examination test. All other dementias,
neurological and psychiatric disorders were excluded.
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Figure 2.2: Gating strategies for the leukocyte panel
FlowJo images of the leukocyte analysis of the rpAD study. Representative examples were chosen from
one AD patient (first and third row) and one healthy control. A and E show the gating strategy for
monocytes (CD14+). B and F show parallel results of the CCR-panel analysis. In C and G the CD40
expression on monocytes can be seen. In D and H CD16 was plotted against CD56 for a NK-cell
identification. I and P - with IgD plotted against CD27 expression - are examples of B-cell phenotypes. J
and M show CD40 expression of CD19+ cells. K and L and N and O show the selection of CD3+ cells
for the leukocyte and the CCR analysis.
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Figure 2.3: Example of the gating strategy used for T-cell subsets with FlowJo software
Populations and their subsets were selected in the following order: lymphocytes according to size and
granularity -> singlets -> living (Red Vid-) CD3+ -> CD4+ (and CD8+) -> differentiation states,
analysed with several markers in parallel, here shown for CD4+ T-cells. CD27 and CD28 characterise
early- and late-differentiated cells. Naïve cells were considered to be CD27+CD28+ as well as
CD45RA+CD45RO-. In the last image CD57 and KLRG1 expression is displayed.
Table 2.3: Clinical parameters of 2nd cohort of Canadian AD patients and healthy elderly indi-
viduals (Table 2.2)
Healthy mild AD moderate AD severe AD
no. of donors 9 10 10 10
with CRP > than 3 0 4 2 3
CMV status 4− /5+ 2− /8+ 2− /8+ 5− /5+
MMSE 30 24− 29 16− 26 < 17
mean cortisol 513± 172 927± 1430 441± 164 466± 123
total cholesterol 5.55± 0.85 4.80± 1.12 4.84± 1.30 4.54± 1.24
mean triglycerides 1.10± 0.50 1.73± 1.18 1.65± 0.72 1.22± 0.45
mean HDL 1.83± 0.60 1.16± 0.31 1.20± 0.22 1.29± 0.37
mean LDL 3.23± 0.46 2.85± 0.85 2.89± 1.13 2.69± 1.17
mean GB 5.3± 1.1 6.6± 1.7 6.7± 1.9 5.8± 1.8
mean hemoglobin 138± 11 130± 16 120± 10 128± 10
CRP: C-reactive protein, HDL: high density lipoprotein cholesterol, LDL: low density
lipoprotein cholesterol.
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Table 2.4: Clinical data of the Chieti study participants
Healthy AD VaD mixed dementia
no. of donors 17 11 6 6
gender 7F/10M 6F/5M 4F/2M 3F/3M
mean age 82± 6 81± 3 85± 5 87± 4
MMSE 28.3± 1.2 8.8± 5.9 8.4± 6.0 6.8± 4.8
Hachinski ischemic score 0 2− 4 5− 8 4− 9
mean CC 216± 159 166± 148 209± 165 168± 106
mean wbc 7.35± 3.45 8.62± 3.59 8.72± 1.95 9.01± 2.02
mean rbc 3.90± 0.65 4.44± 0.41 4.32± 0.33 4.07± 0.56
mean cholesterol 157± 24 158± 26 174± 20 158± 23
mean triglycerids 139± 68 102± 34 113± 26 100± 19
mean ves 42± 31 39± 25 33± 25 60± 3
mean hb 11.6± 1.6 12.5± 1.2 11.9± 0.5 12.0± 1.8
mean total protein 6.1± 0.7 6.8± 0.8 6.3± 0.8 6.4± 0.8
tc atrophy1 1/17 11/11 0/6 6/6
tc vas 3/17 3/11 6/6 6/6
CMV serostatus 16/17+ 11/11+ 6/6+ 6/6+
wbc = white blood cells, rbc = red blood cells, hb = hemoglobin, tc = testicular
Table 2.5: Clinical parameters of healthy controls and AD patients from Göttingen
Healthy MCI AD rpAD other1
no. of participants 20 3 23 7 11
thereof follow-up 0 0 5 0 1
mean age 68± 3 83± 5 69± 9 69± 5 67± 11
gender 1F/2M 12F/11M 5F/2M 3F/8M
CMV range 26-27 0-27 4-27 15-29
mean MMSE 26± 1 19± 8 17± 8 24± 4
mean Aβ level2 n.d.4 390 673± 462 336± 104 464± 230
mean tau level2 n.d.4 144 425± 473 585± 352 231± 188
anti-CMV IgG titre3
negative 8 0 6 3 7
low positive 3 1 7 1 1
high positive 8 2 9 3 3
1 VaD, mixed dementia, Parkinson’s disease, Pseudodementia, possible AD
2 values only for 20 participants available
3 The donors were grouped according their anti-CMV IgG titre: negative < 3 U/ml < low < 5
U/ml < high; 1 AD and 1 healthy excluded
4 n.d. = not determined
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Chapter 3
Results
AD is a difficult to diagnose disease that affects people worldwide. For this study, it was hypoth-
esised that identifying immune biomarkers associated with AD may; 1) Assist in the diagnosis
of AD 2) Allow the identification of people at risk of progressing to AD prior to manifestation of
clinical symptoms. This study therefore assessed the immune profiles of patients with different
disease severity from different countries (Italy, Germany and Canada) with the goal of identi-
fying robust biomarkers found in all AD patients. Given that AD is associated with systemic
inflammation and a compromised blood-brain barrier (which may also be associated with pre-
AD states), blood leukocytes were investigated because they may be potential markers for CNS
events in situ. The primary objective was to determine the phenotype of peripheral immune cells.
The secondary goal was to investigate the functionality of these cells. Because Aβ is a key player
in AD pathology with well-established neurodegenerative effects, the capacity of leukocytes to
take up Aβ was investigated as this may be a mechanism of Aβ clearance in the brain. In ad-
dition, PBMCs were stimulated with Aβ peptides to assess the presence of Aβ-reactive T-cells.
Due to sample volume limitations, not all of these experiments could be performed for every
cohort. The analysis performed for each sample is given in Table 2.2.
3.1 Characterisation of T-cell phenotypes in patients with mild
and moderate AD
3.1.1 Mild AD is associated with dramatic shifts in circulating CD4 but not
CD8 T-cell subsets relative to age-matched controls
For the initial study, a well characterised cohort of mild AD patients from Canada were analysed
according to the Sallusto model for T-cell differentiation outlined in the introduction (Fig. 1.4).
The results of this analysis indicated that lower percentages of CD4+CCR7+CD45RA+ T-cells
were observed in the elderly compared with young individuals, while the frequency of these cells
was even lower in age-matched patients with mild AD. Parallel to this, the percentages of late-
differentiated CD4+CCR7-CD45RA+ T-cells were observed to be higher in the PBMCs of AD
patients compared to the controls (Fig. 3.1). These differences were limited to the CD4+ subset -
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differences between patients and controls were not observed in CD8+ cells. This was most likely
because although CD8+ naïve cells may be affected in AD patients given that the age-matched
controls already displayed very low frequencies of naïve T-cells it was unlikely that additional
effects exerted by AD could have been observed (Fig. 3.2). This is more clearly seen in the
following analyses. In addition to this CCR7/CD45RA model, the expression of costimulatory
molecule CD28 was also analysed. Anti CD28-Alexa700 mean fluorescence values of CD4+
and CD8+ T-cells were significantly lower in AD patients compared to controls. In addition,
percentages of CD28+ T-cells were lower in AD patients as well. These differences between AD
patients and age-matched controls were observed within the total CD4+ and CD8+ population
as well as in differentiation stages. The strongest effect on CD28 expression was observed in the
late-differentiated TEMRA (CCR7-CD45RA+) cells [77].
This pilot investigation also indicated that lower percentages of CD4+ CD25high T-cells (a phe-
notype consistent with cells that are acutely activated) are present in AD patients, by comparison
with healthy controls. This analysis once again indicated that a shift from naïve to late-differentiated
T-cells is associated with ageing and disease. In this case, the percentages of CD8+CD25+ T-
cells was also lower in AD patients compared to controls [77].
3.1.2 Frequency of naïve, late-differentiated and regulatory T-cells in the
peripheral blood of patients with mild and moderate AD
In a second study, a larger cohort of patients was analysed for the frequency of T-cell dif-
ferentiation stages in the peripheral blood. For this analysis, Sicilian patients with mild or
moderate AD were tested, in addition to the previously analysed Canadian cohort with mild
AD. Initially, the expression of CD27 and CD28 was investigated. As described in Section
1.2.1, early-differentiated cells are double positive for these markers, while late-differentiated
cells are considered to be double negative. To clearly identify the naïve cells, CD45RA and
CD45RO were chosen as additional markers. Naïve cells were identified as having the pheno-
type CD27+CD28+CD45RA+ CD45RO- and late differentiated memory cells as CD27-CD28-
CD45RA+CD45RO+. The frequency of naïve cells was observed to be lower in AD patients
compared to controls while the frequency of late differentiated T-cells was higher in this group.
No differences between patients with mild AD and those with moderate AD were detected, sug-
gesting that these phenotypes would not be useful as markers of progression. Henceforth these
patients were considered as a single group (Fig. 3.3). These results confirm previous observa-
tions that differences in the frequency of T-cell differentiation stages are limited to the CD4+
subset [111]. This contrasts with a comparison between young and elderly individuals in which
the predominant differences in T-cell frequencies occur in the CD8+ subset T-cell populations.
To more thoroughly investigate these observations additional markers of T-cell differentiation
were studied. These results indicated that the percentages of CD57+ and KLRG1+ CD4+ and
CD8+ cells were higher in the elderly compared to the young. For CD57, no differences between
healthy elderly and age-matched AD patients were observed. In the case of KLRG1, there was
a trend towards higher frequencies of CD8+KLRG1+ T-cells in AD patients, which was statisti-
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 Figure 3.1: Frequency of CD4+ T-cell phenotypes in AD patients and healthy controls
PBMCs were stained for CD3, CD4, CCR7, and CD45RA to distinguish naïve cells (CD45RA+CCR7+),
CM (CD45RA-CCR7+), EM (CD45RA-CCR/-), and TEMRA (CD45RA+CCR7-) cells. A)
Representative plots of the CD4+ subset distribution of one young (left panel), one old (middle panel),
and one AD patient (right panel). B) Distribution of naïve (top right), CM (top left), EM (bottom left),
and TEMRA (bottom right) CD4+ T-cells. Significant differences are indicated by * p < 0.05, ** p <
0.01 and *** p < 0.001.
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 Figure 3.2: Frequency of CD8+ T-cell phenotypes in AD patients and healthy controls
PBMCs were stained for CD3, CD8, CCR7, and CD45RA for the identification of T cell differentiation
stages as described in Figure 3.1. A) Representative plots of the CD8+ differentiation stages for the
identification of T cell differentiation stages of one young (left panel), one old (middle panel), and one
AD patient (right panel). B) Frequencies of naïve (top right), CM (top left), EM (bottom left), and
TEMRA (bottom right) CD8+ T cell differentiation stages. Significant differences are indicated by * p <
0.05, ** p < 0.01 and *** p < 0.001.
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 Figure 3.3: CD4+ naive and late-differentiated subsets in AD patients and controls.
PBMCs were stained with anti CD3, CD4, CD28, CD27, CD45RA, CD45RO antibodies to identify naïve
and late-differentiated cells. (3A) Representative dot plots of naive (top) and late-differentiated (bottom)
CD4+ T cell distribution in a young control (left panels), in an old control (middle panels) and in an AD
patient (right panels). (3B) Percentages of CD28+CD27+CD45RA+CD45RO- naive cells (left) and of
CD28-CD27-CD45RA+CD45RO+ late-differentiated cells (right) of 11 young controls (black squares),
21 healthy old (black circles) and 40 AD patients (black diamonds). Bars represent means. Differences
between control subjects and AD have been assessed by Mann-Whitney nonparametric U testing with
Bonferroni correction. Significant differences are indicated by * p < 0.005, *** p < 0.0005
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Figure 3.4: "senescence" marker expression on CD4+ and CD8+ T-cells
PBMC were stained with anti CD3, CD4, CD8, KLRG1 and CD57 antibodies. Percentages of
CD4+CD57+ (upper left) and of CD8+CD57+ (bottom left) cells in 11 young controls (black squares),
21 healthy old (black circles) and 40 AD patients (black diamonds) are shown. Frequency of
CD4+KLRG1+(upper right) and of CD8+KLRG1+ (bottom right) cells of young (black squares), healthy
old (black circles) and AD patients (black diamonds). Bars represent means. Differences between control
subjects and AD have been evaluated by Mann-Whitney nonparametric U testing with Bonferroni
correction. Significant differences are indicated by *** p < 0.0005.
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cally significant in the CD4+ population (Fig. 3.4).
As in the study presented in Section 3.1.1, this part of the study also investigated CD25+ T-
cells. In contrast to the previous study, the percentages of CD4+CD25+ T-cells were higher in
elderly compared to young controls, but the frequency of these cells was even higher in AD
patients. To see whether these activated cells were likely to be regulatory T-cells, the expression
of CD127 and Foxp3 was analysed. The results of this analysis showed that age but not health
status (AD compared with healthy controls) was associated with higher percentages of Tregs
(CD25+Foxp3+CD127low cells), as presented in Figure 3.5.
 
Figure 3.5: Percentage of activated and Treg cells within CD4+cells of AD patients and
controls.
Representative dot plots of CD4+CD25+cells in a young control (left panel), an old control (middle
panel) and an AD patient (right panel) (A). Median of CD4+CD25+cells in PBMC of 11 young controls
(black squares), healthy old (black circles) and AD patients (black diamonds) are shown (B left).
Percentages of CD4+CD25+Foxp3+CD127low, putative Tregs, in young (black squares), healthy old
(black circles) and AD patients (black diamonds) (B right). Bars represent medians. Differences between
control subjects and AD have been evaluated by Mann-Whitney nonparametric U testing with Bonferroni
correction. Significant differences are indicated by *** p < 0.0005.
46
3.2 Immune signatures of Canadian patients with mild, mod-
erate or severe AD
This study was designed to distinguish between stages of disease severity among AD patients
using PBMCs obtained from the Sherbrooke population. Subjects were categorised as from
mild, moderate or severe stage of disease and were compared with healthy age-matched controls.
The CMV infection status of the donors were as follows: control group five CMV+ and three
CMV-; mild and moderate groups contained eight CMV+ and two CMV-; while the severe group
contained five CMV+ and five CMV-. In this population, therefore, the impact of CMV on
immune signatures could be assessed.
3.2.1 T-cells
For the analysis of T-cells, they were divided into subsets. Out of the total living CD3+ cells,
the percentages of CD4+, CD8+ and CD4-CD8- cells were evaluated. These results indicated
a large range of values with no significant differences between groups (Fig. 3.6). TCRγδ+
cells were analysed within the CD3+ population and in the CD4-CD8- subset. This showed a
non-significant trend of higher percentages of TCRγδ+ cells in patients with mild and moderate
compared with severe AD (Fig. 3.7). The severe group showed a non-significantly lower fre-
quency of this cell type, similar to those of the healthy controls. Frequencies of γδT-cells within
the CD4-CD8- population were not different between the groups.
Following this, the phenotype of the CD4+ cells was characterised in this cohort. As in the
study of AD samples from Palermo [111], these samples were analysed with respect to CD27
and CD28 expression (Fig. 3.8 A-D shows the gating strategy employed). From the CD27 and
CD28 double-positive and double-negative fractions, the CD45RA and CD45RO expression fre-
quency was investigated. The outcome of this analysis indicated that patients with severe AD
display a similar CD4+ T cell phenotype to healthy controls. In contrast, patients with mild
or moderate AD showed slightly lower percentages of naïve cells (characterised superficially as
CD27+CD28+ or more thoroughly as CD27+CD28+CD45RAhighCD45RO-) and higher per-
centages of late-differentiated cells (CD27-CD28- and CD27-CD28-CD45RO-) compared to
patients with severe AD and healthy controls (Fig. 3.8).
Similarly, the percentages of KLRG1-CD57- CD4+ T-cells decrease with disease severity, al-
though the patients suffering from severe AD showed similar median percentages as the healthy
controls (Fig. 3.9). CD57 and KLRG1 expression levels were higher in patients with mild and
moderate AD than in healthy controls, but this was the case only for a small number of patients
with severe AD. These results might be attributable to differences in CMV infection rates. Eight
out of ten patients with mild and moderate AD were CMV+, while only five of ten patients with
severe AD were CMV+. Figure 3.10B displays the percentages of CD57+ CD4+ T-cells. The
patients with severe AD were grouped according to CMV infection status. Observing these two
groups separately indicates that CMV+ patients showed a slightly higher percentage of CD57+
CD4+ T-cells. This suggests that CMV seropositivity may influence the expression of these pro-
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teins, but that patients with severe AD show similar expression frequencies to those observed in
healthy controls. Taking CMV status into consideration may reveal another perspective for these
data, but the number of patients in each group was too low to be able to draw conclusions.
In addition to the aforementioned analyses, the expression frequency of PD-1 (a marker for im-
mune exhaustion) was analysed on CD4+ cells (Fig. 3.11). No significant differences between
patients and controls were observed.
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Figure 3.6: CD4+ and CD8+ T-cell subset frequencies in dementia patients and healthy
controls
Frequencies of CD4+ (A) and CD8+ (B) T-cells of healthy elderly controls (n = eight) and AD patients (n
=30). The AD patients were divided into three disease stages: mild (ten), moderate (ten) and severe (ten).
Bars represent median values.
3.2.2 Tregs
For Treg analysis, Foxp3+ T-cells were gated from the CD4+ T-cells. The median is consis-
tent across groups and statistical analysis showed no significant differences. Despite this, the
AD patients show a greater range (11% spread) compared with the healthy controls that show
a four percent spread in Treg frequencies. These results also suggest that there may be two
groups of AD patients - those with a greater and those with a lower frequency of Tregs. This
may have been due to disease severity or CMV status, but statistical analysis indicated that they
were not associated with the frequency of Tregs. The regulatory T-cells can be characterised
in more detail with the inclusion of CD45RA+ and CD45RO+ markers [16]. Miyara et al. di-
vided CD4+Foxp3+ T-cells into three functionally and phenotypically distinct subpopulations in
the following way: (1) CD45RA+FoxP3low (resting Tregs), (2) CD45RA-Foxp3high (activated
Tregs) and (3) CD45RA-Foxp3low (cytokine secreting non-Tregs) [98]. In the present study
Foxp3+CD45RO+ and Foxp3lowCD45RA+ cells showed a similar but more pronounced trend
as Foxp3+ cells. Slightly higher values for AD patients were observed compared with healthy
controls, but no significant difference were observed. No differences were observed within AD
patient subgroups either. The expression frequency of CD45RA- in Foxp3-low and -high ex-
pressing cell fractions showed no statistical differences or trends (data not shown).
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Figure 3.7: Frequency of γδT-cells in dementia patients and healthy controls
Percentages of CD4-CD8- (E), TCRγδ+ (F) and CD4-CD8- TCRγδ+ (G) T-cells within the total CD3+
population, in healthy elderly controls and AD patients with different stages of disease. Bars represent
median values. Examples of gating analysis for a healthy control is shown in A and B and for moderate
AD in C and D. The statistical analysis of TCRγδ+ events gated in panels B and D is shown in panel E
and the frequencies of CD4-CD8- events gated in panels A and C are displayed in panel F.
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Figure 3.8: CD4+ T-cell gating strategy and the resulting T-cell phenotype analysis
Representative images from a healthy elderly control (A and B) and a patient with mild AD (C and D)
are given. This gating strategy was employed to identify differentiation stages for CD4+ T-cells. To
achieve this, CD27 was first plotted against CD28 before analysing the double positive CD45RA cells
against CD45RO-expressing cells. The resulting percentages of CD4+CD27+CD28+ are shown in panel
E. These cells were further characterised as CD45RAhighCD45RO- (F). G and H show
late-differentiated CD4+ T-cells (defined as CD27-CD28- and CD27-CD28-CD45RO+)
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Figure 3.9: Frequency of CD4+ KLRG1- and CD57-expressing cells
A and B show typical CD57 and KLRG1 gating analyses for a healthy control and an AD patient
(moderate AD). The percentage of CD4+ cells in the four different populations are grouped in panels C,
D, E and F.
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Figure 3.10: CD57 expression on CD4+ cells in CMV-seronegative and CMV-seropositive
AD patients with severe disease
Frequency of CD57+ CD4+ T-cells in dementia patients and healthy controls (A). Panel B shows the
frequency of CD4+ CD57+ T-cells according to CMV status in dementia patients.
Figure 3.11: Frequency of CD4+ PD-1+ cells in dementia patients and healthy controls
Expression frequency of PD-1 on CD4+ T-cells (A). The analysis gates are shown for a healthy donor (B)
and a patient with moderate AD (C).
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Figure 3.12: Treg gating strategy
An example of the gating strategy is given for a donor with mild AD. To isolate these cells the
lymphocytes were gated first, followed by the singlets (using FSC-W against FSC-A), before identifying
the living cells (EMA-). CD3+ T-cells were then selected, from which CD4+ and CD8+ T-cells were
selected (images not shown). These images show different CD4+T-cell subsets according to Foxp3
expression. Panel A has been gated for CD45RA against Foxp3, while (B) shows Foxp3 against
CD45RO. Panel (C) shows the gating of CD4+Foxp3+ cells. The classification of Tregs into resting
Tregs (CD45RA+Foxp3low), cytokine secreting non Tregs (CD45RA-Foxp3low) and activated Tregs
(CD45RA+Foxp3high) was developed by Miyara et al. [98]. The frequencies of these populations in the
study participants are shown in Figure 3.13 and figure 3.14.
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Figure 3.13: Frequency of Tregs in AD patients and healthy controls
Frequency of Foxp3+ T-cells within the CD4 T-cell compartment. Frequencies are shown for healthy
elderly (n = eight) and AD patients (n = 28). The AD patients were divided into three disease stages:
mild (n = eight), moderate (n = ten) and severe (n = ten) or into CMV- (n = nine) and CMV+ (n = 19).
Bars represent median values.
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Figure 3.14: Frequency of different Treg phenotypes in AD patients and healthy controls
Frequency of Foxp3+ T-cell subsets within the CD4 T-cell compartment of healthy elderly (n = eight)
and AD patients (n = 28). The AD patients were then divided either in three disease stage mild (n =
eight), moderate (n = ten), and severe (n = ten) or in CMV- (n = nine) and CMV+ (n = 19). Bars
represent median values. In panel A the percentages of Foxp3+CD45RO+ cells are given, panel B shows
Foxp3lowCD45RA cells+, panel C Foxp3lowCD45RA- cells and panel D Foxp3highCD45RA- cells.
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3.2.3 Chemokine receptor expression on the leukocytes of AD patients and
healthy controls
Chemokine receptor expression is a factor that may be altered in AD given that immune cells
are known to migrate along chemokine gradients through a defective blood-brain barrier. To
investigate this, the expression frequency of CCR4, CCR5 and CCR6 on PMBCs was analyzed
in dementia patients and healthy controls (Fig. 3.15). Trends across patient groups and controls
in the expression frequency of these cells within the CD45+ population (total leukocytes) were
observable. These trends were more pronounced when T-cells were investigated alone. Within
the CD4+ T-cells, the median CCR4 expression was not observed to be different between healthy
controls and AD patients, although a larger range is apparent for the AD patients. For the AD
patients, the percentage frequency ranges up to almost 40 %, whereas in the healthy elderly
the maximum frequency is 15 %. Dividing the AD patients according to mild, moderate and
severe disease stages, or into CMV- and CMV+ status did not result in statistically significant
differences. Similarly to CCR4, the results for CCR5 show similar median values across groups,
but some AD patients have relatively high frequencies. The results for CCR6 differ slightly.
Although no trends were present, the healthy controls showed slightly higher frequencies of
CCR6 compared with those of CCR4 and CCR5, while ten AD patients for CCR4 and nine for
CCR5 showed higher frequencies compared to the highest control subject, this was true only
for one patient in the case of CCR6. The healthy controls show slightly higher frequencies of
CCR6 compared with those of CCR4 and CCR5 and so no trend compared to the AD patients is
visible. The distribution across AD patient sub-groups is also different. Mild AD patients show
median expression frequencies lower than those of healthy controls, while severe AD patients
show higher frequencies compared with controls. CMV infection status appeared to have no
influence (Fig. 3.15).
3.2.4 Induced cytokine production profiles of CD4+ T-cells in AD patients
and healthy controls
Several previous studies have reported different cytokine levels in the plasma and CSF in AD
patients compared to healthy controls [78]. In the present study, the cytokines produced by
CD4+ and CD8+ T-cells were analysed. Combinations of cytokines characteristic of certain T-
cell subsets (Th1, Th2 and Th17) were considered. This analysis was not performed with all
samples, due to insufficient material. Exclusion criteria were for CD4+ cell events observed with
flow cytometry to be less than 500 (zero samples), and less than 100 events for CD8+ cells (two
samples). Due to reduced sample numbers, all AD patients were considered as a single group
and not according to disease severity. Stimulation of PBMCs with PMA and Ionomycin resulted
in significantly increased cytokine production compared to unstimulated cells, but without differ-
ences between AD patients and healthy elderly controls (data not shown). This indicates that the
capacity of PBMCs from AD patients and healthy controls is comparable in terms of producing
the cytokines IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ and TNF.
One of the hallmark features of AD is amyloid beta accumulation in the brain, and it has been hy-
pothesised that this contributes to the inflammatory conditions typically observed in AD patients.
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Figure 3.15: CD4+ T-cell CCR expression in dementia patients and healthy controls
Figure indicates the frequency of chemokine receptor expressing CD4+ T-cells as follows: CCR4 in A,
CCR5 in B and CCR6 in C. The median value is indicated by the bar. On the right hand side an example
of the gating strategy for the chemokine receptors CCR4 (A), CCR5 (B) and CCR6 (C) in CD4+ T-cells
from a patient with moderate AD is shown. The pre-gating was performed in the same manner as for the
regulatory cells because these markers were tested together in the same panel. Gating was performed in
the following manner: lymphocytes -> singlets (FSC-W vs. FSC-A) -> living (EMA-) CD3+ cells->
CD4+ from CD4 vs. CD8 (images not shown).
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Figure 3.16: Cytokine profile of CD4+ T-cells
Cytokine production of CD4+ T-cells after incubation with Golgi plug alone (-) or with amyloid beta
(abeta) shown for seven healthy elderly (H) and 19 AD patients (AD) (4 mild, 4 moderate, 7 severe AD).
The cytokines analyzed were: IL-2 (A), IL-4 (B), IL-6 (C), IL-10 (D), IL-17 (E), IFN-γ (F) and TNF
(G). The median value is represented by the bar in each column.
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Another hypothesis is that amyloid beta reactive T-cells may be able to manifest an immune re-
sponse that controls inflammation in AD. We therefore investigated the influence of amyloid beta
on PBMC cytokine production. The results indicated that only in a small number of samples did
stimulation with amyloid beta result in cytokine production, whether the PBMCs were from an
AD patient or a healthy donor. In the cases where cytokine production was observed, there were
no differences with respect to pro- or anti-inflammatory cytokines. The unstimulated samples
showed a very low level of cytokine production for both AD and controls, although the AD
patients appeared to show a slightly higher basal production of IL-6 and TNF cytokines (Fig.
3.16). The results were similar for CD8+ T-cells - no clear differences between AD patients and
healthy controls were observed (data not shown).
3.3 Immune profile of Italian patients with AD, VaD or mixed
dementia
The next series of experiments again included AD patients, but also those with vascular demen-
tia to investigate whether immune parameters could contribute to differential diagnosis. Frozen
blood samples from forty individuals with accompanying clinical data were analyzed. This co-
hort consisted of the following groups: healthy controls, AD patients, vascular dementia (VaD)
and a mixed form of dementia (mixed dementia). These groups were formed according to their
Hachinski ischemic score. The results of this analysis were plotted against the MMSE value for
each patient in order to assess how the immune profile may be related to the severity of dementia.
Patient frozen whole blood samples were used to perform four separate experimental investiga-
tions: (1) T-cell subsets; (2) Tregs and chemokine receptor expression; (3) other leukocytes and
(4) amyloid beta uptake.
3.3.1 T-cells and their phenotype
T-cell phenotypes were analysed according to the classification model developed in this labo-
ratory by Pellicanó et al. [111]. The results of this analysis demonstrated that the percentage
of CD4+, CD8+ and TCRγδ+ cells was not different between the groups (Fig. 3.17). The per-
centage of cells with a CD27 CD28 double-positive phenotype has been reported to be lower in
the elderly than in the young, particularly for CD8+ cells, while the CD4+ compartment is less
affected. In contrast, the results of this study indicated that in AD patients, naïve T-cells in both
the CD4 and CD8 compartments occur in lower percentages [77, 111]. This study is the first
to report that the percentage of CD27+CD28+ cells is also significantly lower in VaD compared
with healthy controls (p = 0.019), and in mixed dementia compared with healthy controls (p =
0.039). Reciprocally, CD27-CD28- (late-differentiated) T-cells occur at marginally higher fre-
quencies in VaD patients than in healthy controls, although this was not statistically significant.
This difference was also observed in AD, but to a lesser extent (Fig. 3.18). In order to charac-
terise naïve and memory cells in more detail, more markers were analysed. For the purposes of
this study, naïve cells were characterised as CD27+CD28+CD45RA+CD45RO-. This population
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of cells was observed to be significantly lower in frequency in VaD (p = 0.0389) and tendentially
in AD (p = 0.2041) and mixed dementia (p = 0.0542) than in healthy controls (Fig. 3.19A). In the
dementia patients, the frequency of naïve cells was associated with MMSE values; lower MMSE
values were associated with reduced frequencies of naïve cells (p = 0.0150) (Fig. 3.19F). Given
this observation, the percentage of late-differentiated cells (CD27-CD28-CD45RA+CD45RO+
or CD27-CD28-CD45RA-CD45RO+ or CD27-CD28-CD45RO+CD57+KLRG1+) was expected
to be increased in these patients, but such a relationship was not observed (Fig. 3.19B-E). Even
more unexpected was the observation of a marginal reduction of these populations in mixed de-
mentia. Another characteristic of naïve cells is the lack of CD57 and KLRG1 expression. In AD
and VaD but not mixed dementia patients, the percentage of CD57-KLRG1- CD4+ T-cells was
slightly lower, while CD57+KLRG1+ cells were observed to be slightly higher in frequency (Fig.
3.20). Concerning other T-cell groups, no differences were seen. CD8 and γδT-cell percentages
did not vary. In the CD8 population, the percentage of CD27+CD28+ CD8+ cells remained the
same for all groups tested (Fig. 3.21).
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Figure 3.17: Frequency of CD4+, CD8+ and TCRγδ+ T-cell subsets
Percentages of CD4+ (A) CD8+ (B) and TCRγδ+ (C) cells within the CD3+ T-cells of controls, AD,
VaD and mixed dementia patients. Bars represent the median values.
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Figure 3.18: CD4+ T-cell differentiation stages
Identification of early to late-differentiated CD4+ T-cells according to the expression of CD27 and
CD28. Panel A shows the percentages of CD27-CD28+ cells, (B) CD27+CD28+, (C) CD27-CD28- and
(D) CD27+CD28- cells. The following significance levels were reached with Mann-Whitney test: control
vs. VaD in (B) (p = 0.0190) and (D) (0.0461); control vs. mixed dementia in (B) (0.0389). The bars
represent the median.
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Figure 3.19: CD4+ T-cell phenotyping with additional markers
Detailed characterisation of early- and late-differentiated CD4+ T-cells with the inclusion of CD45RA,
CD45RO, KLRG1 and CD57. Naïve cells (CD27+CD28+CD45RA+CD45RO-) are presented in panel A
and were plotted against the MMSE value of all patients (panel F). Late-differentiated cells with different
marker combinations are given in B, C, D and E. After application of the Mann Whitney test, p = 0.0389
when comparing VaD with the control group, while p = 0.0542 between mixed dementia and the control
group in A. Bars indicate medians.
61
KLRG1+CD57+
control AD VAD MIXED
0
10
20
30
40
50
A
% 
wi
thi
n C
D4
+
KLRG1-CD57-
control AD VAD MIXED0
25
50
75
100
B
% 
wi
thi
n C
D4
+
Figure 3.20: KLRG1 and CD57 expression on CD4+ T-cells in dementia patients and
healthy controls
Frequency of KLRG1 and CD57 expression combinations in dementia patients and healthy controls. The
KLRG1+CD57+ phenotype is characteristically expressed by senescent cells. This population of cells
can be seen in panel A and compared with the frequency of cells negative for these markers in the same
patients (B). Statistical analysis (Mann-Whitney test) revealed p = 0.0152 when comparing VaD with
mixed dementia in panel A.
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Figure 3.21: Frequency of naïve CD8+ cells in dementia patients and healthy controls
CD8+ early-differentiated T-cells characterised by CD27+CD28+ (A) or
CD27+CD28+CD45RA+CD45RO- (B) in healthy controls and patients with dementia (AD, VaD, mixed
dementia). Bars represent median values.
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3.3.2 Regulatory T-cells and chemokine receptors
Particular attention was paid to Tregs and chemokine receptors in this study. With the antibody
panel employed, the aim was to detect activated cells. We established the percentage of CD25+
cells as an acute activation marker for T-cells, but found no difference between healthy controls
and dementia patients (Fig. 3.22A). Following this, CD4+ Foxp3+ cells were evaluated, but
again no differences between patient groups were found (Fig. 3.22B). CD8+ regulatory cells,
characterised by the expression of CD103, also showed no differences across patient and control
groups (Fig. 3.22C).
controls AD VAD MIXED0
10
20
30
40
50
60
A
% 
CD
25
+ w
ith
in 
CD
4+
controls AD VAD MIXED0
5
10
15
20
25
30
35
B
% 
Fo
xp
3+
 w
ith
in 
CD
4+
controls AD VAD MIXED0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
C
% 
CD
10
3+
 w
ith
in 
CD
8+
Figure 3.22: Frequency of activated and regulatory T-cells in dementia patients and healthy
controls
Expression of activation marker CD25 (A) and Foxp3 (B) on CD4+ T-cells and homing receptor CD103
on CD8+ T-cells (C) of healthy controls and patients with AD, VaD and mixed dementia. Bars represent
median values.
The frequency of cells expressing chemokine receptors showed no significant differences,
but only slight trends in the case of CD4+ cells, with the trend becoming more pronounced
for CD4+CD25+ cells. CCR4 (Fig. 3.23) and CCR6 (Fig. 3.24) expression was only slightly
enhanced on CD4+ T-cells. One difference did reach statistical significance, namely, CCR6 ex-
pression between mixed dementia and healthy controls (p = 0.0328 for CD4+ T-cells and p =
0.0157 for CD4+CD25+ T-cells). Plotting the MMSE value against the frequency of CCR ex-
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pressing cells shows a weak correlation between CCR expression and disease severity according
to the MMSE (p = 0.1954 for CCR6+, p = 0.0310 for CD25+CCR6+). Additionally, PD-1 ex-
pression frequency (this protein is not a chemokine receptor, but a marker of exhaustion) was
assessed, but was not observed to be different across patient groups and healthy controls (Fig.
3.25). In the CD8+ T-cell subset, no significant differences were observed, either for CCR4+ or
for CCR6+ cells in healthy controls and patients from the three groups (Fig. 3.26).
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Figure 3.23: CCR4 expression
Percentages of CCR4+ (A) and CD25+CCR4+ (C) CD4+ T-cells plotted against the MMSE values or
against diagnosis (healthy, AD, VaD, mixed dementia) (B, D). In the second column all patients (AD,
VaD and mixed dementia) are grouped together. The medians are shown as bars.
3.3.3 Leukocytes
For this study, an antibody panel was employed to compare the frequency of leukocyte sub-
populations in dementia patients and healthy controls in more detail. Within the CD45+ popula-
tion (a protein expressed by all leukocytes) the frequency of different leukocyte sub-classes was
calculated. No differences were observed between patients and healthy controls in the frequency
of NK-cells (CD16+CD56+CD3-), NKT-like cells (CD16+CD56+CD3+), T-cells (CD3+), mo-
nocytes (CD14+) or B-cells (CD19+), (Fig. 3.27). As expected, in the elderly and particularly
AD patients, the percentage of B-cells was low. Because of this, B-cell subsets could not be ana-
lysed due to insufficient cell numbers. The frequencies of monocytes covered a large range and
showed similar median values for all groups (Fig. 3.27). These results were observed whether
the activation marker CD69 or the scavenger receptor CD36 (which might play a role in amyloid
beta uptake) were included or not (Fig. 3.28).
3.3.4 Amyloid beta uptake
Aβ is one of the hallmark features of AD. The amyloid beta hypothesis proposes different roles
that this protein may have in AD pathology (see Section 1.1.2). Aβ promotes tau hyperphos-
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Figure 3.24: Frequency of CCR6 expressing CD4+ T-cells in dementia and healthy controls
The percentages of total CCR6+CD4+ (A) and CD25+CCR6+CD4+ (C) cells were plotted against the
corresponding patient MMSE values(p = 0.1954 for (A) and p = 0.0310 for (C)). In (B) the total CCR6+
percentages for healthy elderly and the different diseases are given (AD, VaD, mixed dementia) and in
(D) CD25+CCR6+ cells. The only significant differences were in the case of healthy controls compared
with mixed dementia (p = 0.0328 for panel B and p = 0.0157 for D). These differences were assessed
with Mann-Whitney test and statistically significant differences were no longer significant after
Bonferroni correction.
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Figure 3.25: PD-1 expression frequency on T-cells of dementia patients and healthy controls
Frequencies of PD-1+ (A) and CD25+PD-1+ (B) CD4+ T-cells of healthy and patients (AD, VaD, mixed
dementia). No significant differences between the groups were observed with Mann-Whitney tests.
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Figure 3.26: Frequency of CD8+ T-cells expressing CCR4 and CCR6 in dementia and
healthy controls
CCR4 (A) and CCR6 (B) expression on CD8+ T-cells of healthy elderly and patients (AD, VaD, mixed
dementia)
phorylation which leads to microtubule depolymerisation, impairing axonal transport. Aβ also
regulates protein degradation by the proteasome and may act as an antigen for certain immune
cells. A method of reducing the negative effects of Aβ is through promoting its phagocytosis by
brain macrophages. Giving the function of these macrophages may be less effective in AD, the
recruitment of monocytes from the periphery into the brain might assist in reducing the pathol-
ogy caused by Aβ. Because of those roles, the capacity of blood leukocytes to take up Aβ was
investigated in this study.
After incubating frozen thawed blood for 17 h with amyloid beta, the degree uptake of Aβ was
determined. Mean fluorescence intensity (MFI) of HiLyte Fluor dye conjugated to amyloid beta
was used as a measure of Aβ uptake by PBMCs. To assess the degree of uptake, HiLyte fluor
MFI of PBMCs incubated with HiLyte-conjugated Aβ was divided by the MFI of PBMCs that
were incubated in parallel without Aβ in order to express the fold increase in fluorescence. This
was performed for total leukocytes as well as monocytes (CD14+ cells within the CD45+ pop-
ulation) (Fig. 3.29). No significant differences between patients (AD, VaD and mixed dementia
were considered as a single group) and controls were observed, but in contrast to the controls
which all showed similar low levels of fluorescence, a small number of dementia patients showed
relatively high fluorescence values. These findings suggest that leukocytes of some individual
dementia patients may be more effective in taking up Aβ than healthy individuals.
3.3.5 Cytokine profile
As cytokines can serve as biomarkers for inflammation, six different cytokines were measured
in the plasma of dementia patients and healthy controls with a BD CBA multiplex kit. In almost
all cases, the level of detected cytokine was below the sensitivity range of the multiplex kit used
to measure it. Results are therefore not shown.
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Figure 3.27: Leukocyte subset frequency in dementia patients and healthy controls
Percentages of B-cells (CD19+, A), monocytes (CD14+, B), NK-cells (CD56lowCD16+CD3-, C),
T-cells (CD3+, D) and NKT-like cells (CD56lowCD16+CD3+, E) within the total leukocyte population
(CD45+). Bars represent median values.
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Figure 3.28: Frequency of monocyte phenotypes in dementia patients and healthy controls
Percentages of CD36+CD11b+ (A) and CD69+ cells (B) within the CD14+ leukocytes of healthy
controls and patients (AD, VaD and mixed dementia were grouped together). Bars show the
corresponding median values. Mann-Whitney test showed no significant differences between groups.
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Figure 3.29: Amyloid beta uptake by leukocytes in dementia patients and healthy controls
Aβ uptake by the total leukocyte population (CD45+) and monocytes (CD14+). The fold fluorescence
increase of samples incubated with fluorochrome-labelled Aβ compared with samples not incubated with
Aβ is given on the Y-axis. Comparing controls with dementia patients (AD, VaD, mixed dementia)
showed there to be no significant difference between groups.
68
3.3.6 CMV serostatus
Plasma titre of anti-CMV IgG was measured with a CMV ELISA kit in order to determine the
CMV infection status of dementia patients and healthy controls. This was performed because of
the likelihood that CMV infection influences the immune signatures of interest in this study. The
results indicated that 39 of the 40 subjects were CMV-seropositive. Therefore, it was not possible
to distinguish CMV-associated influences on immune signatures. Preliminary analysis indicated
that the anti-CMV IgG titres was also not associated with differences in immune signatures.
3.4 Comparison of rpAD, MCI, AD and healthy immune sta-
tus
The final cohort of patients investigated was a more diverse group including rapidly progressive
AD (rpAD) patients. The aim of this project was to characterise the special form of AD that
is rpAD. This disease is often misdiagnosed as Creutzfeldt-Jakob disease. Patients examined in
this study had a median age of 73 and a median survival of 26.4 months from diagnosis. The
parameters examined in this study were tau and amyloid beta CSF levels, genetic factors such as
PRNP (prion protein gene) and ApoE and comorbidity analysis. It was observed that amyloid
beta levels were decreased in AD and rpAD compared to healthy controls, while tau levels were
increased in AD but not rpAD. The ApoE-E4 distribution was different for rpAD compared to
AD in that it was more similar to the healthy controls. In addition, frozen whole blood was
analysed for immune profiles. The patients have either AD, rpAD, MCI or other dementias
as shown in Table 2.5. T-cell and leukocyte analysis (n = 20) and chemokine receptor surface
marker analysis (n = 30) was performed in this sample cohort.
3.4.1 T-cell phenotypes in AD patients and healthy controls
In the previous studies differences in the T-cell subsets were found between AD patients and
healthy controls. Therefore also in these cohorts T-cell phenotypes were investigated. Percent-
age frequencies of CD4+, CD8+ and γδT-cells within the CD3+ cells were not observed to
be different between AD patients and healthy controls (Fig. 3.31). Only in the case of rpAD
was a slight trend of more CD8+ and γδ cells observed (Fig. 3.30). However a more detailed
analysis of the T-cell subsets did reveal differences. The expression of CD27 and CD28 on CD4+
(Fig. 3.31) and CD8+ (Fig. 3.33) T-cells differed between the groups. The percentage of early-
differentiated CD27+CD28+ cells was reduced in AD patients compared to healthy controls (p
= 0.0156) and the percentage of late-differentiated CD27-CD28- cells was also increased (p =
0.054). These results were consistent when using more surface markers to characterise these cell
types. Naïve cells - characterised as CD27+CD28+ CD45RA+CD45RO- - are more frequent in
healthy controls than AD patients (p = 0.0130) and late memory cells - defined by CD27-CD28-
CD45RO+ - less frequent (p = 0.0466) (Fig. 3.32). In the CD8+ compartment, the percentages
of late-differentiated T-cells were higher in AD patients compared to healthy elderly (p = 0.019
for CD27-CD28- cells and p = 0.0211 for CD27-CD28-CD45RO+ cells).
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Another observation was that of the large range of percentage frequencies of CD27-CD28- cells
in the AD patients. It was speculated that this may be explained by different disease stages given
that MMSE values ranged from 0 to 27, but statistical analysis showed no correlation. CMV
infection status may account for these differences as well, even though CMV is not known to
influence CD4+ T-cells. Separating healthy donors according to CMV+ and CMV- status and
AD patients into low and high anti-CMV IgG titre failed to explain differences; the percent-
ages of CD27+CD28+ and CD27-CD28- in these groupings did not change appreciably (Fig.
3.35). Within the CD8+ compartment, slight CMV-associated differences were observed, in ac-
cordance with previously published studies. In the study by Kujipers et al. late-differentiated
CD8+ T-cells (defined as CD45RA+CD27-) appeared in association with acute CMV infection
and expansion of these cells appeared to be unique for CMV-seropositive individuals [75]. In the
present study, the percentages of late-differentiated CD27-CD28- CD8+ cells were observed to
be slightly higher in AD patients and healthy controls that showed the highest levels of anti-CMV
IgG titre (Fig. 3.36).
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Figure 3.30: T-cell subsets in AD patients and healthy controls
Frequencies of CD4+ (A), CD8+ (B) and γδT-cell subsets in AD patients and healthy controls.
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Figure 3.31: Early and late-differentiated CD4+ T-cells in AD patients and healthy controls
Frequencies of early-differentiated CD4+ T-cells defined as CD27+CD28+ are shown in (A) and
late-differentiated CD27-CD28- CD4+ T-cells in (B). Bars indicate median values. Displayed p values
are the result of Mann-Whitney test.
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Figure 3.32: Naïve and memory CD4+ T-cells in AD patients and healthy controls
Frequencies of early-differentiated CD4+CD27+CD28+CD45RA+CD45RO- T-cells (A) and
late-differentiated CD4+CD27-CD28-CD45RO+ T-cells (B) in AD patients and healthy controls. p
values derive from Mann-Whitney tests.
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Figure 3.33: CD27 and CD28 expression on CD8+ T-cells in AD patients and healthy con-
trols
The CD27 and CD28 double positive population is shown in (A) and the double negative in (B). p values
derived from Mann-Whitney test are given above. Significant differences were only observed when
comparing the healthy elderly with the AD patients; patient sub-groups were not observed to be different
(p values not shown).
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Figure 3.34: CD8+ T-cell phenotypes in AD patients and healthy controls
Frequencies of early-differentiated CD8+CD27+CD28+CD45RA+CD45RO- T-cells (A) and
late-differentiated CD8+CD27-CD28-CD45RO+ T-cells (B) in AD patients and healthy controls. Bars
represent median values
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Figure 3.35: Association of CMV with CD4+ T-cell phenotypes
Expression of CD27 and CD28 on CD4+ T-cells analysed in association with the CMV infection status.
The patients and healthy controls were grouped according their anti-CMV IgG titre: negative < three
U/ml < low < five U/ml < high. Due to low sample numbers for the healthy donors "low" and "high"
groups were considered together as a single CMV+ group.
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Figure 3.36: Correlation of anti-CMV IgG titre with CD8+ T-cell phenotypes
CD27 and CD28 expression on CD4+ T-cells in association with CMV status. The patients and healthy
controls were grouped according their anti-CMV IgG titre: negative < three U/ml < low < five U/ml <
high. Due to low sample numbers for the healthy donors, "low" and "high" groups were considered
together as a single CMV+ group.
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3.4.2 Tregs
For this part of the investigation, activated and regulatory CD4+ T-cells were analysed. In the
inflammatory milieu in vivo amyloid beta and cytokines secreted by activated brain cells may
stimulate T-cells in the periphery. In the first pilot study lower percentages of CD25+ CD4+
T-cells in patients with mild AD were observed compared to healthy controls. Tregs are pos-
itive for CD25, but not all CD25+ cells are Tregs. In order to clearly identify Tregs, more
markers were used in this study. Combining Foxp3 with CD127, Tregs can be characterised as
CD25+CD127lowFoxp3+. All three markers were included in the antibody panel for this study,
but due to the limited cell number in the samples, maximum of two markers were used together.
Looking at the CD25+ population within CD4+ T-cells showed a clear increase in AD patients
compared to healthy controls. A non-significant trend of increased percentages of CD25+Foxp3+
and Foxp3+CD127low cells in AD patients was observed (Fig. 3.37). Another marker for Tregs
that was not included in these experiments is CCR4, but the chemokine receptor panel (Fig. 2.1),
that was performed in parallel, indicated that higher percentages (p = 0.0454) of CCR4+CD4+
T-cells were observed in AD patients compared to controls (Fig. 3.47).
3.4.3 Other leukocytes
As in the Chieti study, a panel was created for this study in order to analyse different leukocyte
populations. After selecting the leukocytes in the FSC-SSC plot, the singlets were gated and
the living CD45+ cells selected. This fraction was analysed for the expression of the following
markers: CD3 to identify T-cells, CD19 in the case of B-cells, CD14 for monocytes, and CD56
and CD16 for NK-cells. Figure 2.2 shows an example of how these populations were gated.
The percentages of T-cells for AD patients and healthy controls are shown in Figure 3.38A. The
percentages of CD3+ cells were increased in AD patients compared to healthy individuals. The
CCR panel was not employed to analyse CD3+ and CD45+ cells, but CCR analysis required that
these markers be included (Fig. 3.38B). Thus, the CD3 and CD45 frequencies may be compared
across two independent experiments. Due to exclusion of FSC high (presumably activated) cells
and perhaps due to the use of different CD3 antibodies conjugated to different fluorochromes
(CD3-Alexa Fluor instead of CD3-PerCP) the percentages of CD3+ were observed to be higher
in general for the CCR experiment, but overall both experiments show similar results in that
all patient groups showed higher percentages of T-cells. In the third image (C) in Figure 3.38
the CD3+ frequencies are plotted against the MMSE values of the corresponding patients. For
this analysis, all patients have been included, irrespective of dementia type. The results of this
analysis indicate that the frequency of T-cells is not altered with disease severity. These results
of lower T-cell frequencies in healthy elderly differ from those obtained in the Chieti study (Sec-
tion 3.3), where no differences between patients and controls were observed with respect to the
frequency of CD3+ cells. More studies are needed in order to clarify the relationship between
the frequency of T-cells and AD.
The next part of this study investigated NK-cells. In order to exclude NKT-like cells, NK-cells
were defined as CD56lowCD16+CD3- (Fig. 3.39B). First CD56 and CD16 were gated and then
CD3, but due to limited numbers of CD56lowCD16+ cells not always. As thereby some dif-
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Figure 3.37: Treg gating strategy and frequencies of Tregs in patients and healthy controls
FlowJo images with gating applied to PBMCs from a representative AD patient (upper images) and a
healthy elderly control (lower images). Percentages of CD25+ T-cells (A), CD25+Foxp3+ T-cells (B)
and Foxp3+CD127low T-cells (C) within the CD4+ T-cells in rpAD, AD patients and healthy elderly.
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ferences might not be detected any more, the frequencies of CD56CD16+ was analysed as well
(Fig. 3.39A). This is reasonable, because the frequencies of NKT-like cells only represent a very
small fraction of CD56lowCD16+ cells. The results of this analysis indicate that there were no
differences between patients and healthy controls with respect to the frequency of NK-cells.
Another leukocyte subset considered were monocytes. From the whole CD45+ population, the
percentage frequency of CD14+ cells was determined. The outcome of these experiments in-
dicated an increase in monocyte frequencies in AD patients compared to healthy controls, but
after Bonferroni correction was not statistically significant (the p value of 0.014 is slightly above
the required significance threshold of 0.01) (Fig. 3.40A). The frequency of CD14+ cells was
also investigated in the CCR study (Section 3.4.5) (Fig. 3.40B). A similar trend of higher per-
centages of CD14+ cells in AD patients compared to the healthy controls, was observed, but
with a greater p value (0.0969). Noteworthy is that both studies employed the same antibody
(Qdot655-conjugated anti-CD14), therefore these differences may be explained by the use of
different PBMC donors from the same cohort of healthy controls. To investigate these results in
more detail, the MMSE values from these patients was plotted against the percentages frequen-
cies of CD14+ cells (Fig. 3.40C). The results of this analysis were not supportive of the trend
observed in Figure 3.40 A and B. Figure 3.40D shows a more detailed characterisation of mono-
cytes in AD patients and healthy controls which included CD40. The results were not different
between AD patients and controls.
3.4.4 B-cell phenotype frequencies in AD patients and healthy controls
Frequencies of different B-cell phenotypes were investigated in addition to the previously pre-
sented results for T-cells in order to assess potential differences between AD patients and healthy
controls. According to a phenotype model that includes IgD and CD27, B-cells were divided
into four differentiation states. Naïve cells were characterised as IgD+CD27-. As shown in Fig-
ure 3.41A, the percentage frequency of these cells was slightly lower in AD patients compared
with healthy controls. In contrast, cells with a phenotype corresponding to late differentiation
stages (Fig. 3.41 C and D) were observed to be more frequent in AD patients. For the IgD-
CD27+ late-differentiated cells, the non-significant trend of higher frequencies of this cell type
was true for all AD patients (Fig. 3.41D), but for the IgD-CD27- late differentiated cells, this
was only observed in AD patients - not in rpAD or MCI patients. This trend of a shift towards
late differentiated B cell phenotypes in AD patients is consistent with the observation for CD4+
T-cells. Increased frequencies of late differentiated CD4+ T-cells were observed in AD patients
compared to healthy controls (Fig. 3.32). The MMSE values for the patients was plotted against
the frequencies of early- and late-differentiated B-cells, but no significant correlations were ob-
served (Fig. 3.41 E and F). In addition, CD40 expression on CD19+ B-cells was examined (Fig.
3.42). The results indicate that there was a wide range of percentages of CD40+ B-cells across
dementia patients and healthy controls. Comparing the median values for the respective groups,
healthy elderly controls were observed to be higher, although this was not statistically signifi-
cant. There was no association between the frequency of CD40+ B-cells and disease severity as
measured by MMSE scores (Fig. 3.42B).
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Figure 3.38: frequency of T-cells in dementia and healthy controls
Percentages of CD3+ cells within the total CD45+ population in dementia patients and healthy controls.
For A n = 42 and B n= 28.
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Figure 3.39: Frequency of NK-cells in dementia and healthy controls
Percentages of CD56lowCD16+ cells (n = 43) (A) and percentages of CD56lowCD16+CD3- cells (n =
35) (B) from CD45+ cells in patients with rpAD, AD and MCI and in healthy controls. Donors with
insufficient CD56lowCD16+ cell numbers (n<100) were excluded from the analysis in panel B.
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Figure 3.40: Frequency of monocytes in AD patients and healthy controls
CD14+ expression in; (A) on PBMCs used in the leukocyte analysis study (n = 23) and (B) on PBMCs in
the CCR study. The CD14+ percentage frequencies of all donors of the entire study (n = 29), were
plotted against the MMSE values of patients (C). D shows the frequencies of CD40+ cells out of the
CD14+ cells in panel A.
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Figure 3.41: B-cell phenotypes in dementia patients and healthy controls
Four B-cell (CD19+ cells) differentiation stages defined according to the expression of IgD and CD27.
The corresponding gating strategy is shown in Figure 2.2 and the resulted percentage frequencies are
presented here in panels A to D. The percentages of E and F show the same values of A and D, but are
plotted against the MMSE values of the patients. Figures shown in panel E and F include all 48 patients
of this study, not just those in the 4 categories shown in A to D. Thus pseudodementia and Parkinson’s
Disease patient are also included.
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Figure 3.42: B-cell phenotypes in dementia patients and healthy controls
Percentages of CD40+CD19+ cells in different dementia groups and healthy controls (rpAD, AD, MCI
and healthy elderly) (A) and percentages of CD40+ B-cells plotted against the MMSE values of the
patients. For (B), the entire dementia cohort, including pseudodementia and Parkinson’s disease, has
been analysed.
3.4.5 Chemokine receptor expression
Brain and periphery may be more closely related in conditions such as AD due to a defective
blood-brain barrier that is typically associated with AD pathology. This may allow the migration
of leukocytes into the brain via chemotaxsis that would not normally occur. Therefore, this
study investigated the expression of chemokine receptors on different leukocyte populations.
The results indicated that CD25+ cells within the CD45+ leukocyte population were increased
in AD patients compared to age-matched controls. In addition, the cell exhaustion marker, PD-
1, was observed to be more frequent in AD patients (Fig. 3.43). Following this, chemokine
receptor expression was investigated. The expression of CCR2 and CCR4 was observed to be
slightly higher in AD patients compared to controls (Fig. 3.44). In contrast, a greater difference
in the frequency of CCR5 (p = 0.0512) and CCR6 (p = 0.0138) was observed in AD patients and
healthy controls (Fig. 3.45). Given the significant result for CCR6, a more detailed investigation
took place in which monocytes (CD14+), B-cells (CD19+) and T-cells (CD3+) were analysed
separately for the frequency of CCR6 expression. This analysis indicated that CCR6 expression
was more frequent on all of these leukocyte types in AD patients compared to healthy controls
(Fig. 3.46). Analysing the T-cells in more detail indicated that CD4+ T-cells more frequently
express CCR4 (p = 0.0454), CCR5 (p = 0.0490) and CCR6 (p = 0.0009) in AD patients compared
to controls, while the same trends were observed for CD8+ T-cells, significant results were only
observed for CCR6 (p = 0.0006) (Fig. 3.47).
In addition to the analysis of percentage frequencies, the mean fluorescence values were obtained
(data not shown), These results were similar in that CCR2, CCR4, CCR5 and CCR6 tended to
be higher in AD patients compared to healthy controls, thereby supporting the results obtained
as a percentage frequency.
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Figure 3.43: Percentages of activated and exhausted leukocytes in AD patients and healthy
controls
Percentage frequencies of CD25+ (A) and PD-1+ (B) cells within the CD45+ in AD patients and healthy
controls are presented.
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Figure 3.44: CCR2 and CCR4 expression on CD45+ cells in AD patients and healthy con-
trols
Percentage frequencies of CCR2+ (A) and CCR4+ (B) cells in total CD45+ leukocyte population. Bars
represent median values.
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Figure 3.45: CCR5 and CCR6 expression on leukocytes in AD patients and healthy controls
Percentage frequencies of CCR5+ (A) and CCR6+ (B) leukocytes (CD45+)
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Figure 3.46: CCR6 expression on leukocyte subsets in AD patients and healthy controls
Percentage frequencies of CCR6 on CD19+ B-cells (A), CD3+ T-cells (B) and CD14+ monocytes (C).
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Figure 3.47: Chemokine receptor expression on T-cell subsets in AD patients and healthy
controls
Expression of CCR4 (A and D), CCR5 (B and E) and CCR6 (C and F) on CD4+ and CD8+ T-cells.
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Table 3.1: Summary of the results obtained in the different studies for this thesis
% of within Canada 1 Palermo Canada
2
Chieti Göttingen
CD3+ CD45+ = +, AD*
CD4+ CD3+ -, mAD * = = = =
CD8+ CD3+ = = = = =
early-diff. CD4+ -, mAD* -, mAD* -, mADt -, Dt -, AD*
late-diff. CD4+ +, mAD* +, mAD* +,
mAD*
+, ADt +, AD*
CD57+ CD4+ = +,
mAD*
=
KLRG1+ CD4+ +, mAD* +,
mADt
=
early-diff. CD8+ = = -, AD*
late-diff. CD8+ = = +, AD*
CD57+ CD8+ = =
KLRG1+ CD8+ +, mAD* =
CD25+ CD4+ -, mAD* +, mAD* = +, AD*
Tregs CD4+ = +,
mADt
= +, ADt
CD19+ CD45+ =
early-diff. CD19+ -, ADt
late-diff. CD19+ +, ADt
CD14+ CD45+ = +, ADt
NK-cells CD45+ = =
NKTL CD45+ =
CCR2+ CD45+ +, ADt
CCR4+ CD45+ +, ADt
CCR4+ CD4+ +, ADt +, Dt +, AD*
CCR4+ CD8+ = +, ADt
CCR5+ CD45+ +, ADt
CCR5+ CD4+ +, ADt +, AD*
CCR5+ CD8+ +, ADt
CCR6+ CD45+ +, ADt
CCR6+ CD3+ +, AD*
CCR6+ CD4+ = +, Dt +, AD*
CCR6+ CD8+ +, Dt +, AD*
CCR6+ CD14+ +, AD*
CCR6+ CD19+ +, AD*
diff = differentiated, NKTL = NKT-like cells, + = higher frequencies, - = lower frequencies, = =
similar frequencies, * = significant, t = non significant trend, mAD = mild or moderate AD, D =
dementia (AD, VaD, mixed dementia)
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Chapter 4
Discussion
4.1 T-cell phenotypes: a shift from early- to late-differentiated
CD4+ T-cells in AD patients
Early literature reports: CD45RA/CD45RO ratio as a diagnostic marker for AD
In AD patients, a state of inflammation is found in brain and in the periphery. As the BBB is
compromised, there is an enhanced interaction between the brain and the periphery. Instead of
analysing the brain or CSF, this study focused on blood lymphocytes which may have a use for
diagnostic and treatment purposes. Amyloid beta is considered to be a chronic antigenic stimulus
in AD. Monsonego and coworkers showed increased T-cell reactivity to Aβ-42 in the elderly and
in AD patients [103]. When T-cells are stimulated, they become activated and differentiate. To
monitor this process, the expression of two isoforms of a receptor that plays an important role
in T-cell activation can be assessed. A transition from CD45RA to CD45RO occurs as T-cells
undergo differentiation. Tan and collaborators considered this transition as a marker for AD. The
authors found lower levels of CD45RA+ on CD4+ T-cells and a higher CD45RO/CD45RA ratio
in AD patients, compared to healthy aged-matched subjects. Additionally, this study combined
this immune phenotype with Apolipoprotein E (ApoE) genotyping. ApoE is used as a diagnostic
marker for AD - the E4 allele is associated with a higher risk of developing AD [94]. The authors
showed that assessing the frequency of CD45RA expression in combination with the ApoE-E4
allele or the CD45RO/CD45RA ratio is more predictive for the risk of developing AD than as-
sessing ApoE alone. Therefore, the authors of this study postulated that CD45RA is a potential
diagnostic marker for AD [149]. Because analysis of CD45RA expression alone is not sufficient
to identify truly naïve T-cells, the studies presented in this thesis included further markers.
Pilot study: T-cell differentiation in AD according to the CCR7-CD45RA model
As reviewed by Appay et al., naïve and memory T-cells can be characterised on the basis of cell
surface markers that play roles in homing, proliferation and effector functions [6]. This thesis
pilot study was based on a model employing CCR7 and CD45RA (Fig. 1.4, Section 1.2). CD4+
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and CD8+ T-cells were divided into four differentiation stages: naïve (CD45RA+CCR7), cen-
tral memory (CM, CD45RA-CCR7+), effector memory (EM, CD45RA-CCR7-) and terminally
differentiated effector memory cells (TEMRA, CD45RA+CCR7). In a small group of well-
defined Canadian patients diagnosed with mild AD, significantly lower percentages of naïve
CD4+ (CCR7+CD45RA+) cells in AD patients than in controls were found. Reciprocally, sig-
nificantly more EM and TEMRA cells were observed in AD patients. For CD8+ cells, no sig-
nificant differences compared to healthy elderly were observed. The only differences were the
age- and CMV-related increases in late-differentiated CD8+ cells compared to young individuals
that would normally be expected. In addition to this, the expression frequency of CD28 was
analysed. These results indicated that the fraction of CD28- cells within CD4+ and CD8+ T-
cells was significantly higher in AD samples compared to young and elderly healthy controls.
Therefore these results suggest that both the CD4+ and CD8+ T-cells are affected in AD. An
explanation as to why no differences regarding the CD8 phenotype were observed between AD
patients and controls using the CCR7/CD45RA model may be that the effects of age are so pro-
nounced and thus the frequencies of late-differentiated CD8+ T-cells already so low that it leaves
little room for the influence of any additional effects [77]. To investigate whether this hypothesis
is true, combinations of other markers where analysed in the subsequent studies.
An extended differentiation model reveals lower frequencies of naïve CD4+ T-cells in AD
patients
Following these findings, these results were confirmed in a separate study with a larger cohort
from a different population. In patients with mild and moderate AD from Sicily, a shift from early
to late differentiated stages in CD4+ but not CD8+ T-cells was also observed. For this study, a
different model of T-cell classification was applied, in which the expression of CD27 and CD28
was examined, followed by CD45RA and CD45RO. Naïve cells were defined as CD27+CD28+
CD45RA+CD45RO- and late-differentiated cells as CD27-CD28- CD45RA+CD45RO+. A tran-
sition from early- to late-differentiated cells in the elderly compared to the young individuals was
predominately observed for CD8+ T-cells. In contrast to this, comparing AD patients and age-
matched controls the differences were limited to CD4+ T-cells, but again in case of naïve CD8+
T-cells the frequencies were already so low in the age-matched elderly, that a further reduction
due to the AD pathology is not detectable. A reason why this age-related effects are so strong in
this cohort compared to others (e.g. Götttingen study participants) is that all young individuals
were CMV- and all elderly (controls and AD patients) CMV+.
To support the hypothesis of immune exhaustion and "immunosenescence" caused by chronic
stimulation, further markers of immune exhaustion and senescence were investigated. KLRG1
(Killer cell lectin like receptor G1) belongs to a superfamily of inhibitory receptors expressed on
NK-cells. Its expression identifies mature CD4+ or CD8+ T-cells capable of secreting cytokines,
but with decreased or absent proliferation capacity upon stimulation [125]. CD57 (HNK1) is a
receptor that negatively regulates NK-cells that is also expressed on CD8+, and to a lesser extent,
on CD4+ T-cells. This has been proposed to be a marker of "replicative senescence" in T-cells
[18]. In the cohort of Sicilian AD patients the percentage of CD57+ cells was significantly higher
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within T-cells of CMV+ elderly compared to CMV- young. Within the age-matched controls we
could identify two groups, one with over ten percent of CD57+CD4+ T-cells and one with under
ten percent, but still higher frequencies than in young individuals (3.4). One explanation could be
that all age-matched individuals are CMV+, but some possess a higher anti-CMV IgG titre. Be-
cause this wasn’t determined in this study the answer to this question remains to be investigated.
Comparing AD patients and elderly controls no differences were observed, neither within CD4+
nor CD8+ T-cells. The frequency of KLRG1+ CD4+ T-cells was found to be significantly higher
in AD patients than in healthy controls (3.4). Regarding CD8+ T-cells the difference was a non
significant trend [111].
Confirmation of previous findings; more advanced CD4+ T-cell differentiation in AD
To examine and expand upon the reported finding of higher frequencies of more advanced T-
cell differentiation in AD, cohorts with different genetic backgrounds and environments were
used to perform three further studies for this thesis. PBMC and blood samples of AD patients
from different locations (Canada, Germany and Italy) were collected. For these studies, the sam-
ple cohort was extended to include patients with severe AD, VaD and mixed dementia. The
T-cell analysis was based on models relying on markers employed in previous studies [6, 111].
The results of these studies indicated that CD4+ T-cells expressing the costimulatory molecules
CD27 and CD28 occur in higher percentages in healthy controls than in AD patients. Par-
allel to this, the CD27 CD28 double negative population of late-differentiated T-cells was in-
creased in AD patients, although these results were not all statistically significant. The trends
were consistent when the CD45 isoforms were included in the analysis. The percentages of
CD27+CD28+CD45RA+CD45RO- CD4+ T-cells were found to be lower in the AD cohorts
compared to healthy controls. A shift from early- to late-differentiated CD4+ T-cells was de-
termined, consistent in all cohorts. To investigate whether this is a phenomenon of early onset
which increases in late AD, patients of different AD stages were analysed.
T-cell phenotypes in different disease stages
While the initial studies included patients with mild and moderate AD, subsequent investiga-
tions with the Chieti cohort included patients with more severe disease (indicated by low MMSE
scores). Correlating the MMSE scores with T-cell phenotypes showed no significant relation-
ships. In the Canadian study cohort, patients with mild, moderate and severe AD were recruited.
Those with mild and moderate AD showed similar immune signatures, while patients with se-
vere AD were more similar to the healthy elderly controls in that they showed slightly higher
frequencies of naïve T-cells and lower frequencies of late-differentiated cells. A follow-up of the
Göttingen AD patients hinted towards a reversal of these differences. The frequencies of naïve
CD4+ T-cells were higher after the follow-up period, but follow-up was only available for five
patients which did not allow the application of statistical analysis (data not shown). If inflamma-
tion is the driving force for enhanced T-cell differentiation in AD, a chronically stimulated and
exhausted immune system with reduced production of inflammatory cytokines might explain the
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decreased frequencies of late-differentiated T-cells observed upon follow up. Supporting this
idea of immune exhaustion is a study that reported LPS stimulated blood cells to release less
IL-6 and IL-1β in patients with severe AD [168].
Impact of CMV on T-cell phenotypes
Given the observation that CMV impacts the immune system in addition to the impacts exerted
by AD, CMV+ and CMV- individuals were investigated separately. In the Chieti and Canadian
cohorts, the number of CMV- participants was too low to allow for statistical analysis of these
groups separately. The Göttingen cohort was analysed while considering CMV status, but no
significant differences were observed. Only a trend of higher frequencies of late-differentiated
CD8+ T-cells in CMV+ healthy elderly controls and AD patients compared to their CMV- coun-
terparts.
Suggestions of the effect of CMV were provided by Wikby et al. in their immune pro-
file analysis of an elderly Swedish population. In this four year follow-up study, cognitive
impairment together with an "immune risk profile" (IRP) predicted 58% of observed mortal-
ity. Suggesting an allostatic overload amongst the IRP individuals, all those with cognitive
impairment did not survive the follow-up period. The IRP markers included were an inverted
CD4/CD8 ratio, higher frequencies of late differentiated CD8+ T-cells and persistent CMV in-
fection. Analysis of late-stage CD8+ cells (CD27-CD45RA+) in IRP individuals revealed lower
numbers of these cells in those with cognitive impairment. On the other hand, higher numbers
of CD8+ T-cells with an intermediate phenotype (CD27+CD45RA- and CD27-CD45RA-) were
found. The authors suspected impaired maturation of CD8+ T-cells in individuals with the IRP
and point to studies in which reduced effector cells were associated with decreased immunity to
latent EBV and CMV infections in immuno-suppressed individuals. Once activated, cells of indi-
viduals in the IRP category produced reduced levels of the growth factor IL-2 and differentiated
poorly, compared to their counterparts in the non-IRP group [168].
Phenotype of brain infiltrating T-cells in AD
That memory cells are present in the brains of AD patients was demonstrated by Togo and col-
leagues who examined the expression of CD45 isoforms on cells in the brain. The authors ob-
served that CD45RA+ cells (defined as naïve cells in that study), were infrequently found among
cells in the brains of AD patients, whereas CD45RO, a marker for activated or memory cells, was
commonly observed on cells in the brain of AD patients. The authors of this study also exam-
ined the expression of CD27. In the hippocampus it was observed that CD3+CD27- cells were
more frequent than CD3+CD27+ cells in the brains of AD patients [151]. Although this study
did not employ a comprehensive naïve cell phenotyping strategy, instead relying on CD45RA,
these findings agree with those of studies examining T-cells in the peripheral immune system of
AD patients. The observation that memory T-cells but not naïve cells migrate to the brain [163],
implies that T-cells undergo stimulation in the brain and the periphery separately independently.
One hypothesis to explain a parallel stimulation is that Aβ, which can cross the disrupted BBB
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in AD, is responsible for T-cell activation and differentiation in both compartments. On the other
hand, CSF levels of Aβ in the cohort of AD patients in this study were, in agreement with cur-
rent literature, decreased compared to healthy controls, which questions its role as a stimulus
[136]. Soluble Aβ applied in the T-cell in vitro stimulation assay in this study did not result
in cytokine production. Therefore other candidates responsible for immune stimulation, for ex-
ample CMV might be considered. In healthy individuals, CMV infection was shown to cause
chronic antigenic stress, resulting in higher frequencies of late differentiated T-cells [30] and also
in this study AD patients with an high anti-CMV IgG titre tended to have higher frequencies of
late-differentiated T-cells compared to CMV- patients. As CMV-infected cells were shown to
occur in the brains of AD patients by Lin et al., it may act as an immune stimulus within the
brain [83]. The BBB is composed of endothelial cells and van de Berg et al. reported endothelial
cell damage caused by CMV-induced effector T-cells [155]. The associated chronic endothelial
cell inflammation is characterised by the production of the chemokine fractalkine (CX3CL1) by
these cells. Responsible for this endothelial cell activation are pro-inflammatory cytokines, such
as TNF and INFγ, secreted by T-cells [15]. Bolovan-Fritts et al. further demonstrated that this
effect is limited to CD4+ T-cells which were stimulated by CMV antigens. CD8+ T-cells, NK-
cells and monocytes did not induce fractalkine production, but were attracted by the chemokine,
possibly contributed to the vascular damage and migrated through endothelial cells in an in vitro
model [15, 14]. Induction of adverse effects on the BBB could explain why a higher anti-CMV
IgG titre is considered a risk factor for AD (see Table 1.1). Collectively, these data indicate that
immunological stress may contribute to AD and the inflammation that is typically observed in
AD patients.
Conclusions
A study in elderly individuals with impaired functional status reported fewer B-cells and CD4+ T-
cells and more CD8+ T-cells and NK-cells and a resultant decreased CD4:CD8 ratio. In addition
to lower responses to CD3 stimulation, higher CMV responses were reported. These observations
were attributed to the limited leukocyte and B-cell repertoire and greater differentiation of these
cells, caused by CMV infection. In addition, anti-CMV titres were higher in the group with
poor motor ability. The authors concluded "that the functional decline of elderly individuals was
clearly associated with the aging of their immune system, and the intensity of the response to
CMV" [101]. Negative CMV effects could also be suggested for AD patients.
Another contributor to immune cell differentiation and health status could be Aβ. Jozwik et al.
observed higher percentages of activated (CD69+, HLA-DR+) CD4+ T-cells in PBMCs of AD
patients with a high proliferative response to Aβ compared to those with a low response [69].
Their report indicates that Aβ has a direct influence on leukocytes. A suggestion that increased
T-cell differentiation leads to higher patient mortality is evidenced by the IRP. The immune risk
profile was established in the longitudinal OCTO NONA studies in a Swedish population. In
addition to earlier death, participants in the risk category showed lower leukocyte proliferative
capacity, lower B-cell counts, fewer naïve CD8+ cells and CMV seropositivity [168].
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4.2 Distribution of regulatory T-cell subsets in AD patients
Frequencies of activated T-cells in AD
Together with systemic inflammation, many other immunological alterations can be observed in
AD. One of these is an increase in activated leukocytes in the brain and periphery [154, 81]. Two
markers of early stage activation are CD69 (a human transmembrane C-Type lectin protein) and
CD25 (the alpha chain of the IL-2 receptor). Schindowski et al. investigated CD69 expression
in AD patients and demonstrated an increased frequency of activated CD4+ and CD8+ T-cells in
AD patients compared to healthy elderly controls [134]. Pellicanó et al. observed a significant
increase in CD69+ T-cells only after stimulation with Aβ-42 in vitro. In addition, the authors
found no significant differences in CD69 and CD25 expression frequency in B-cells between AD
patients and healthy controls, showing a limitation of the activation among immune cells [110].
Jozwik et al. divided AD patients and healthy elderly into two groups according to their prolif-
erative response to Aβ peptide in vitro. These authors found an increase in HLA-DR and CD69
expression frequency, but not CD25 on CD4+ T-cells in patients who showed a greater response
to Aβ stimulation compared to those who showed less of a response [69].
Conflicting studies regarding the change in CD25 expression frequency have been reported.
Some studies have reported an increase in CD25+ T-cells in AD patients [88, 110], while in
the pilot study in this thesis lower levels were found (Section 3.1.1)[77]. In addition, the phe-
notype of CD4+CD25high T-cells was determined using a model with CCR7 and CD45RA. In
this study it was found that effector memory cells (CCR7-CD45RA-) dominate in AD patients
and that the frequencies of earlier differentiation stages were lower compared to healthy young
and old controls. This trend is similar for the phenotypes of all CD4+ T-cells in AD patients
compared with healthy controls (Section 3.1.1)[77]. The frequency of CD4+CD25+ T-cells was
not different between AD patients and controls in the Chieti cohort, while higher frequencies
were observed in AD patients in the Göttingen cohort. The differences between the studies may
be attributable to differences in the AD patient cohorts. One explanation is that in MCI and early
AD the percentages of activated cells increases but due to stress and immune exhaustion in AD
patients, the frequency of these cells is lower. This hypothesis could not be confirmed in the
present studies, as no correlation between disease stage according to patient MMSE scores and
CD25 expression was detected. For true proof longitudinal studies are needed.
Treg frequencies and phenotypes in AD patients
The population of CD25+ T-cells includes regulatory cells. To define the populations of Tregs,
Rosenkranz et al. measured the Foxp3 expression frequency in healthy young and old indivi-
duals as well as dementia patients. The authors only observed differences in CD4+ Foxp3+
percentages between young and old individuals, not between healthy elderly and patients with
AD or Parkinson’s disease [127]. The inclusion of the CD127 protein re-confirmed these results.
As determined in a pilot study of this thesis, the percentages of CD4+CD25+CD127lowFoxp3+
Tregs were increased in elderly compared with young individuals in a Sicilian population. This
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study failed to observe differences between healthy elderly and age-matched patients with mild
or moderate AD (Section 3.1.2) [111]. As well in the following three studies presented in this
thesis (Chieti, Canada and Göttingen) no significant differences in Treg percentages between
patients and controls were found using CD25, Foxp3 and CD127 proteins to characterise Tregs,
but a non-significant trend of increased Foxp3+ CD4+ T-cells in CMV+ compared with CMV-
AD patients was observed.
Even if the percentages of Tregs are not altered in AD, these cells may still play an important
role in AD pathology. Rosenkranz et al. observed that Tregs from AD or Parkinson’s patients,
compared to healthy controls, more effectively suppressed T-cell proliferation [127]. A study
reported by Saresella et al. showed that Aβ-stimulated-T cell proliferation was reduced in MCI
patients compared to AD patients and Treg-mediated suppression was more efficient in MCI
patients compared to AD patients. In healthy elderly controls, stimulation with immunogenic
Aβ peptides did not elicit the generation of Aβ-specific T-cells. This study indicates a potential
connection between Treg activity and disease progression. Furthermore the authors examined
the Treg phenotype and observed PD-1- Tregs to be increased in MCI patients. PD-1-expressing
Tregs cells are considered to possess the highest suppressive capacity. These results suggest that
in AD patients the immune system is attempting to limit the degree of inflammation by enhancing
Treg activity, although given that increased inflammation is commonly observed in AD patients
this would suggest that the immune system is unsuccessful in this attempt. At early stages of
dementia (MCI patients), the activity of Tregs increases, but later drops in AD patients, at least
in the study of Saresella et al. In contrast to previous reports, the results from their study indicate
that the total percentages of CD25highFoxp3+ CD4+ T-cells were diminished in healthy elderly
compared to middle aged controls, MCI and AD patients [132]. These differences compared to
our pilot study may be explained by the greater age range of the controls, and the use of different
Treg marker proteins.
Given that in the pilot study presented in this thesis (Section 3.1.1), the phenotype of CD4+
CD25high T-cells shifted to a predominantly memory type in AD patients, CD45RA and CD45RO
were included in subsequent Treg analyses. By gating resting and activated Tregs according to
the models published by Miyara et al. and Booth et al. [98, 16] several Treg populations were
observed, but there were no significant differences between patients and controls. In the Chieti
study of chemokine receptors, trends of higher CCR expression on CD25+ T-cells of AD patients
compared with controls were observed. Although these results were not significant, they suggest
an association between activated T-cells and AD. As possible reasons several factors could ac-
count for this (viral infection, systemic inflammation, tau and Aβ), but so far no definite evidence
has been provided.
4.3 Leukocytes in healthy controls and AD patients
4.3.1 Controversial results concerning the frequency of T-cells in AD
Previous studies have observed a decrease in the total frequency of CD3+ T-cells in AD patients
compared to age-matched controls [124], but analysis of T-cell subsets led to contradictory re-
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sults. In the pilot study presented in this thesis (Section 3.1.1) significantly reduced CD4+ T-
cells were observed in AD patients. This resulted in a lower CD4+/CD8+ ratio in the T-cell
population in patients with mild AD compared to healthy age-matched controls [77]. This obser-
vation might be explained by greater susceptibility to apoptosis of CD4+ T-cells in AD patients
compared to controls. This is supported by a study describing apoptosis of CD4+ T-cells and
NK-cells in AD patients [135]. In contrast, Richartz-Salzburger et al. found no difference in
the CD4+/CD8+ ratio between AD patients and healthy controls [124], while other reports have
observed a higher CD4+/CD8+ ratio [138]. The cause of these discrepancies is not known, but
may be associated with disease stage of the patients analysed, or with the failure to exclude
NK-cells that express CD8 from the analysis. Therefore the present studies included NKT-like
cells in the analysis. In the Chieti and Göttingen cohorts, no differences in the percentages of
CD56lowCD16+CD3+ NK-T-cells within the total CD45+ cells were seen between AD patients
and controls. This observation led to the conclusion that the frequency of NKT-like cells does not
influence the percentages of CD8+ T-cells in AD patients compared with controls. In addition,
in three of the four studies in this thesis, no differences in the percentages of CD4+ and CD8+
T-cells in patients and controls were detected. Another T-cell subset of interest was γδT-cells.
These cells are predominately found among CD4-CD8- T-cells and relevant, because γδT-cell
subsets were shown to produce predominantly pro-inflammatory cytokines or function as APCs
to induce a Th2 response of CD4+ T-cells [102] and so might contribute to inflammation in AD.
Another point is their ability to "operate as a professional phagocyte" [173]. γδT-cells were
investigated in the Canadian cohort. No significant differences were found in the percentages
of CD4-CD8- and CD4-CD8-TCRγδ+ cells when comparing AD patients with healthy elderly
controls. In the CD4-CD8-TCRγδ+ population, a marginal increase in the frequencies of these
cells was observed in AD patients, which could not be confirmed in the cohort of donors from
Chieti and Göttingen. Besides antibody opsonisation, CD16 plays a main role in phagocytosis
[173]. Therefore the hypothesis could be investigated, that the frequency of the whole γδT-cell
population does not differ between patients and controls, but that percentages of individual sub-
sets, such as CD16+ γδT-cells, are altered. Phagocytic capacity was demonstrated for bacteria
and synthetic beads, but the uptake of Aβ is one of the many open questions in this field to
be investigated. In addition a phenotype analysis could reveal differences as shown for CD25+
T-cells [77].
4.3.2 Reduced frequencies of naïve B-cells in AD patients compared with
healthy controls
The frequency and phenotypes of B-cells
Few studies have investigated B-cells in AD patients. While some studies led to the conclusion
that the frequency of CD19+ B-cells is decreased in AD patients, e.g. [124], other studies have
observed no differences in the frequency of CD19+ B-cells in patients with MCI or AD, as re-
viewed by Rezai-Zadeh et al. [123]. Patients from the Chieti cohort in the present study showed
no differences in the percentage of CD19+ within the CD45+ leukocyte population across the
different dementia types examined.
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Another aspect that was investigated was the lymphocytic expression of APP - within lympho-
cytes primarily related to B-cells - which was found to be increased in MCI patients. This finding
is thought to be related to dysregulated APP metabolism in the brain. These findings hint at the
systemic failure of B-cells to activate and effectively process APP, thus they contribute to AD
pathology [123]. As reviewed by Rezai-Zadeh et al., further B-cell analysis included measure-
ments of CD69 on the surface of B-cells following mitogenic treatment. The results indicated that
the expression of CD69 was decreased in AD patients compared with controls. The consequences
of CD69 on AD have so far not been investigated. One consideration is the production of Aβ
autoantibodies, which may be related to Aβ neurotoxicity. Several studies have been performed
by separate investigators, but the outcomes have been contradictory, perhaps reflecting the dif-
ferent experimental techniques employed [123]. The production of antibodies is predominately
by differentiated B-cells. In a more detailed analysis, this study assessed B-cell phenotypes.
Four differentiation stages were characterised according to the expression of IgD and CD27.
The results indicated no significant differences in the frequency of these phenotypes between
AD patients and healthy controls, but a slight trend of lower frequencies of naïve IgD+CD27-
B-cells, and a slightly higher level of late-differentiated (IgD-CD27+ and IgD-CD27-) B-cells in
AD patients compared to healthy elderly was observed. This trend is similar to the finding of
higher frequencies of more differentiated T-cells in AD patients and counts as another sign for
ageing of the immune system in AD.
Relevance of CD40
CD40 is a glycoprotein and member of the TNF-receptor superfamily that is upregulated by
the pro-inflammatory cytokine IFNγ. Ramirez et al. investigated CD40 expression on brain
endothelial cells of patients affected by HIV-1 encephalitis (HIVE). The authors concluded that
there was an important role for CD40 and its ligand CD40L in BBB regulation [118]. When ex-
amining HIVE patients with cognitive impairment, CD40-CD40L interactions led to increased
inflammation and production of adhesion molecules in endothelial cells. Levels of reactive oxy-
gen species and as a consequence chemokine secretion were enhanced as well. Soluble CD40L
can decrease levels of ATP. Appropriate ATP levels are required for maintenance of tight junc-
tion permeability in the BBB [27]. Other reports have demonstrated that CD40 expressed on
B-cells resulted in their activation and differentiation via T-cells [47]. B-cell-T-cell interactions
are probably influenced by CMV, as mouse CMV glycoprotein m155 was shown to inhibit CD40
expression [86]. The results of the study performed in this thesis suggest that a more differenti-
ated B-cell phenotype is found in AD patients, which might be related to CD40. Therefore the
analysis of CD40 expression was included in this study. In the Göttingen cohort, CD19+ cells
in AD and MCI patients did not show significant differences in the frequency of CD40+ cells
compared to controls. The values show a broad range with a slightly higher median in case of
the healthy elderly, although this trend did not reach significance.
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4.3.3 No difference in the frequency of NK- and NKT-like cells in AD
patients
The percentages of NK-cells were not shown to be different between dementia patients and con-
trols in earlier reports [123]. Both, the Chieti and the Göttingen studies from this thesis, confirm
these reports. The percentages of CD56low CD16+CD3- cells within the CD45+ population did
not differ between AD patients and controls. This means that either NK-cells do not play an im-
portant role in AD, or that sufficient NK-cells are produced to compensate NK-cell exhaustion
in the brain. A third hypothesis is that NK-cell numbers are not affected by AD, but instead their
functionality is altered with disease progression. This is supported by studies that have found
increased or decreased NK-cell activity in AD patients compared to healthy controls [123].
A less frequent leukocyte subset, the NKT-like cells, was also investigated but the percentage of
these cells (defined as CD56lowCD16+CD3+) did not differ between patient and control groups.
Because NKT-like cells respond to cytokines and have a role in modulating the immune system,
they might be associated with AD pathology. The hypothesis proposed for NK-cells may also
apply to NKT-like cells - the frequency of these cells does not vary, but their functional capacities
might be altered. This remains to be investigated in future studies.
A previously reported finding that may be an important consideration is that NK-cells play a role
in the recognition and regulation of virally infected cells. They are also particularly important
in immunosurveillance against CMV [101]. NK-cell numbers increased with age and this has
been proposed to be due to an increased response against CMV. Greater frequencies of NK-cells
with reduced functional status have been reported in the elderly. In these elderly individuals
higher anti-CMV antibody titer was also observed [101]. Originally, it was an aim of this thesis
to investigate if NK-cells differ between CMV- and CMV+ AD patients, but due to insufficient
participant numbers this outcome was not achieved.
4.3.4 No significant differences in the frequency of monocytes between de-
mentia patients and healthy controls
Characterisation of the monocyte population in AD patients
To the best of my knowledge, the total number of monocytes in dementia patients has not pre-
viously been assessed. Here the frequencies of monocytes defined as CD14+CD45+ cells were
determined. In the Chieti study cohort no differences between patients and controls were de-
tected, while in the Göttingen cohort a slight decrease of CD14+ cells within the CD45+ popula-
tion was observed in AD patients. In previous studies using a transgenic murine AD model, the
loss of CD14 expression was associated with enhanced expression of genes encoding the pro-
inflammatory cytokines TNF and IFNγ [122] and a systemic inflammation is characteristically
in AD patients. CD14 - an LPS receptor - was demonstrated to interact with Aβ and to create an
inflammatory response in mice. One hypothesis is that aggregated Aβ fibrils mimic pathogen-
associated microbial patterns that are biophysically similar. Other promoters of LPS-mediated
inflammation are scavenger receptors and CD11b/CD18. In hybridisation experiments, CD14
mRNA from APP23 transgenic mice was more highly expressed compared with wild type mice
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[37]. These results show that in addition to the frequencies of CD14+ cells as analysed in the
Chieti and Göttingen studies, the relative proportion of different monocyte subsets could be of
importance. Seidler et al. showed that healthy elderly compared to healthy young did not differ
in terms of total leukocyte or monocyte frequencies, but the proportion of the subsets of these
cell types did. "Non-classical CD14+CD16+ monocytes significantly increased with age, but
displayed reduced HLA-DR and CX(3)CR1 surface expression in the elderly". But the authors
state that there was no significant correlation between "Classical CD14++CD16-" monocyte
frequencies or counts and age [137]. It is possible that certain monocyte subtypes are present
in differing proportions in AD patients or that their activation status or functionality is different,
even if the frequency of monocytes is constant or diminished due to AD-associated immune ex-
haustion.
This may also be the case for CD11b and the scavenger receptor CD36, which helps to mediate
microglial and macrophage response to Aβ fibrils and which seems to play a key role in AD-
associated inflammation [48]. In the Chieti study cohort, the frequencies of monocytes did not
differ significantly between patients and controls, but the mean fluorescence intensities were not
considered. Considering this, it is possible that even though the proportion of cells was not dif-
ferent, the expression of the proteins of interest on each monocyte may have been different in the
AD patients compared to the controls. More detailed studies are required, particularly consider-
ing that CD11b+ cells and CD11c+ cells have been reported to be localized with Aβ plaques in
APP transgenic mice. CD11b+ are phagocytic cells which produce pro-inflammatory cytokines
including IL-1β, TNF in addition to promoting NO, free radicals, chemokines and activating
complement. After incubation with IFNγ, microglia differentiated into CD11b+ and CD11c+
cells that served as APCs for both Aβ 1-40 and Aβ-42 and supported CD86-dependent prolifer-
ation of Aβ-reactive T-cells. In addition, IFNγ and Aβ-stimulated microglia and astrocytes led
to NO-mediated toxicity that affected T-cells resulting in apoptosis [99]. This may also account
for the observed decrease of CD14+ leukocytes in the Göttingen cohort.
CD40 expression on monocytes
Lymphocytes as well as microglia are activated in AD. One mediator for this microglia activation
is an interaction between CD40 and CD40 ligand (CD40L). These two molecules are typically
up-regulated in AD [123]. Both CD40 and CD40L are present as soluble and membrane-bound
forms. In addition to their role in costimulation of immune cells, these interaction partners are re-
ported to enhance neuroinflammation, modulate APP processing and reduce Aβ clearance from
the brain. When microglia were cocultured with primary neurons in the presence of Aβ peptide,
together with IFNγ or CD40L, microglia secreted high levels of TNF, which led to neuronal
injury [47]. Given that reactive microglia in the brain express CD40 and that vascular CD40
expression has been found to be elevated in AD-associated brain lesions [152], the expression
of CD40 on monocytes was investigated in the Göttingen AD cohort in this thesis. This study
showed similar frequencies of CD14+CD40+ cells in AD patients and healthy elderly controls.
The results were similar in the case of CD40+ B-cells. Given that this study only examined the
frequency of these cells, the degree of CD40 expression may have been different between the two
groups. Another aspect that could be examined in future studies could be the characterisation of
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CD40 on monocyte subsets (CD16+ monocytes, for example). But it may also be the case that
CD40 on monocytes and B-cells does not play an important role in AD.
Activated monocytes in AD
To investigate the activation state of monocytes, Kusdra et al. assessed the expression of CD69 on
monocytes and macrophages. The results indicated that the percentages of CD14+CD69+ cells
were higher in AD patients compared to healthy controls. The Chieti study cohort investigated
in this thesis did not confirm the results of Kusdra et al. No differences between patients and
controls were seen in the frequency of CD14+CD69+ cells. Another suggestion of the impor-
tance of CD69 in AD was provided by Schindowski et al., who reported a higher percentage of
CD8+CD45RO+CD69+ T-cells after mitogenic stimulation in AD patients compared to healthy
elderly [134]. Given that in the study by Schindowski et al., the basal levels of CD69+ T cells
were similar between the two groups, the Chieti cohort studied in this thesis may show dif-
ferences between AD patients and controls in the frequency of CD69-expression T cells after
exposure to a stimulus. Chronic immune stimulation might be the normal state in AD patients.
This is supported by several studies such as that by Pellicanó et al. This study showed that
CD69-expressing T-cells in AD patients in a Sicilian population were slightly more frequent in
comparison to those in healthy controls. These slight increases were statistically significant when
PBMC samples were cultured with Aβ-42 protein [110]. Given that these differences were not
seen in CD19+ cells, it is not possible to comment on whether or not these results are indicative
for other leukocyte cell types. These experiments remain to be performed in future studies. The
conditions for these experiments should be carefully chosen as a wide range of conditions have
been employed by other investigators. For example Stieler et al. incubated PBL with phyto-
haemagglutinin (PHA, 12 µg/ml), pokeweed mitogen (PWM, 4 µg/ml), Protein A (50 µg/ml) or
nerve growth factor (NGF, 100 ng/ml). Stieler et al. used siliconized glass tubes to prevent the
adhesion of isolated cells on the surface of the tubes during the incubation time of 4 h. Whether
the authors investigated CD3+CD4+ or CD19+ lymphocytes, the stimulation index (defined as
the ratio of CD69 expression after mitogenic stimulation to unstimulated control) correlated in-
versely with patient MMSE scores, irrespectively of the stimulus applied. PHA was reported
to be the strongest stimulus. For other leukocyte cell types studied (CD45+, CD3+ or CD8+)
the observed trends did not reach significance [145]. The conditions contrast with the study by
Pellicanó et al. in which 24-well plates for 48 h of stimulation at 37◦C were used [110] and this
could explain different results.
4.4 Degree of T-cell cytokine production does not differ be-
tween AD patients and healthy controls
Along with age the level of C-reactive protein and pro-inflammatory cytokines increase. The
resulting low-grade systemic inflammation termed "inflammageing" is associated with several
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age-related diseases including cardiovascular disease, type 2 diabetes and dementia [8]. The
OCTO and NONA longitudinal studies demonstrated that in a Swedish cohort low-grade inflam-
mation predicted two-year mortality in very old individuals independently of their health status
[169]. In addition, levels of the pro-inflammatory cytokine IL-1 and the "multifunctional" IL-
6 were suggested to be associated with impaired cognition [168]. To place their results in the
context of AD, the authors referred to studies in which intracerebral injection of an APP peptide
in mice resulted in increased brain and plasma-IL-6. Based on these and other findings, Wikby
et al. suggested to characterise late life neurodegeneration as chronic inflammatory condition
where microglia are activated. In their study of predictors of mortality the authors established an
immune risk profile (IRP) with CMV seropositivity as one main hallmark. To control persistent
CMV infection CD8+CD28- T-cells are generated and the number of these differentiated CD8+
cells were elevated in individuals of the IRP cohort. A correlation between the IRP and IL-6
levels was not found; both parameters predicted survival independently [168, 169]. Bartlett et al.
investigated the role of CMV in inflammageing over ten years and concluded that "CMV infec-
tion is not a primary causative factor in the age-related increase in systemic inflammation" [8].
This indicates that CMV does not act as a stimulus that causes the inflammation present in AD,
but adds an additional burden. In the OCTO and NONA studies all individuals with cognitive
impairment which were in the IRP group were deceased at follow-up [168]. As an alternative
factor, in this thesis a possible role of Aβ as driving force for the inflammation was investigated.
The expression of cytokines by leukocytes in the peripheral immune system and the best method
for their assessment remains a controversial topic. A review of the literature was provided by
Lee et al. [78]. The authors report that amyloid beta synthesis was induced by cytokines secreted
from microglial cells, astrocytes and/or neurons. Aβ, in turn, induced the production of IL-1β,
TNF and IL-6 in astrocytes and microglia in vitro. AD is a disorder of the brain, thus CSF is
the ideal source to measure cytokines. But it is far easier and more cost effective to obtain blood
from patients as it is tested as part of routine clinical examination. Therefore, biomarkers for
AD that are present in the blood would be very useful for diagnosis and for the determination
of disease progression. Given that the inflammatory state in AD is not only limited to the brain
but is systemic, blood may provide relevant information regarding the disease. Damage to the
BBB is common in AD patients, which allows the passage of small molecules. Aβ may be able
to pass the BBB and go on to damage lymphocytes in the periphery. This could result either in
reduced cytokine production, or may result in activation with a subsequent increase in cytokine
production, as Blurton-Jones and La Ferla postulate for what may be occurring in the brain [13].
A potential clue is provided by Fiala et al. - they show that Aβ stimulates monocytes to secrete
cytokines [40].
In the present study cytokine production by PBMCs from healthy donors and AD patients was
analysed. PBMCs may migrate to the brain where PBMCs along with the cytokines they produce
may play an important role in the pathology of AD. Therefore it was of interest to investigate
the capacity of these cells to produce cytokines. The experiments summarised in Section 3.2.4
showed no reduction in cytokine production, which if observed, may have been due to Aβ tox-
icity in the blood. The live:dead cell discriminator EMA did not indicate a large increase in the
proportion of dead cells after Aβ stimulation (data not shown). PMA / ionomycin stimulation
resulted in a similar increase in cytokine production in both AD patients and controls. Future
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studies could examine not only the frequency of cytokine producing cells, but also the degree by
which the positive cells express the cytokines (either by using the MFI with flow cytometry or
by measuring cytokine levels in the plasma).
Additionally, a co-culture experiment with PBMCs and Aβ protein and stimulation with PMA
and ionomycin may assist in investigating if Aβ protein is capable of inhibiting cytokine produc-
tion. Other experiments performed in this study do not confirm another hypothesis that there is
increased cytokine production in AD patients due to Aβ-reactive T-cells as incubating PBMCs
with Aβ did not result in an appreciable increase in cytokine production. Despite these results,
Monsongeo et al. observed increased T-cell reactivity to different amyloid beta peptides mea-
sured by proliferation and cytokine production, in elderly individuals and AD patients. But the
authors of this study used longer incubation times (30 h compared with the 17 h in this thesis)
and did not detect the production of all cytokines (for example, low levels of IL-4 and IL-10 were
observed) [103]. A review of T-cells and cytokines in AD patients is presented by Town et al.
The authors point out that clinical trials with vaccination of Aβ in humans (in contrast to mice)
led to a strong Th1 response and production of inflammatory cytokines such as IL-2 and IFN-γ.
This was thought to result in the observed side effects such as meningoencephalitis, resulting
in termination of the trial [154]. Other factors might be considered, for example the basal level
of cytokines appears to be slightly higher in a proportion of AD patients compared to healthy
elderly controls. This might be due to other stimuli in the blood of AD patients. The difference
was marginal; the employed technique of flow cytometry was not able to clearly detect the dif-
ference. Follow-up experiments to more thoroughly investigate this potential difference could
use either a longer incubation time, in vitro stimulation with other potential immune stimulants,
or an assay capable of assessing plasma cytokine levels in AD patients. In summary, this study
observed that amyloid beta did not influence PBMC cytokine production. Future studies should
employ modified experimental parameters in order to investigate this topic in more detail.
4.5 Higher chemokine receptor expression in AD patients compared
with healthy controls
In AD patients, cells of the immune system migrate along a chemokine gradient from the periph-
ery, through the blood-brain barrier, to the brain. Due to this, this study investigated chemokine
receptor expression on PBMCs of AD patients compared with healthy controls. Reale et al. pos-
tulate that chemokine receptors are present and some up-regulated in the brain of AD patients by
comparison with healthy individuals. The system of chemokines and their receptors is thought
to lead to an accumulation of microglia in senile plaques and may play a role in a cascade which
results in neuronal death. Increased concentrations of cytokines and chemokines in AD have
been reported for the periphery and the brain, but which of these is the primary driving force and
which is altered in consequence is still under debate. Using genetic and cytofluorimetric analysis,
Reale et al. showed that CCR2, CCR5 and CCL5/RANTES were more highly expressed, while
CCL2/MCP-1 showed lower expression in AD patients compared to controls. The results of this
study indicated that CD4+ CCR2- and CCR5-expressing T-cells were more frequent compared
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to CD8+ T-cells. An increase in CCR5, CCL5, CCL2 and IFNγ was also observed when PBMCs
were stimulated in vitro with Aβ-42 [119].
The present study analysed CCRs from a different perspective. This study investigated the
expression of CCRs on PBMC and the results confirmed those reported by Reale et al. Addi-
tionally, this study included CCRs that were not studied by Reale et al. In the Chieti sample
cohort, the expression frequency of CCR4 and CCR6 was analysed on T-cells. The results indi-
cated a slight trend; CD4+ T-cells of AD and VaD patients tended to express CCR4 and CCR6
more frequently, particularly when these cells were activated (that is, positive for CD25). This
analysis was repeated with the inclusion of CCR5 in the Canadian cohort. The results showed
that CCCR4 and CCR5, but not CCR6, was expressed more frequently on CD4+ T-cells in AD
patients compared to healthy controls, although the results did not reach statistical significance.
These results were independent of disease severity.
Another study indicated increased CCR2 and CCR5 expression frequency on T-cells and
B-cells after the stimulation of PBMCs from AD patients and healthy controls with Aβ-42 pro-
tein. In the case of CCR5, T-cells from AD patients expressed this protein in higher amounts
than in controls [110]. This study also investigated the expression frequency of CCRs on other
leukocyte cell types. In the Göttingen AD cohort, CCR2, CCR4, CCR5 and CCR6 were slightly
more frequently expressed on the entire leukocyte population (defined as CD45+) in AD patients
compared with controls. Greater differences were observed when the leukocytes were divided
into subsets. CCR6 was observed to be more frequently expressed on T-cells (CD3+), B-cells
(CD19+) and monocytes (CD14+) in AD patients compared with controls. Within the CD4+
and CD8+ T-cell subsets, the difference of higher CCR4 and CCR5 expression was more pro-
nounced in the CD4+ subset compared to the CD8+ subset. This is in line with previous studies
showing that CD4+ T-cells are more differentiated than CD8+ T-cells in AD patients [77, 111].
A particularly important observation by previous investigators is that of higher expression of the
CCR5 ligand MIP-1α by T-cells. CCR5 expression on human brain microvascular endothelial
cells (HBMECs) may provide a mechanistic explanation for T-cell migration through the BBB
to the brain [110].
Lee et al. detected higher Aβ-42 and beta-secretase levels in the brain of CCR5 knockout
mice compared with wild-type mice. The authors hypothesised that the absence of CCR5 leads
to an activation of CCR2, which through astrocyte activation in turn leads to Aβ deposition and
memory dysfunction [79]. The CCR5 signalling pathway also influences the expression of other
chemokine receptors. In CD4+ T-cells of CCR5 knockout mice, the expression of CCR1, CCR2
and CXCR3 is reduced. These mice showed altered CNS trafficking [49]). Therefore, these re-
sults suggest that CCR5 may act to suppress the development and progression of AD pathology.
The more frequent CCR5 expression on leukocytes in AD patients is perhaps a mechanism by
which the body is attempting to counteract AD pathology. Further support for this hypothesis is
given by a previous study that reported a possible neuroprotective role for CCR5 [144]. Thus,
the observation in this study that PBMCs express CCR5 more frequently may reflect attempts by
the body to counteract the pro-inflammatory nature of AD pathology mediated by other CCRs
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such as CCR6.
It is thought that CCR6 may also play an important role in this context. Together with adhesion
molecules such as selectins and integrins, CCR6 influences T-cell migration through the choroid
plexus into the CSF [129]. Previous studies have reported higher CCR6 expression in the brain
and periphery of transgenic mice with AD-like disease. The authors of this study suggested that
this was due to the systemic inflammation that is present in AD [147]. The findings presented
in this thesis indicate that AD in humans is similar to AD-like disease in mice in relation to its
inflammatory nature. One hypothesis is that certain immune cells which infiltrate the brain con-
tribute to inflammation while exerting anti-disease activity. Thus, limiting trafficking of immune
cells to the brain which secrete pro-inflammatory cytokines might help to reduce inflammation.
Additionally, brain-recruited microglia might secrete neurotoxins, causing neurodegeneration
[34]. This could be reduced by preventing those microglia from entering the brain (Fig. 4.1). On
the other hand migration of immune cells with anti-disease activity should be promoted.
An advantage of studying several chemokine receptors simultaneously is that different leuko-
cyte subsets may not express all of the receptors. This may allow the identification of expression
patterns on leukocyte subsets so that it may be possible to develop therapies that specifically
target subsets that play a role in AD pathology. For example, B-cells may play a role in con-
trolling CNS inflammation through IL-10 secretion [41] in addition to releasing nerve growth
factors that promote regeneration of brain cells [153]. Aβ activates neuroprotective microglia to
amyloid plaques via a signalling cascade that begins with the scavenger receptor CD36 [104].
Aβ can be phagocytosed by macrophages which in turn reduces the negative effects of Aβ (Fig.
1.2). Experiments from Zaghi et al. showed that "AD macrophages ingested and cleared less,
and underwent apoptosis upon exposure to soluble, protofibrillar, or fibrillar Aβ" [176]. Another
study by Fiala et al. showed that in contrast to those from controls, monocytes from the blood
of AD patients take up Aß but insufficiently mediate its clearance, have less capacity for dif-
ferentiation into macrophages, and more readily undergo apoptosis [39]. In transgenic mice,
experiments with GFP-labelled Aβ showed that blood-derived monocytes enter the brain and
phagocytose Aβ [92, 142]. Because these experiments were performed in chimeric mice in
which the host animal was irradiated and the bone marrow replaced with that of transgenic mice
in which lineage markers or selection genes had been introduced, the brain infiltration of bone
marrow-derived cells might be artifactual (reviewed by Cameron et al.) [22]. However, the data
presented in thesis observed increased expression frequency of CCR6 in monocytes and B-cells
in AD patients, suggesting that they may have an immune regulatory role in the brain.
A direct influence of CCR2 on disease progression was shown by El Khoury et al. [34].
In mice lacking CCR2, the authors observed less microglial accumulation and Aß clearance in
addition to the promotion of early disease progression [34]. On the other hand, it has been
stated that "Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for
the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer’s
disease" [100]. A correlation between CCR2 expression and MMSE scores in an elderly cohort
was reported by Harries et al. along with data associating CCR2 expression with ApoE haplo-
type status - an AD risk factor [59]. Evidence in mice has been reported that suggests Ly-6C(hi)
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CCR2+ monocytes are recruited to brain lesions which then differentiate into microglia [96].
Regarding CCR2 ligands, Westin et al. observed a correlation between increased CCL2 levels
in the CSF and more rapid cognitive decline in MCI patients that had developed prodromal AD
upon follow-up [164].
The results presented in this thesis confirm differences in the frequency of chemokine recep-
tor expression on PBMCs of AD patients compared to controls, potentially linking inflammatory
cells of the immune system to AD-associated brain damage. The results of this study are not able
to determine whether these differences are beneficial or harmful with respect to the development
and progression of AD. In order to determine this, follow-up studies, which are already under-
way, are required. It is speculated that interactions between certain immune cell types may be
beneficial at the onset of disease but harmful in later stages of disease, as evidenced by several
studies [41, 34, 176, 153]. In future experiments it would be of interest to investigate whether
blocking or enhancing the migration of peripheral leukocytes to the brain is associated with
changes in brain-associated inflammation, amyloid plaque accumulation or immune exhaustion,
or whether this results in adverse effects. The present studies suggest several novel therapeutic
targets (Fig. 4.1) based on proteins observed to be more frequently expressed on peripheral blood
cells from AD patients than in healthy elderly controls.
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Figure 4.1: Overview of AD immunotherapy opportunities in AD
Beneficial and negative effects of enhanced cell migration in AD due to an altered blood-brain barrier,
systemic inflammation and enhanced chemokine expression by activated brain cells resulting in possible
targets for immunotherapy.
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Chapter 5
Summary
This study investigated the immune profiles of patients with dementia (AD, VaD, mixed demen-
tia). The focus of this study was on leukocyte populations found in the blood. Initial experiments
assessed the frequency of major leukocyte subsets in AD patients and healthy controls, but no
differences were observed - the frequencies of B-cells, NK-cells and NKT-like cells were similar
for all groups. The monocyte marker CD14 tended to be less frequently expressed in control
subjects compared to AD patients, but the results differed across the cohorts that were studied.
In the second phase of this study, the phenotype of different leukocyte populations was ana-
lysed. B-cells showed a tendency towards a lowered frequency of CD27-IgD+ naïve cells in AD
patients compared to healthy controls. This trend was even more pronounced for T-cells, notably
in the case of CD4+ T-cells. This decrease was observed in pilot studies using samples from
the Canadian and Sicilian cohorts, but also in studies in the three other cohorts examined. In
these studies, different phenotype models were applied. Naïve T-cells were either characterised
as CCR7+CD45RA+ or as CD27+CD28+CD45RA+CD45RO-. In both cases the percentages
of CD4+ T-cells were lower in AD patients than in controls. Parallel to this, the percentages of
late-differentiated CD4+ T-cells were found elevated in AD patients. In addition, the frequency
of CD57- and KLRG-positiv cells tended to be greater in patients than controls, but these dif-
ferences were only statistically significant in some cohorts. Another observation, indicative of
immune exhaustion, was an increased level of PD-1 in T-cells of AD patients compared with
controls, although this was also not statistically significant. The question remains, which is the
factor causing these immune changes in AD. One possible explanation is that Aβ is causing
chronic antigenic stress and driving T-cell differentiation.
Another aspect that was studied was the functionality of the PBMCs in AD patients compared
with healthy controls. The aim was to assess the capacity of T-cells to produce cytokines and
control inflammation. If the cells are still able to produce anti-inflammatory cytokines, they could
serve as a target for immunotherapy. Another option to reduce inflammation is to identify and
neutralize the antigen triggering pro-inflammatory responses in AD. Aβ is one candidate which
was investigated in this study. After overnight stimulation with either PMA and ionomycin or
Aβ-42 together with brefeldin A, the levels of intracellular cytokines in CD4+ and CD8+ T-cells
were determined with flow cytometry. The results of these experiments showed no major differ-
ences between controls and AD patients. They were also independent of the disease stage.
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Further studies investigated chemokine receptor expression. In AD, a compromised and po-
tentially leaky blood-brain barrier results in an exchange between the periphery and the brain
that does usually not occur. A consequence is that cytokines, Aβ protein and cells may mi-
grate through the BBB. One consequence of this is systemic inflammation. One aspect of AD
pathology is the potential recruitment of immune cells to the brain. To elucidate the mecha-
nisms behind these processes, the frequency of peripheral leukocytes expressing CCR2, CCR4,
CCR5 and CCR6 was determined. The results indicated that leukocytes from AD patients more
frequently expressed these proteins, although the differences were not always statistically signi-
ficant in all cohorts. In the case of CCR6, it was observed that this receptor was not only more
often expressed on a single leukocyte subset, but expressed more frequently on B-cells, mono-
cytes, CD4+ and CD8+ T-cells as well.
In conclusion, this work provides evidence that hints toward a more differentiated and exhausted
immune system in AD patients. What still remains unclear is whether the recruitment of immune
cells to the brain is a consequence or cause of the disease. Experiments using in vitro models
where the entry of immune cells to the brain can be blocked may provide insight into this lin-
gering question. These experiments may also assist in determining if the migration of immune
cells results in beneficial effects, for example by phagocytosing Aβ protein, or if they function
to promote disease progression assuming that in vitro models accurately parallel human disease.
A way of investigating this could be to enhance the chemokine gradient in vivo, as the immune
cells examined in this study demonstrated increased CCR expression. In the event that immune
cells are found to promote AD, it may be possible to treat patients with CCR-blockers in order to
reduce immune cell migration to the brain. Using this approach, it may be possible to selectively
block B-cell migration as they were observed to express CCR6, but not CCR4 or CCR5. After
determining which leukocyte subset contributes to the promotion of disease, it may be possible
to employ antibodies specific to CCRs that are predominately expressed on this subset.
Previous studies in healthy elderly individuals showed that CMV serves as a chronic stimulus for
the immune system, particularly for CD8+ T-cells. In AD patients, Aβ might play a similar role.
In the present study, the cytokine production of T-cells stimulated with Aβ-42 was assessed, but
this did not result in appreciable cytokine production. Aβ may influence the immune system
through more than one mechanism, and it is possible that Aβ contributes to the observed shift
from early-differentiated to late-differentiated T-cells and B-cells in AD patients. This could
be tested by culturing T-cells with and without Aβ protein and analysing the resultant immune
profile. It is hypothesised that a rejuvenation of the immune system may be beneficial for AD
patients. This might be achieved through improving Aβ clearance, possibly by enhancing mono-
cyte migration from the periphery to the brain. Reduced Aβ load may result in reduced T-cell
differentiation, i.e. fewer memory T-cells and more naïve T-cells. It is thought that in AD patients
as in healthy elderly individuals that CMV is the driving force of CD8+ T-cell differentiation and
Aβ may have a similar effect in AD patients. Whether the effects of CMV and Aβ are additive
remains to be determined. A larger cohort of study participants - as recruited here - including suf-
ficient CMV- and CMV+ AD patients and controls would be necessary to investigate this. This
question may be of particular importance given that CMV may contribute to the inflammatory
state in AD patients and thus provide another burden to the functioning of the immune system
thereby decreasing the ability of the body to control the disease. The role that CMV may play
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in the functional decline of the immune system may also be related to cognitive decline, such as
that in AD.
5.1 Summary in German
In dieser Studie wurden Immunprofile von Patienten mit verschiedenen Demenzformen (AD,
VaD, mixed dementia) erstellt. Der Fokus lag dabei auf verschiedenen Blutleukozyten. Die
Prozente an B-Zellen, NK-Zellen und NKT-Zellen waren ähnlich in allen Gruppen. Der Mono-
zytenmarker CD14 scheint in Kontrollen weniger exprimiert zu sein als in Alzheimer-Patienten,
doch die Aussagen sind nicht schlüssig, da verschiedene Studien zu unterschiedlichen Ergebnis-
sen geführt haben.
In einem zweiten Teil wurde der Phänotyp der Leukozyten untersucht. B-Zellen wiesen dabei
tendenziell geringere Prozentzahlen an CD27-IgD+ naiven Zellen in Alzheimer-Patienten im
Vergleich zu gesunden Kontrollen auf. Dieser Trend ist stärker ausgeprägt in T-Zellen, vor allem
in den CD4+, und wurde durchgängig in allen Studien festgestellt. Dabei wurden verschiedene
Differenzierungsmodelle angewandt, in denen naive T-Zellen als CCR7+CD45RA+ oder als
CD27+CD28+CD45RA+CD45RO- charakterisiert wurden. In beiden Fällen war die Häufigkeit
in Patienten niedriger als in Kontrollindividuen. Parallel dazu war die Frequenz an weit dif-
ferenzierten CD4+ T-Zellen höher in Alzheimer-Patienten. Zusätzlich war die Häufigkeit von
CD57- und KLRG1-positiven T-Zellen in Patienten höher, wenn auch nicht immer signifikant.
Ein weiteres Anzeichen für ein erschöpftes Immunsystem ist das nicht signifikant höhere Level
von PD-1 auf T-Zellen von Patienten der Alzheimer-Krankheit. Daraus stellt sich die Frage, was
für die immunologischen Veränderungen in Bezug auf die Alzheimer-Krankheit verantwortlich
ist. Eine Hypothese ist, dass Aβ als antigener Stressor T-Zell Differenzierung vorantreibt.
Ein weiterer untersuchter Aspekt war die Funktionalität von PBMC. Ziel war es, die Kapazität
von T-Zellen, Zytokine zu produzieren, zu untersuchen. Falls diese Zellen in der Lage sind,
ausreichend anti-inflammatorische Zytokine zu produzieren, so könnten sie als Ziel für eine Im-
muntherapie dienen. Eine weitere Maßnahme, um die Entzündung zu reduzieren, ist die Identi-
fikation und Neutralisation des Antigens, was Zellen stimuliert, pro-inflammatorische Zytokine
auszuschütten. Aβ ist ein möglicher Kandidat, dessen Wirkung auf T-Zellen in dieser Studie
untersucht wurde. Nach Übernachtstimulation mit PMA und Ionomycin oder Aβ-42 zusam-
men mit Brefeldin A wurde die Expression von verschiedenen Zytokinen in CD4+ und CD8+
T-Zellen mittels intrazellulärer Färbung für Durchflusszytometrie gemessen. Ergebnisse dieses
Versuches zeigen keine größeren Unterschiede zwischen der Kontrollgruppe und den Patienten
auf, unabhängig vom Schweregrad der Krankheit.
In weiteren Versuchen wurde die Expression von Chemokinrezeptoren untersucht. In AD führt
eine in Mitleidenschaft genommene Blut-Hirn-Schranke zu einem intensiven Austausch zwi-
schen Peripherie und Gehirn, der so normalerweise nicht stattfindet. Zytokine, Aβ und Zellen
passieren die Schranke und eine der Konsequenzen ist eine systemische Entzündung. Ein entschei-
dender Punkt ist dabei die Rekrutierung von Immunzellen ins Gehirn. Um dies zu veranschau-
lichen, wurde die Expression von CCR2, CCR4, CCR5 und CCR6 auf Leukozyten im Blut
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bestimmt. Dabei wurde eine höhere Expression auf Leukozyten von Patienten der Alzheimer-
Krankheit vorgefunden, wenngleich auch nicht alle Unterschiede signifikant waren. Am Beispiel
von CCR6 konnte gezeigt werden, dass die höhere Expression sich nicht auf eine bestimmte Zell-
gruppe beschränkt, sondern bei B-Zellen, Monozyten, CD4+ und CD8+ T-Zellen auftrat.
Insgesamt bietet diese Arbeit Hinweise für ein erschöpftes Immunsystem mit weiter differen-
zierten Zellen. Was dabei noch unklar ist, ist die Frage, ob die Rekrutierung von Immunzellen
ins Gehirn Folge oder Ursache der Erkrankung ist. Dies zu beantworten benötigt weitere Unter-
suchungen. Ein Beispiel könnte die Blockade des Gehirneindringens in Modellsystemen sein.
Dies würde auch zum Verständnis beitragen, ob die Unterstützung der Zellmigration den Aβ Ab-
bau fördert und Neurodegeneration verlangsamt oder ob diese Zellen weiter zu einer verstärkten
Entzündung beitragen. Als Untersuchungsmethode könnte die Erhöhung des Chemokingradien-
ten dienen. Im Falle von negativen Effekten von Immunzellen im Gehirn könnte eine Behand-
lung von Patienten mit CCR-Blockern die Zellanhäufung vermindern. Dabei kann man auch
gezielt bestimmte Zellen anvisieren und andere ausschließen durch die Wahl des zu blockenden
Rezeptors. B-Zellen exprimieren z.B. CCR6, aber nicht CCR4 und CCR5. Nach Experimenten,
die zeigen, welche Zellpopulation zur Entzündung beiträgt, könnte man spezifische Antikörper
gegen Rezeptoren verwenden, die vorwiegend auf diesen Zellen exprimiert werden.
Frühere Studien an gesunden, älteren Menschen zeigten, dass CMV als chronischer Stimu-
lus für das Immunsystem wirkt, vor allem für CD8+ T-Zellen. In AD könnte Aβ diese Rolle
übernehmen. In dieser Studie wurde die Zytokinproduktion von T-Zellen nach Stimulation mit
Aβ-42 analysiert, jedoch keine nennenswerte Produktion nachgewiesen. Ein anderer möglicher
Effekt von Aβ könnte die Verschiebung von früh zu spät differenzierten Zellen sein. Dies könnte
in Experimenten untersucht werden, in denen Zellen mit und ohne Aβ inkubiert werden und
anschließend Immunprofile analysiert werden. Man könnte vermuten, dass eine Verjüngung
des Immunsystem hilfreich für AD Patienten sein könnte. Ein Weg, dies zu erreichen, könnte
das Verbessern des Aβ-Abbaus sein, zum Beispiel durch Erhöhung der Infiltration von peri-
pheren Monozyten ins Gehirn. Eine Reduktion von Aβ könnte die Differenzierung von naiven
zu Gedächtniszellen stoppen. Wie bei gesunden älteren Menschen CMV die Rolle der treibenden
Kraft der CD8+ T-Zelldifferenzierung zugedacht wird, so könnte Aβ einen ähnlichen Effekt in
AD besitzen. Ob CMV und Aβ Effekte additiv sind, bleibt noch zu untersuchen. Dafür wäre
eine größere Anzahl an Studienteilnehmern als hier untersucht nötig, die genügend CMV- und
CMV+ AD Patienten und Kontrollen beinhaltet. Diese Fragestellung ist von besonderer Bedeu-
tung, da CMV zur Entzündung beitragen und somit eine weitere Belastung des Immunsystems
darstellen könnte, welche die Kontrolle der Krankheit erschwert. Der Effekt von CMV auf das
Immunsystem in funktionellem Verlust könnte auch bei kognitivem Verlust relevant sein.
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Glossary
Aβ
Amyloid β.
AD
Alzheimer’s Disease.
ADDTC
The State of California Alzheimer’s Disease Diagnostic and Treatment Centers.
APC
Antigen presenting cell.
ApoE
Apolipoprotein E.
APP
Amyloid precursor protein.
BBB
Blood-brain barrier.
CCL
CC chemokine ligand.
CCR
Chemokine receptor.
CMV
Cytomegalovirus.
CNS
Central nervous system.
CRP
C-reactive protein, an inflammation marker.
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CSF
Cerebrospinal fluid.
CT
X-ray computed tomography.
DC
Dendritic cell.
DMSO
Dimethylsulfoxide.
EDTA
Ethylenediaminetetraacetic acid.
ELISA
Enzyme-linked immunosorbent assay.
EMA
Ethidium monoacide bromide used to label dead cells.
FBS
Fetal bovine Serum.
Foxp3
Forkhead box P3, a marker for regulatory T-cells.
HBMECs
Human brain microvascular endothelial cells.
HSV
Herpes simplex virus.
ICD-10
International Statistical Classification of Diseases criteria, including six subtypes of VaD.
IFNγ
Interferon gamma, a pro-inflammatory cytokine.
Ig
Immune globulin.
IL
Interleukin, interleukins are a group of chemokines.
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IRP
Immune risk profile, set of immune parameters which correlate with survival.
KLRG1
Killer cell lectin-like receptor subfamily G member 1.
LPS
Lipopolysaccharide, an endotoxin.
MHC
Major histocompatibility complex.
MMSE
Mini mental state examination; 30 point questionnaire established 1975 by Folstein to
diagnose cognitive impairment.
MRI
Magnetic resonance imaging (MRI), nuclear magnetic resonance imaging (NMRI), or
magnetic resonance tomography (MRT).
NFT
Neurofibrillary tangles.
NINCDS-ADRDA
NINCDS-ADRDA National Institute of Neurological and Communicative Diseases and
Stroke - Alzheimer’s Disease and Related Disorders Association.
NINDS-AIREN
National Institute of Neurological Disorders and Stroke - Association Internationale pour
la Recherche et l’Enseignement en Neurosciences.
NK-cell
Natural killer cell.
PBMC
Peripheral blood mononuclear cell.
PBS
Phosphate buffered saline.
PD-1
Programmed cell death protein 1, a marker of immune exhaustion.
PET
Positron emission tomography.
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PMA
Phorbol 12-myristate 13-acetate.
PS
Presenilins, a family of transmembrane proteins that are found in the complex which pro-
cesses APP to Aβ.
rpAD
Rapidly progressive Alzheimer’s disease.
TCR
T-cell receptor.
TNF
Tumour necrosis factor, a pro-inflammatory cytokine.
Treg
Regulatory T-cell.
VaD
Vascular dementia.
XVIVO-15
Culture medium for PBMC.
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